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Part I Expansion Of Type Ii Anion Relay Chemistry (arc); Part Ii Synthesis Of A 
Recyclable Polymer-Supported Siloxane Transfer Agent For Transition Metal-
Catalyzed Cross-Coupling Reactions (ccr) Of Organolithiums 
Abstract 
Part 1: This work describes recent advances in Type II Anion Relay Chemistry (ARC), a three-component 
coupling tactic employing a bifunctional linchpin, developed by the Smith group to permit the rapid 
synthesis of natural product fragments. Our group has developed several novel linchpins and coupling 
tactics to achieve diastereoselective and stereoretentive transformations, but enantioselective methods 
remained elusive. By merging asymmetric [1,2]-additions of lithium acetylides with Type II ARC we have 
achieved an enantioselective three-component coupling ARC tactic. Additionally, we report here the 
development of a novel bifunctional Type II linchpin, employing fluorine as an Anion Stabilizing Group 
(ASG). The design of a synthetic route to access a variety of organofluorine linchpins, in conjunction with 
Type II ARC, has enabled access to diverse difluoromethylene scaffolds, which are of significant interest 
to the pharmaceutical and agrochemical industries. 
Part 2: This work describes the design, synthesis, and application of a polystyrene supported siloxane 
transfer agent for use in transition metal-catalyzed cross-coupling reactions (CCRs) of organolithium 
reagents with aryl halides. Siloxane transfer agents, discovered during our investigation of Anion Relay 
Chemistry (ARC), permit cross-coupling reactions of organolithium reagents with high functional group 
tolerance with respect to the electrophile component. Organolithium reagents represent a convenient 
organometallic coupling component, as they can be generated from commercially available 
organohalides, and are in many cases used in the synthesis of other organometallic reagents. However, 
these reagents are often overlooked in synthesis due to their strong basicity, nucleophilicity, and tendency 
to afford homo-coupling products in transition metal catalyzed CCRs. Here we describe the development 
of a novel polystyrene supported siloxane transfer agent as a progression over previous generations of 
transfer agents, ultimately arriving at a highly efficient and recoverable transfer agent that can be used in 








Amos B. Smith III 
Subject Categories 
Organic Chemistry 




EXPANSION OF TYPE II ANION RELAY CHEMISTRY (ARC) 
 
PART II 
SYNTHESIS OF A RECYCLABLE POLYMER-SUPPORTED SILOXANE TRANSFER 
AGENT FOR TRANSITION METAL-CATALYZED CROSS-COUPLING REACTIONS OF 
ORGANOLITHIUMS 
 




Presented to the Faculties of the University of Pennsylvania 
in 
Partial Fulfillment of the Requirements for the 
Degree of Doctor of Philosophy 
2020 
 
Supervisor of Dissertation    Graduate Group Chairperson   
________________________   ________________________   
Dr. Amos B. Smith III    Dr. David W. Christianson   
Rhodes-Thompson Professor of Chemistry  Professor of Chemistry 
 
Dissertation Committee  
Dr. Jeffrey D. Winkler, Merriam Professor of Chemistry 
Dr. Gary A. Molander, Hirschmann-Makineni Professor of Chemistry 




































I would like to acknowledge my many mentors throughout my undergraduate and 
graduate career. First, I would like to thank Professor Amos B. Smith III for his support and 
guidance during my graduate studies. Additionally, I would like to thank Professor Jeffrey D. 
Winkler for introducing me to graduate level chemistry research by taking me into his laboratory 
before my first year of graduate school. Finally, I would like to thank Professor Lark J. Perez who 
inspired me to pursue a career in chemistry in both his undergraduate organic chemistry I and II 
classes, and also through research by inviting me to join his group studying medicinal chemistry. I 
also owe gratitude to my committee members, Professor Jeffrey D. Winkler, Professor Gary A. 
Molander, and Professor Virgil Percec, who have overseen my Ph.D. work for the last several 
years. Of course, I also want to thank my many colleagues in the Smith group who I have 
interacted with over the years who have helped me to develop not only skills in the laboratory, but 















EXPANSION OF TYPE II ANION RELAY CHEMISTRY (ARC) 
PART II 
SYNTHESIS OF A RECYCLABLE POLYMER-SUPPORTED SILOXANE TRANSFER 
AGENT FOR TRANSITION METAL-CATALYZED CROSS-COUPLING REACTIONS (CCR) OF 
ORGANOLITHIUMS 
Kevin T. O’Brien 
 Amos B. Smith III 
Part 1: This work describes recent advances in Type II Anion Relay Chemistry (ARC), a three-
component coupling tactic employing a bifunctional linchpin, developed by the Smith group to 
permit the rapid synthesis of natural product fragments. Our group has developed several novel 
linchpins and coupling tactics to achieve diastereoselective and stereoretentive transformations, 
but enantioselective methods remained elusive. By merging asymmetric [1,2]-additions of lithium 
acetylides with Type II ARC we have achieved an enantioselective three-component coupling 
ARC tactic. Additionally, we report here the development of a novel bifunctional Type II linchpin, 
employing fluorine as an Anion Stabilizing Group (ASG). The design of a synthetic route to 
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to diverse difluoromethylene scaffolds, which are of significant interest to the pharmaceutical and 
agrochemical industries.  
Part 2: This work describes the design, synthesis, and application of a polystyrene supported 




organolithium reagents with aryl halides. Siloxane transfer agents, discovered during our 
investigation of Anion Relay Chemistry (ARC), permit cross-coupling reactions of organolithium 
reagents with high functional group tolerance with respect to the electrophile component. 
Organolithium reagents represent a convenient organometallic coupling component, as they can 
be generated from commercially available organohalides, and are in many cases used in the 
synthesis of other organometallic reagents. However, these reagents are often overlooked in 
synthesis due to their strong basicity, nucleophilicity, and tendency to afford homo-coupling 
products in transition metal catalyzed CCRs. Here we describe the development of a novel 
polystyrene supported siloxane transfer agent as a progression over previous generations of 
transfer agents, ultimately arriving at a highly efficient and recoverable transfer agent that can be 
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EXPANSION OF TYPE II ANION RELAY CHEMISTRY (ARC) 
 
1-1: Introduction to Anion Relay Chemistry (ARC) 
The challenge of organic synthesis is not only the ability to synthesize a target, 
but also the efficiency with which the target is constructed. Nature has demonstrated the 
elegance with which structurally elaborate compounds can be synthesized with highly 
selective and iterative reaction sequences from simple building blocks. The desire to 
emulate this synthetic efficiency has driven many chemists to develop innovative 
methods for C – C bond formation. Introduced and developed by the Smith laboratory, 
Anion Relay Chemistry (ARC) comprises a one-pot three-component union tactic in 
which a linchpin component sequentially forms a C – C bond to each of two other 
components via an anionic cascade reaction.1 This tactic permits the assembly of 
complex polyketide fragments from simple building blocks, thereby minimizing the 
number of synthetic steps required to achieve the synthetic target. ARC can be divided 
into two types depending on the nature of the linchpin.  
 Type I Anion Relay Chemistry (Scheme 1-1a) comprises an initial nucleophilic 
attack of a lithiated α-silyl linchpin on an enantioenriched epoxide electrophile to arrive at 
an alkoxide intermediate. Once triggered, a [1,4]-Brook rearrangement of the alkoxide 
intermediate occurs, resulting in the formation of a carbanion species via through space 
charge migration. Stabilized by the presence of an anion stabilizing group (ASG), the 
carbanion can attack a second electrophilic species to afford a three-component adduct.  
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Scheme 1-1. Type I and Type II Anion Relay Chemistry (ARC) 
Ch1_S cheme 1  
 
The Type II Anion Relay Chemistry tactic also comprises a three-component 
coupling reaction (Scheme 1-1b). The key difference between Type I and Type II ARC is 
the pathway by which the alkoxide intermediate is accessed. An ambiphilic bifunctional 
linchpin is employed in Type II ARC to permit the linchpin to serve both electrophilic and 
nucleophilic roles during the reaction.2 This protocol is initiated by nucleophilic addition 
of an organolithium reagent to the bifunctional linchpin to generate an alkoxide 
intermediate. In a manner analogous to Type I ARC, this alkoxide species undergoes 
[1,4]-Brook rearrangement and electrophile capture to afford the three-component ARC 
adduct. Whereas the Type I ARC linchpin can be considered an anion/anion (-/-) 
synthon, Type II linchpins can be considered cation/anion (+/-) synthons. 
Both Type I and Type II Anion Relay Chemistry have been exploited to permit the 
total synthesis of several natural products. Type I ARC, having been first developed, has 
been employed in a number of syntheses as the key disconnection, including (-)-
mandelalide A,3 (-)-enigmazole A,4 and the gram scale synthesis of (+)-spongistatin 15 
(Scheme 1-2). In this ARC application, TBS-dithiane 1.1 is lithiated with n-BuLi to 
generate nucleophile 1.2 which undergoes first an epoxide opening with epoxide 1.3. 
Subsequent treatment with HMPA triggers a [1,4]-Brook rearrangement and electrophile 
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capture of a second epoxide (1.4). Quenching of the reaction with methyl iodide permits 
methylation in the same flask, affording multi-component adduct 1.5. After several 
functional group manipulations, a key spirocyclic core of (+)-spongistatin 1 (1.6) was 
achieved.  
Scheme 1-2. Type I ARC in the Total Synthesis of (+)-spongistatin 1 
Ch1_S cheme 2  
 
Type II ARC has also been utilized in several synthetic strategies by the Smith 
group, permitting the construction of the C(1)-C(25) fragment of spirastrellolide A,6 as 
well as the total synthesis of (-)-nahuoic acid Cii,7 and (-)-secu’amamine A (1.12)8 
(Scheme 1-3). The ARC tactic employed in the synthesis of (-)-secu’amamine A (1.12) 
was initiated by lithiation of alkyl dithiane 1.7 to arrive at nucleophile 1.8 which 
undergoes epoxide opening with epoxide 1.9. Here, an enantioenriched aldehyde 1.10 
serves as the terminal electrophile after [1,4]-Brook rearrangement, enabling Felkin-Anh 
diastereoselectivity for the [1,2]-addition and affording three-component adduct 1.11 as a 
single diastereomer.9 Thus, the linear carbon skeleton of alkaloid natural product 1.12 
was constructed in a single transformation employing the Type II ARC tactic. Clearly, the 
ARC tactic represents a valuable approach for the construction of architecturally 
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elaborate polyketide and alkaloid scaffolds, while minimizing the number of synthetic 
steps required to achieve such complexity. 
Scheme 1-3. Type II ARC in the Total Synthesis of (-)-secu’amamine A 
Ch1_S cheme 3  
 
 
1-2: Merging Asymmetric [1,2]-Additions of Lithium Acetylides to 
Carbonyls with Type II Anion Relay Chemistry (ARC) 
(This work was published in O’Brien, K. T.; Smith, A. B., III. Org. Lett. 2019, 21, 7655.) 
Over the years the Smith group has developed a variety of Type II ARC linchpins 
as well as new tactics exploiting these linchpins. It is true that all Type II linchpins 
employ a bifunctional linchpin which affords an alkoxide intermediate upon addition of a 
nucleophile. However, several different electrophilic termini have been investigated, 
including epoxides,10 aldehydes,11 and more recently Weinreb amides12 (Figure 1-1). 
While Weinreb amide linchpin 1.13 is useful for the synthesis of achiral ketone products, 
epoxide (1.14) and aldehyde (1.15 and 1.16) linchpins afford stereochemistry in the ARC 
product. With respect to the three-component adducts obtained utilizing epoxide linchpin 
1.14, retention of stereochemistry is observed. However, when the Type II ARC 
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sequence is initiated via a [1,2]-addition to aldehyde linchpin 1.15 or 1.16 a new 
stereocenter is formed. High diastereoselectivity has been achieved employing 
bifunctional aldehyde linchpin 1.16 via Felkin-Anh control wherein the absolute 
configuration of the alcohol is set by the α-methyl stereogenic center present in 1.16. 
Thus, several linchpins have been developed to permit access to enantioenriched and 
diastereomerically enriched three-component adducts. 
Figure 1-1: Variety of Type II Linchpins and Stereochemistry of ARC Adducts 
Figure 1  
 
 The α-stereogenic center of 1.16 permits high diastereoselectivity for the [1,2]-
addition via Felkin-Anh control (Scheme 1-4a). However, diastereoselectivity in Type II 
ARC has been achieved not only through the use of enantioenriched linchpins, but also 
by employing achiral linchpins in a novel manner. Recently, our group developed a 
formal [3+2] annulation tactic employing aldehyde linchpin 1.18.13 In a single reaction 
flask 3 stereocenters were generated with high diastereoselectivity (Scheme 1-4b). The 
reaction is initiated with a racemic [1,2]-addition of achiral enolate 1.17 to aldehyde 
linchpin 1.18 to afford alkoxide 1.19. Steric factors impart a bias for the relative trans 
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configuration of annulation alcohol adduct 1.20 formed with a diastereomeric ratio >20:1 
observed. Here, both the initiation of the ARC sequence and the electrophile capture are 
diastereoselective, differing from previous methods. Thus, effective diastereoselective 
tactics within the scope of ARC have been established. 
Scheme 1-4. ARC Tactics for Achieving Diastereoselectivity 
Ch1_S cheme 4  
 
Although stereoretentive and diastereoselective processes have been 
successfully incorporated into the ARC protocol, at this juncture an enantioselective 
tactic had not been developed. We turned our attention to the development of an ARC 
tactic which could impart enantioselectivity via catalyst control. Asymmetric 
organometallic [1,2]-carbonyl additions commonly employ Zn acetylides, although Sn, B, 
Li, and other metals have been employed.14 Thus, we reasoned this could be achieved 
by initiation of the ARC reaction by an asymmetric [1,2]-carbonyl addition. Several 
others, including Marek15 and Johnson,16 have exploited this approach to three-
component couplings via initiation with a Zn acetylide. In both examples, a [1,2]-Brook 
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rearrangement was employed to permit electrophile capture, whereas our envisioned 
tactic required a [1,4]-Brook rearrangement. To the best of our knowledge there are no 
reported examples of a [1,4]-Brook rearrangement of a Zn alkoxide. Thus, our focus has 
been on lithium acetylides.  
The enantioselective [1,2]-carbonyl addition of a lithium acetylide was first 
disclosed by Mukaiyama17 and later improved by the Merck18 group in the synthesis of 
HIV-1 reverse transcriptase inhibitor Efavirenz. However, in these early examples 
several equivalents of ligand were required to effect high enantioselectivity. Recently, 
Nakajima reported a catalytic method for the asymmetric [1,2]-addition of an acetylene 
(1.21) to an achiral ketone (1.22) to yield enantioenriched propargyl alcohol (1.23) 
utilizing BINOL derivative 1.24 (Figure 1-2a).19 We sought to utilize 1.24 in conjunction 
with a lithium acetylide (1.25) to access enantioenriched alkoxide 1.27 via an 
asymmetric [1,2]-addition to achiral linchpin 1.26. In this way, enantioenriched three-
component adduct 1.28 could be obtained after [1,4]-Brook rearrangement and 
electrophile capture (Figure 1-2b). 
Our efforts were first directed toward evaluation of the enantioselectivity of [1,2]-
addition of lithium phenyl acetylide to linchpin 1.29 to afford propargyl alcohol 1.30, 
wherein the alkoxide is quenched prior to [1,4]-Brook rearrangement (Table 1-1). The 
reaction was initiated by deprotonation of phenylacetylene in the presence of (R)-1.24 at 
-78 °C, followed by the addition of linchpin 1.29 over a period of 10 minutes. The rate of 
ketone addition was examined first. Decreased enantioselectivity was observed with 
rapid drop-wise addition of linchpin 1.29. However, no significant improvement in 
enantioselectivity was observed when linchpin 1.29 was added over a 30-minute period, 
as compared to a 10-minute period. Next, the influence of silyl substitution on the 
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linchpin was assessed by comparing TMS and TBS linchpins 1.29a and 1.29b, 
respectively. Greater enantioselectivity was observed for [1,2]-addition to 1.29a than 
1.29b. Importantly, using only one equivalent of phenylacetylene afforded the [1,2]-
addition product 1.30a with excellent enantioselectivity.  
Figure 1-2: Development of Asymmetric ARC Concept 
Figure 2  
 
Having optimized the enantioselectivity of the [1,2]-addition, we turned our 
attention to the full ARC sequence. The temperature dependence of the [1,4]-Brook 
rearrangement and electrophile capture was examined first (Table 1-2). In these 
experiments, benzyl bromide (BnBr) was added to the reaction mixture after completion 
of the [1,2]-addition at -78 °C. Upon addition of BnBr (2.0 eq), the mixture was warmed 
to a range of temperatures from -78 °C to 50 °C and held at the corresponding 
temperature for 1 hour before the reaction was quenched. We anticipated the formation 
of products 1.31 and 1.32, whereby [1,4]-Brook rearrangement is followed either by 
alkylation or protonation, respectively. The [1,4]-Brook rearrangement was observed at 
temperatures as low as -30 °C. The highest ratio of alkylation to protonation product 
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(1.31:1.32) was observed with immediate transfer of the reaction vessel to a water bath 
at room temperature. Allowing the reaction to gradually warm to room temperature was 
deleterious, as was either addition of HMPA, or reduction of the BnBr stoichiometry. 
Additionally, maintaining the temperature of the reaction at -30 °C, the lowest 
temperature at which [1,4]-Brook rearrangement was observed, for 24 h did not increase 
the formation of 1.31. 
Table 1-1: Optimization of Enantioselectivity of [1,2]-Addition 
Table 1  
 
With optimized conditions for the full ARC sequence in hand, we first determined 
the absolute configuration of the tertiary alcohol present in the three-component adduct. 
While the absolute configuration of stereogenic secondary carbinols can be readily 
determined via Mosher ester analysis, such methods for tertiary alcohols are lacking. 
Thus, we set out to determine the absolute configuration by preparing a known 
compound using our ARC tactic for comparison of optical rotation (Scheme 1-5).20 First, 
10 
 
employing catalyst (R)-1.24, [1,2]-addition of lithiated trimethylsilyl acetylene (1.33) to 
linchpin 1.29a was performed, followed by [1,4]-Brook rearrangement and capture of a 
proton as the terminal electrophile to afford silyl ether adduct 1.34. Next, dithiane 
hydrolysis to the aldehyde, followed by reduction with NaBH4, and silyl deprotection 
afforded 1.35 in good yield over three steps. The optical rotation was compared to the 
values observed for both enantiomers, reported by Ghosh21 and Furstner,22 allowing 
assignment of the tertiary alcohol in the (S)-configuration employing (R)-1.24.  
 
Table 1-2: Optimization of Full ARC Sequence 
Table 2  
 
Having determined the absolute configuration of the propargyl alcohol product, 
we turned our attention to the nucleophile scope. Reactions were performed with 
11 
 
linchpin 1.29a and BnBr as the electrophile (Figure 1-3). The influence of steric and 
electronic factors of the lithium acetylide on enantioselectivity was clear. Electron rich 
acetylides afforded greater enantioselectivity than electron poor acetylides. This trend is 
most evident in three-component adducts 1.37a–1.37c, wherein enantioselectivity and 
yield are positively correlated with the electron donating character of the para 
substituent.23 Perhaps of greater significance is the influence of steric encumbrance of 
the nucleophile on enantioselectivity. Bulky nucleophiles such as TBS acetylene (1.36dii) 
and TMS acetylene (1.36di) afforded 1.37d with modest to moderate enantiomeric ratios 
of 72:28 and 90:10, respectively. This steric influence was further exemplified in the 
comparison of cyclic and linear aliphatic lithium acetylides, wherein a greater 
enantiomeric ratio was observed for 1.37f than 1.37e. Pleasingly, the use of benzyl 
propargyl ether was well tolerated, providing access to diversifiable three-component 
adduct 1.37g in good yield and excellent enantioselectivity. 
 
 Scheme 1-5: Determination of Absolute Configuration of [1,2]-Addition 






Figure 1-3: Asymmetric ARC Nucleophile Scopea 
Figure 3  
 
Next, the scope of electrophiles was evaluated using lithium phenyl acetylide as 
the nucleophile and ketone linchpin 1.29a with a variety of electrophiles (1.38) to afford 
1.39 (Figure 1-4). Benzyl (1.38a) and allyl bromide (1.38b) electrophiles provided the 
desired three-component adducts 1.39a and 1.39b in good yield. Di-yne product 1.39c 
was obtained from the corresponding silyl propargyl bromide (1.38c) after TBAF 
deprotection, albeit in modest yield. While an excellent yield of 1.39d was achieved 
using MeI, a poor yield was observed for 5-bromo-1-pentene (1.38e), likely due to the 
competing elimination reaction. Epoxide electrophiles were found to be viable, affording 
adducts 1.39f–1.39h in modest to good yield, permitting inclusion of an additional 
stereocenter. In each case, the product was observed by 1H/13C-NMR as a single 
diastereomer. Benzaldehyde was also employed, proceeding with high enantioselectivity 
(99:1 er) to yield 1.39i as an expected mixture of diastereomers (1.5:1). 
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Figure 1-4: Asymmetric ARC Electrophile Scopea 
Figure 4  
 
To qualify as an effective cascade reaction, such a process should afford the 
final product in greater yield than that obtained by the sequential execution of the 
constituent reactions. The ARC cascade was therefore divided into a two-pot sequence 
for comparison. The first step of the ARC sequence is [1,2]-addition of lithium 
phenylacetylide to linchpin 1.29a to arrive at alkoxide 1.40. A [1,4]-Brook rearrangement 
of alkoxide 1.40 is then thermally triggered with subsequent electrophile capture 
terminating the standard one-pot ARC sequence (Scheme 1-6). Alternatively, alkoxide 
1.40 can be acidified at -78 °C to afford alcohol 1.30a. In the two-pot protocol, purified 
alcohol 1.30a enters the ARC sequence via deprotonation to 1.40. The one-pot and two-
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pot methods were compared for the ARC sequence employing linchpin 1.29a with 
phenylacetylene and benzaldehyde serving as the nucleophile and electrophile, 
respectively, to afford three-component adduct 1.39i. A drastic difference in the product 
distribution was observed between the one and two-pot methods. Whereas the one-pot 
protocol provided 1.39i in good yield (73%), the two-pot process provided only trace 
1.39i with most of the recovered material consisting of quenched product 1.41 (89%) 
and benzyl alcohol (48%). We suspect the reduction of benzaldehyde to benzyl alcohol 
occurs via a single-electron transfer (SET) process that is favored by the two-pot 
reaction sequence.24 The role of the two-pot approach in favoring a SET pathway is 
unclear but may be a consequence of a different aggregation state that occurs via 
access of 1.40 by an alternate route. Thus, this one-pot asymmetric three-component 
union tactic circumvents the undesired reactivity and is more efficient than the sum of its 
parts.  
 
Scheme 1-6: Comparison of One-Step and Two-Step ARC Approaches 





Having demonstrated the generality of the one-pot protocol with respect to 
acetylides and electrophiles, we examined the viability of aldehyde linchpins 1.42a and 
1.42b to afford secondary alcohol 1.43 with phenylacetylene and BnBr serving as the 
nucleophile and electrophile, respectively (Scheme 1-7). Pleasingly, good yields and 
moderate enantioselectivites of 1.43 were achieved employing aldehyde linchpins 1.42a 
and 1.42b. As opposed to ketone linchpins 1.29a and 1.29b (Table 1-1), the size of the 
silyl substituent did not affect the enantiomeric ratio of the corresponding three-
component adducts 1.43. Thus, either silyl ether product can be obtained at no expense 
to enantioselectivity, permitting convenient integration into a protecting group strategy. 
The greatest limitation to the generality of this tactic with respect to 
enantioselectivity is derived from the steric factors of the acetylene. Although many 
lithium acetylide substrates enabled excellent enantioselectivity with linchpin 1.29a, 
synthetically useful silyl acetylenes afforded moderate enantioselectivity for three-
component adduct 1.37d (Figure 1-3). To overcome this limitation, the relationship 
between catalyst loading and enantioselectivity was investigated (Figure 1-5). First, we 
examined the ARC sequence with highly sterically encumbered TBS acetylene (1.36dii) 
and linchpin 1.29a to afford three-component adduct 1.37d. Acetylene 1.36dii was 
chosen because it is the least ideal nucleophile examined herein. A logarithmic 
relationship between enantiomeric excess (%ee) and catalyst loading (mol% (S)-1.24) 
was observed, reaching a maximum of 80%ee (90:10 er) with 80 mol% (S)-1.24. 
Alternatively, excellent enantioselectivity (97:3 er) can be achieved for the same synthon 
type using TMS acetylene (1.36bi). Generally, most carbon substituted terminal 
acetylenes are less sterically hindered than a TBS group and as such, this method holds 
the promise of excellent enantioselectivity for a broad range of terminal acetylenes. In 
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addition, (S)-1.24 was employed instead of (R)-1.24, to demonstrate the interchangeable 
nature of the catalyst to afford the opposite enantiomer. 
 
Scheme 1-7: Asymmetric ARC Employing Aldehyde Linchpin 
Ch1_S cheme 7  
 
 
In summary, disclosed herein is a new method for the preparation of 
enantioenriched three-component union adducts from achiral components via an ARC 
tactic initiated by an organocatalytic asymmetric [1,2]-addition of a lithium acetylide. 
Excellent enantioselectivities were observed in the coupling of a variety of acetylenes 
and electrophiles with ketone linchpin 1.29a. Reduced enantioselectivity observed with 
highly sterically encumbered acetylenes can be attenuated with increased catalyst 
loading to permit good to excellent enantioselectivity. This tactic enables effective 
diversity-oriented synthesis by virtue of, not only a three-component nature, but also the 
control over absolute configuration that is exerted via the application of either (S)-
Ph2BINOL-1.24 or (R)-Ph2BINOL-1.24. With respect to the expansion of ARC, there are 
now linchpins and tactics that permit not only stereoretentive and diastereoselective 
processes, but enantioselective reaction sequences as well, demonstrating the breadth 




Figure 1-5: Catalyst Loading Experiments with Hindered Silyl Acetylenes 








1-3: Novel Difluoromethylene Type II Anion Relay Chemistry (ARC) 
Linchpin Employing Fluorine as an Anion Stabilizing Group (ASG) 
During the course of our investigation of novel Type II ARC linchpins several 
different Anion Stabilizing Groups (ASGs) have been explored (Figure 1-6). While the 
1,3-dithiane (1.44) moiety is by far the most frequently employed ASG, other groups 
have proven effective, including nitrile (1.45), vinyl/aryl (1.46), benzyl (1.47), and phenyl 
sulfide (1.48) functionalities.25 The prevalence the 1,3-dithiane moiety as the principle 
ASG can be attributed primarily to the versatility of this functional group. Hydrolysis of 
1,3-dithiane affords a carbonyl, which may in many applications play a direct role in 
natural product synthesis, via spiroketalization or stereoselective reduction, among 
others. However, in other cases the 1,3-dithiane moiety must be reduced to the 
methylene, typically employing Raney Ni or nBu3SnH. For certain applications such 
harsh conditions are feasible, but in more sensitive substrates, such as those bearing 
alkenes, removal of the ASG is difficult to achieve selectively. In such cases, the ideal 
ASG would not require removal and would be either a part of the target framework or a 
desirable functional group to incorporate in the target. To this end, we turned our 
attention to the potential of fluorine as a chemically inert anion stabilizing group.  
Figure 1-6: Anion Stabilizing Groups (ASGs) in Type II ARC Linchpins 
Figure 6  
 
Organofluorine compounds are ubiquitous in modern society, with 
polyfluorotetraethylene (PFTA) polymers and hydrofluorocarbon (HFC) refrigerants 
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seeing widespread use.26 Over the last several decades, the role of fluorine in small 
molecule therapeutics has gained significant attention, with approximately 20% of 
approved active pharmaceutical ingredients and 35% agrochemicals containing at least 
one fluorine atom.27 The strong polarization of the C – F bond, in conjunction with the 
short bond length and small Van der Waals radius of the fluorine atom, results in a 
variety of useful properties.28 In medicinal chemistry, these properties manifest in myriad 
ways, permitting fluorine to serve as an isostere,29 modifying the basicity and acidity of 
adjacent functional groups,30 altering the solubility of compounds,31 modifying 
metabolism,32 and/or control of the conformation of structures,33 among other attributes. 
Accordingly, numerous methods for the incorporation of fluorine atoms into 
organic compounds have been developed, which utilize either direct or indirect 
fluorination tactics. A single fluorine atom may be added directly, utilizing reagents such 
as DAST or Selectfluor. Alternatively, an organofluorine reagent such as the Rupert-
Prakash reagent (1.49), already possessing fluorine substitution, may be employed to 
functionalize an organic compound (Figure 1-7).34 Ideally, fluorination could be 
performed as a convergent synthetic step, permitting the reaction to serve as a point of 
diversification, which is often desirable from the perspective of the medicinal chemist. To 
act as a convergent manner, such a synthon requires a divalent nature, such as 1.50. 
Figure 1-7: Mono- and Di-Valent Organofluorine Synthons 
Figure 7  
 
Recently, Dilman has exploited di-valent difluoromethylene synthons for use in 
multi-component coupling tactics (Figure 1-8a).35 While highly effective, this method 
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lacks a broad scope of coupling partners and requires multiple steps to achieve. We 
reasoned that a one-pot three-component ARC coupling tactic could be achieved by 
employing an ambiphilic linchpin in which the anionic carbon is stabilized by geminal 
fluorine substituents. In a manner analogous to our previous work with Type II ARC, we 
envisioned a tactic comprising [1,2]-addition of an organolithium reagent to aldehyde 
linchpin 1.51 to afford an alkoxide intermediate (1.52), and [1,4]-Brook rearrangement of 
alkoxide 1.52 with electrophile capture to afford a three-component adduct (1.53), with 
the relative stereochemistry of the three-component adduct under Felkin-Anh 
stereocontrol (Figure 1-8b). Such a method would hold great promise if the scope of 
each component was broad, the diastereoselectivity high, the reaction performed in a 
single flask, and the linchpin readily constructed.  
Figure 1-8: Development of Organofluorine Linchpin Concept 
Figure 8  
 
We set out first to validate a synthetic route to access diverse linchpins (1.51), 
which would be amenable to varied substitution at the α-position.  Drawing inspiration 
from the work of Mikami and co-workers, we sought to construct the β-difluoro-linchpins 
via a direct α-silyldifluoromethylation of an oxazolidinone derived lithium enolate.36 
Initially, oxazolidinone 1.54a was acylated with an acid chloride to afford 1.55a (Scheme 
1-8).  Next, the lithium enolate of 1.55a was generated with LiHMDS and subsequently 
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α-silyldifluoro-methylated, to furnish 1.56a as a single diastereomer. The absolute 
stereochemistry of 1.56a was unambiguously determined by X-ray crystallography.  
Finally, the desired linchpin was obtained via reduction of oxazolidinone 1.56a with 
LiAlH4 to provide 1.57a, followed by oxidation of alcohol 1.57a with Dess-Martin 
Periodinane (DMP) to afford 1.58a in good yield. Following this synthetic sequence 
linchpins 1.58b and 1.58d were also prepared, with 1.58c and 1.58e prepared following 
a similar sequence with only minor modifications. 
Scheme 1-8: Synthesis of Difluoromethylene Linchpins 
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With the desired linchpin 1.58a in hand, we next sought to validate the proposed 
reaction sequence (Figure 1-9). High diastereoselectivity of the initial [1,2]-addition was 
deemed critical for the utility of this transformation. We thus first performed the initial 
[1,2]-addition of n-BuLi to linchpin 1.58a at -78 °C in Et2O, and subsequently quenched 
the reaction with HCl in Et2O to arrive at alcohols 1.59a and 1.59b as separable 
diastereomers. High diastereoselectivity was observed (9:1 by 1H-NMR analysis), with 
the absolute configuration of 1.59a determined by Mosher ester analysis, demonstrating 
that Felkin-Anh diastereoselectivity was operative (Table 1-3).20 Next, deprotonation of 
1.59a was achieved with n-BuLi at -78 °C in Et2O and benzaldehyde added. The 
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required [1,4]-Brook rearrangement was then triggered by use of the polar additive 
HMPA. Pleasingly, tri-component adduct 1.60a was obtained in good yield as an 
expected 1:1 mixture of diastereomers at the benzylic position. Having demonstrated the 
proof-of-concept via a two-pot ARC sequence utilizing 1.58a, we next turned attention to 
validation of the one-pot, three-component coupling ARC tactic. To this end, employing 
the defined conditions, three-component adduct 1.60a was observed in modest yield as 
the major product from the one-pot reaction. 
Figure 1-9: Stepwise Evaluation of ARC Sequence 
Figure 9 
 
Having validated the ARC sequence, we turned to evaluation of the electrophile 
scope. Reactions were performed using n-BuLi as the nucleophile and linchpin 1.58a, 
with a variety of electrophiles (Figure 1-10).  Benzaldehyde was employed first, resulting 
in an improved yield of the three-component adduct 1.60a with TBAF silyl group removal 
prior to chromatography (Figure 1-9). Evaluation of (E)-cinnamaldehyde as an 
electrophile demonstrated that α,β-unsaturated aldehyde electrophiles are also 
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amendable to the ARC sequence to provide allyl alcohol 1.60b.  Next, a series of alkyl 
halide electrophiles were employed, with allyl and benzyl bromide affording three-
component adducts 1.60c and 1.60d in modest to moderate yield, and with MeI affording 
1.60e in good yield. Pleasingly, enantioenriched sulfonyl imine electrophiles also served 
as successful electrophiles in the ARC sequence, providing β-difluoroamine substrates 
as three-component adducts as single diastereomers; both (S)- and (R)-phenyl sulfonyl 
amine furnished ARC adducts 1.60f and 1.60g as single diastereomers in good yield. 
Additionally, employing the (R)-α,β-unsaturated sulfonyl imine of cinnamaldehyde 
permitted access to β-difluoro-allyl amine 1.60h. Thus, this ARC tactic holds the promise 
of a valuable method for the construction of enantioenriched β-difluoroamines, for which 
limited methods are currently available.37 
Table 1-3. 1H-NMR Chemical Shift Analysis of (R)- and (S)-Esters of 1.59a 
Table 3  
Nucleus δ (R)-ester (B) (ppm) δ (S)-ester (A) (ppm) ΔSR (ppm) 
1 0.86 0.89 0.03 
 2 1.2 1.25 0.05 
3 1.29 1.35 0.06 
4 1.5 1.61 0.11 
5 1.68 1.77 0.09 
6 2.12 2.12 0 
7 1.04 1.03 -0.01
8 0.2 0.18 -0.02
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Figure 1-10: Electrophile Scope Employing Organofluorine Linchpin 
Figure 10  
 
While there is no diastereoselectivity in the second [1,2]-addition for the ARC 
product when aldehydes electrophiles are employed, such diol products can be used to 
access difluorocyclopentyl ketals diastereoselectively. (Figure 1-11). Similar pseudo-
pentose structural motifs are found in a number of bioactive compounds, such as the 
approved drug Gemcitabine.38 For example, benzylic oxidation of 1.60a with MnO2 leads 
spontaneous to ketal formation to arrive at 1.61, as a 4:1 mixture of diastereomers in 
excellent yield. Thus, this tactic serves as a useful method to synthesize such ketals. 
Figure 1-11: Synthesis of Difluorocyclopentyl Ketal 




Next, our attention turned to the scope of organolithium reagents that could be 
employed as initiating nucleophiles in the ARC sequence. Standard reaction conditions 
were employed, utilizing linchpin 1.58a and MeI as the electrophile to evaluate a variety 
of organolithium reagents (Figure 1-12). Having demonstrated that alkyl lithium reagents 
were amenable to the ARC tactic, we next attempted commercially available PhLi. 
Accordingly, the three-component adduct 1.62a was obtained as a single diastereomer 
in good yield. Vinyl- and alkynyllithium reagents were also successfully employed to 
afford allyl- and propargyl alcohols 1.62b and 1.62c both in good yield and high 
diastereoselectivity.  Equally pleasingly, lithiated 1,3-dithiane can be utilized successfully 
in the ARC sequence, permitting the incorporation of this versatile functionality in adduct 
1.62d. Thus, alkyl, vinyl, alkynyl, aryl, and dithianyllithium reagents comprise viable 
nucleophiles in this three-component ARC coupling tactic.  
Figure 1-12: Nucleophile Scope Employing Organofluorine Linchpin 
Figure 12  
 
Arguably, the most significant aspect of this coupling tactic would be the 
tolerance on variability of the linchpin.  At this juncture, we had examined exclusively the 
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viability of linchpin 1.58a, bearing an α-Me substitution. While this substitution is useful 
for polyketide synthetic targets, larger substituents or functional handles would serve to 
provide access to a more diverse pool of difluoromethylene scaffolds. We therefore set 
out to examine several linchpins with varied α-substitution.  For the evaluation of 
linchpins 1.58b-1.58e, standard reaction conditions were employed, utilizing n-BuLi as 
the nucleophile and MeI as the electrophile (Figure 1-13). Increasing the size of the 
substituent from Me to Et had no significant effect, arriving at the three-component 
adduct 1.63a in good yield. Olefin moieties were also well tolerated at the α-position, 
affording homoallyl and allyl products 1.63b and 1.63c. Pleasingly, Ph and vinyl α-
substitutions were also well tolerated, despite the expected increased acidity of the 
corresponding linchpins.  
Figure 1-13: Organofluorine Linchpin Scope 
Figure 13  
 
A number of synthetic methods are predicated upon the manipulation of 
difluoromethyl radicals.39 The σ-withdrawing, π-donating properties of the fluorine atom 
permit access to difluoromethyl radicals, anions,40 and carbenes.41 Mechanistic studies 
were performed to provide support for an anionic reaction mechanism for the [1,4]-Brook 
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rearrangement with alkylation (Scheme 1-9a). Here, the principle concern was the [1,4]-
Brook rearrangement, rather than the [1,2]-carbonyl addition. Thus, the ARC sequence 
was entered via the deprotonation of alcohol 1.59a. Next, the [1,4]-Brook rearrangement 
was triggered via the addition of a solution of benzaldehyde in Et2O/HMPA, with or 
without an equivalent of TEMPO. In both cases, three-component adduct 1.60a was 
obtained in good yield. Additionally, TEMPO adduct 1.64 was not identified in the 
trapping experiment. Next, to offer support for a [1,4]-Brook rearrangement we 
demonstrated the isolation of silyl ether ARC product 1.65 (Scheme 1-9b). The labile 
nature of TMS ethers led us to remove this group prior to purification for simplicity. 
However, isolation of 1.65 here demonstrates that C – Si to O – Si migration indeed 
occurs. 
Scheme 1-9: Mechanistic Studies 




In summary, we disclose here a new ambiphilic organodifluoromethylene synthon 
which can be employed in a three-component ARC coupling tactic to afford a variety of 
difluoromethylene adducts with high diastereoselectivity.  Moreover, we have disclosed a 
synthetic route that permits access to these β-difluorosilyl aldehyde linchpins in which 
the α-substituent and absolute stereochemical configuration can be readily controlled by 
selecting the appropriate acid chloride and oxazolidione substrates, respectively, many 
of which are commercially available. The value of this synthon and the corresponding 
three-component coupling tactic is also apparent in the great variety of nucleophiles, 
linchpins, and electrophiles that can be employed.   Thus, one can envision numerous 
difluoromethylene scaffolds that can be prepared employing this tactic as a key 


















We have reported here the further development of our highly effective multi-
component Anion Relay Chemistry (ARC) coupling tactic in new areas, including 
asymmetric catalysis and organofluorine chemistry. 
Although the recently developed [3+2] annulation ARC afforded high 
diastereoselectivity, products of these reactions were racemic unless an enantioenriched 
bifunctional linchpin was employed. Thus, all of our previously disclosed Type II ARC 
tactics necessitated an enantioenriched bifunctional linchpin to afford diastereoselectivity 
via Felkin-Anh control or simple stereoretention. By merging BINOL catalyzed 
asymmetric [1,2]-additions with Type II ARC we were able to overcome this issue and 
exert absolute stereocontrol by employing an enantioenriched catalyst, thereby 
accessing enantioenriched three-component adducts with achiral bifunctional linchpins. 
 Additionally, ARC relies heavily on the use of an Anion Stabilizing Group (ASG), 
most commonly 1,3-dithiane to permit the [1,4]-Brook rearrangement and subsequent 
electrophile capture. While our group has explored this area before, this work has 
demonstrated that fluorine can serve as an effective ASG in ARC. This may prove useful 
to synthetic chemists wishing to avoid removal of the ASG and to take advantage of the 
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1-6: Experimental Section 
 1-6-a: General 
 All reactions were performed in flame- or oven-dried (120 °C) glassware under 
an atmosphere of nitrogen or argon. All aqueous work-ups were performed open to air 
and all organic solutions were dried over magnesium sulfate prior to filtration through a 
cotton plug and rotary evaporation. Reactions were magnetically stirred unless otherwise 
stated. Tetrahydrofuran (THF) and diethyl ether (Et2O) were dried by passage through 
alumina in a Pure SolveTM PS-400 solvent purification system.  Subsequently THF and 
Et2O were distilled from sodium/benzophenone prior to use. Unless otherwise stated, 
solvents and reagents were used as received. Thin layer chromatography (TLC) was 
performed on pre-coated silica gel 60 F-254 plates (40-55 micron, 230-400 mesh) and 
visualized by UV light or staining with p-anisaldehyde (acetic acid, sulfuric acid, and 
methanol) and heating. Yields refer to chromatographically and spectroscopically pure 
compounds unless otherwise noted. 1H-NMR and 13C-NMR spectra were recorded at 
500 MHz/125MHz on a Bruker Avance III 500 MHz spectrometer at 300 K, `H-NMR, 13-
CNMR and 19F-NMR spectra were also recorded at 400 MHz/100 MHz/76 MHz on a 
Bruker NEO-400 NMR. Chemical shifts are reported in parts per million with the residual 
chloroform solvent peak (δ 7.26) as an internal standard. 1H-NMR spectra are tabulated 
in the following manner: chemical shift (multiplicity, coupling constant, integration). The 
following abbreviations were used to explain the multiplicities: s=singlet, d=doublet, 
t=triplet, q=quartet, dd=doublet of doublets, ddd=doublet of doublet of doublets, 
dt=doublet of triplets, td=triplet of doublets, tt=triplet of triplets, qt=quartet of triplets, 
m=multiplet. 13C-NMR spectra are tabulated by observed peak. Supercritical Fluid 
Chromatography (SFC) analyses were performed with a JASCO system equipped with a 
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Chiralcel® AD-H column (5 µm, 4.6 mm x 250 mm), a PU-280-CO2 plus CO2 Delivery 
System, a CO-2060 plus Intelligent Column Thermostat, an HC-2068-01 Heater 
Controller, a BP-2080 plus Automatic Back Pressure Regulator, an MD-2018 plus 
Photodiode Array Detector (200-648 nm), and PU-2080 plus Intelligent HPLC Pumps. 
High-resolution mass spectra (HRMS) were acquired on a Waters LC-TOF mass 
spectrometer (model LCT-XE Premier) at the University of Pennsylvania. 
1-6-b: General Procedures 
1-6-b-1: Catalyst Synthesis 
 
 (R)- and (S)-1.24 were prepared as previously reported (Angew. Chem. 
Int. Ed. 2003, 52, 9266-9270) – spectral data matches reported values. 1H-NMR (500 
MHz, CDCl3) δ 8.03 (s, 2 H), 7.93 (d, J = 8.7 Hz, 2 H), 7.75 (d, J = 7.4 Hz, 4 H), 7.51 (t, J 
= 7.5 Hz, 4 H), 7.44 –7.39 (m, 4 H), 7.33 (t, J = 8.1 Hz, 2 H), 7.25 (d, J = 8.7 Hz, 2 H), 
5.38 (s, 2 H); 13C-NMR (125 MHz, CDCl3) δ 150.1, 137.4, 132.9, 131.4, 130.7, 126.9, 
129.4, 128.5, 128.4, 127.7, 127.3, 124.3, 124.2, 112.4; IR (thin film, NaCl) vmax 3450 (br), 
2977, 2934, 2863, 2803, 1905, 1635, 1490, 1444, 1415, 1350, 1297, 1122, 1077, 934, 
845 cm-1; [α]D22 = +84.5 (c 1.2 mg/mL, CHCl3); HRMS (ES) m/z (M+) Calculated for 




1-6-b-2: Synthesis of Achiral Linchpins 
 To a solution of bis(trimethylsilyl)acetylene (6.5 mL, 29 mmol, 1.09 eq) 
and acetyl chloride (1.92 mL, 27 mmol, 1.0 eq) in CH2Cl2 (54 mL, 0.5M) was added 
portion-wise AlCl3 (4.3 g, 32.0 mmol, 1.2 eq). After 1 h at 0 °C the reaction was 
quenched by the addition of 0.5 M HCl and allowed to stir for 1 h at 0 °C. The reaction 
mixture was warmed to RT then extracted 2 x with 20 mL CH2Cl2, dried over MgSO4, 
and concentrated in vacuo to provide the crude product. Product purified by short path 
distillation (40 mbar, 90-100 °C bath temperature) to afford acetylene intermediate as a 
colorless oil. Acetylene intermediate (2.88 g, 20.53 mmol, 1.0 eq) dissolved in i-PrOH 
(41 mL, 0.5 M) then 1,3-propanedithiol (2.06 mL, 20.53 mmol, 1.0 eq) added. Next, the 
mixture was cooled to 0 °C then t-BuOK (1.15 g, 10.3 mmol, 0.5 eq) added portion-wise. 
After 1 h at 0 °C the reaction was diluted with dH2O (20 mL) and brine (20 mL). 
Extracted with Et2O (2 x 20 mL), washed with brine (20 mL), then dried over MgSO4. 
Purified by silica gel chromatography (3% EtOAc/Hex) to afford 1.29a as a colorless oil 
(4.8 g, 71%). 1H-NMR (500 MHz, CDCl3) δ 3.33 (s, 2 H), 3.09 (dd, J = 13.1, 2.6 Hz, 2 H), 
2.52 (dt, J = 14.1, 4.0 Hz, 12 H), 2.30 (s, 3 H), 2.14-2.08 (m, 1 H), 1.91 (qt, J = 12.9, 3.4 
Hz, 1 H), 0.22 (s, 9 H); 13C-NMR (125 MHz, CDCl3) δ 207.0, 50.3, 34.8, 32.2, 24.7, 23.9, 
-2.7; IR (thin film, NaCl) vmax 3379 (br), 2932, 2246, 1490, 1375, 1248, 1132, 1068, 910, 




 To a solution of tert-butyldimethylsilyl acetylene (4.5 mL, 24.2 mmol, 
1.0 eq) in THF (31 mL, 0.78 M) at -78 °C was added n-BuLi (11.1 mL, 26.6 mmol, 1.1 
eq, 2.4 M). After 20 min at -78 °C acetaldehyde (1.56 mL, 27.8 mmol, 1.15 eq) was 
added. The mixture was allowed to gradually warm to RT then quenched by the addition 
of saturated NH4Cl. Extracted with Et2O (2 x 20 mL), dried over MgSO4, and 
concentrated in vacuo to provide crude product as a yellow oil. The crude product was 
dissolved in CH2Cl2 (160 mL, 0.15 M) then MnO2 (10.5 g, 121 mmol, 5.0 eq) was added. 
The mixture was allowed to stir for 48 h then filtered through celite and concentrated in 
vacuo to afford crude product as a colorless oil. Crude product (4.42 g, 24.24 mmol, 1.0 
eq) dissolved in i-PrOH (48 mL, 0.5 M) then 1,3-propanedithiol (2.43 mL, 24.24 mmol, 
1.0 eq) added. Next, the mixture was cooled to 0 °C then t-BuOK (1.36 g, 12.12 mmol, 
0.5 eq) was added portion-wise. After 1 h at 0 °C the reaction was diluted with dH2O (20 
mL) and brine (20 mL). Extracted with Et2O (2 x 20 mL), washed with brine (20 mL), then 
dried over MgSO4. Purified by silica gel chromatography (3% EtOAc/Hex) to afford 1.29b 
as a colorless oil (3.9 g, 56%). 1H-NMR (500 MHz, CDCl3) δ 3.40 (s, 2 H), 3.08 (dd, J = 
13.2, 2.7 Hz, 2 H), 2.49 (t, J = 4.1 Hz, 1 H), 2.46 (t, J = 4.1 Hz, 1 H), 2.31 (s, 3 H), 2.10-
2.45 (m, 1 H), 1.88 (qt, J = 12.7, 3.2 Hz, 1 H), 1.03 (s, 9 H), 0.23 (s, 6 H); 13C-NMR (125 
MHz, CDCl3) δ 207.0, 51.6, 36.0, 32.4, 28.6, 24.4, 24.3, 20.0, -5.8; IR (thin film, NaCl) 
vmax 2929, 2899, 2856, 2714, 2348, 2249, 1725, 1700, 1471, 1424, 1391, 1353, 1290, 
1271, 1248, 1173, 1006, 955, 914, 821, 772, 734, 693 cm-1; HRMS (ES) m/z (M+): 
Calculated for C13H26OS2Si: 290.1194; observed: 290.1198. 
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 To a solution of trimethylsilyl-1,3-dithiane (1.2 g, 6.23 mmol, 1.0 eq) in 
THF at -30 °C was added n-BuLi (1.19 mL, 6.85 mmol, 1.1 eq, 2.4 M). The mixture was 
allowed to stir at -30 °C for 1 h, then bromoacetaldehyde dimethyl acetal (810 µL, 6.85 
mmol, 1.1 eq) added neat. The reaction was maintained at -30 °C for 2 h, then warmed 
to RT and 3M HCl (5 mL) was added. The reaction mixture was stirred vigorously 
overnight. Next, brine (25 mL) was added and the reaction mixture was extracted with 
Et2O (3 x 30 mL), dried over MgSO4, and concentrated in vacuo. The crude product was 
purified by silica gel chromatography (5% EtOAc/Hex) to afford 1.42a as a pale yellow 
solid (630 mg, 43%). 1H-NMR (500 MHz, CDCl3) δ 9.79 (t, J = 3.1 Hz, 1 H), 3.17 (d, J = 
3.11, 2 H), 3.03 (dd, J = 12.3, 2.6 Hz, 2 H), 2.56 (t, J = 4.1 Hz, 1 H), 2.53 (t, J = 4.1 Hz, 1 
H), 2.13 – 2.08 (m, 1 H), 1.94 (qt, J = 12.5, 3.2 Hz, 1 H), 0.23 (s, 9 H); 13C-NMR (125 
MHz, CDCl3) δ 201.2, 49.0, 33.9, 24.5, 23.5, -3.25; IR (thin film, NaCl) vmax 2951, 2901, 
2830, 1715, 1424, 1250, 1047, 910, 843, 730, 649, 559, 548, 525 cm-1; HRMS (ES) m/z 
(M+) Calculated for C9H18OS2Si: 234.0568; observed: 234.0569. 
Procedure performed as described for 1.42a using tert-butyldimethylsilyl-
1,3-dithiane (2g, 8.53 mmol, 1.0 eq), n-BuLi (3.8 mL, 9.38 mmol, 1.1 eq, 2.4 M), 
bromoacetaldehyde dimethyl acetal (1.1 mL, 9.38 mmol, 1.1 eq) to afford 1.42b as a 
yellow oil (1.95 g, 83%). 1H-NMR (500 MHz, CDCl3) δ 9.85 (t, J = 3.1 Hz, 1 H), 3.27 (d, J 
= 3.3 Hz, 2 H), 3.04 (dd, J = 12.5 Hz, 2.8 Hz, 1 H), 3.01 (dd, J = 12.5, 2.8 Hz, 1 H), 2.52 
(dd, J = 4.4, 3.3 Hz, 1 H), 2.50 (dd, J = 4.4, 3.3 Hz, 1 H), 2.11-2.05 (m, 1 H), 1.99 – 1.90 
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(m, 1 H), 1.06 (s, 9 H), 0.22 (s, 6 H); 13C-NMR (125 MHz, CDCl3) δ 201.5, 49.7, 35.7, 
28.3, 24.4, 23.6, 19.7, -6.1; IR (thin film, NaCl) vmax 2931, 2899, 2857, 2742, 1716, 1657, 
1471, 1436, 1425, 1392, 1363, 1278, 1251, 1046, 1007, 910, 882, 837, 762, 733, 690, 
670, 647, 582, 539 cm-1; HRMS (ES) m/z (M+) Calculated for C12H24OS2Si: 276.1038; 
observed: 276.1062. 
1-6-b-2: General Procedure – [1,2]-Addition without [1,4]-Brook 
Rearrangement 
 
To a cooled solution of phenylacetylene (1.0 – 2.0 equiv) and Ph2BINOL (10 mol%) in 
THF (0.5 M) under argon at -78 °C was added n-BuLi (1.2 – 2.2 equiv, 2.5 M in hexanes) 
dropwise.  The reaction mixture was stirred for 1 h at -78 °C. In a separate flask, linchpin 
(1 equiv) was dissolved in THF (2 M) and added to the reaction mixture over a period of 
time (20 seconds – 30 minutes) by carefully running the solution down the side of the 
flask. Once the addition was complete, the reaction was allowed to stir for an additional 
2 h at -78 °C, then HCl (1.5 – 2.5 eq, 2.0 M in Et2O) was added and the mixture was 
warmed to RT. The reaction mixture was diluted with Et2O and a saturation NH4Cl 
solution was added.  The phases were separated, and the aqueous phase was extracted 




 Following the general procedure using phenylacetylene (44 µL, 
0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL), n-BuLi (200 µL, 
0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), HCl (300 µL, 6.0 
mmol, 2.0 M in Et2O). Purified by silica gel chromatography (5% EtOAc/Hexanes) to 
afford 1.30a as a colorless oil. SFC ChiralPak® AD-H column, 5% MeOH/CO2, 4mL/min, 
12 MPa, tmajor = 4.5 min, tminor = 3.5 min.  1H-NMR (500 MHz, CDCl3) δ 7.40 – 7.39 (m, 2 
H), 7.30 – 7.28 (m, 3 H), 4.90 (s, 1 H), 3.28 (dd, J = 13.1, 3.0 Hz, 1 H), 3.17 (J = 13.1, 
3.0 Hz, 1 H), 2.81 (d, J = 15.3 Hz, 1 H), 2.70 (d, J = 15.3 Hz, 1 H), 2.54 (t, J = 4.0 Hz, 1 
H), 2.51 (t, J = 4.0 Hz, 1 H), 2.10 – 2.05 (m, 1 H), 1.91 (qt, J = 12.5, 3.3 Hz, 1 H), 1.68 
(s, 3 H),  0.34 (s, 9 H); 13C-NMR (125 MHz, CDCl3) δ 131.3, 128.2, 128.1, 123.0, 95.1, 
84.2, 67.8, 47.5, 36.6, 33.8, 24.3, 24.6, 24.1, -1.7. IR (thin film, NaCl) vmax 3391 (br), 
2917, 2848, 2247, 1489, 1247, 1132, 1068, 1027, 914, 820, 755, 714, 690 cm-1; HRMS 
(ES) m/z (M+): Calculated for C18H26OS2Si: 350.1194; observed: 350.1215. 
 Following General Procedure A using phenylacetylene (44 µL, 0.4 
mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL), n-BuLi (200 µL, 0.48 
mmol, 2.4 M), linchpin 1.29b (116 mg, 0.4 mmol) in THF (200 µL), HCl (300 µL, 6.0 mmol, 2.0 
M in Et2O). Purified by silica gel chromatography (5% EtOAc/Hexanes) to afford 1.30b as a 
colorless oil. SFC ChiralPak® AD-H column, 5% MeOH/CO2, 1mL/min, 12 MPa, tmajor = 17.7 
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min, tminor = 16.5 min.  1H-NMR (500 MHz, CDCl3) δ 7.42-7.40 (m, 2 H), 7.30 – 7.29 (m, 3 H), 
4.87 (s, 1 H), 3.31 (ddd, J = 14.1, 11.3, 2.8 Hz, 1 H), 3.16 (ddd, J = 14.3, 11.1, 3.2 Hz, 1 H), 2.73 
(q, J = 15.5 Hz, 2 H), 2.63 – 2.56 (m, 2 H), 2.06 – 2.02 (m, 1 H), 1.97 – 1.92 (m, 1 H), 1.67 (s, 3 
H), 1.09 (s, 9H), 0.35 (s, 3 H), 0.32 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 131.4, 128.2, 128.1, 
123.1, 95.4, 84.2, 68.0, 50.1, 37.7, 33.7, 28.7, 25.8, 25.4, 24.0, 20.3, -4.9, -5.0. IR (thin film, 
NaCl) vmax 3401 (br), 3056, 2928, 2855, 1947, 1621, 1597, 1572, 1489, 1442, 1424, 1361, 1270, 
1198, 1167, 1128, 1069, 967, 914, 871, 835, 691, 673, 616, 579, 498, 471 cm-1; HRMS (ES) m/z 
(M+): Calculated for C21H32OS2Si: 392.1664; observed: 392.1664. 
 
1-6-b-3: General Procedure – Optimization of ARC Sequence 
 
To a cooled solution of phenylacetylene (1.0 equiv) and Ph2BINOL (10 mol%) in THF 
(0.5 M) under argon at -78 °C was added n-BuLi (1.2 – 2.2 equiv, 2.5 M in hexanes) 
drop-wise.  The reaction mixture was stirred for 1 h at -78 °C. In a separate flask, 
linchpin 1.29a (1 equiv) was dissolved in THF (2 M) and added to the reaction mixture 
over a period of 10 mins by carefully running the solution down the side of the flask. 
Once the addition was complete, the reaction was stirred for an additional 2 h at -78 °C, 
then BnBr (1 – 2 equiv) was added neat. Next the reaction mixture was warmed to a 
temperature ranging from -78 °C to 50 °C, and maintained at that temperature for 1 – 24 
h. Subsequently, the reaction mixture was warmed or cooled to RT and diluted with 
Et2O, then saturated NH4Cl was added. The phases were separated, and the aqueous 
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phase was extracted with Et2O three times, washed with brine, and dried over MgSO4. 
1H-NMR analysis was performed on the crude product to compare ratio of 1.31:1.32. 
1H-NMR (500 MHz, CDCl3) δ 7.52 (d, J = 6.5 Hz, 2 H), 7.44 – 7.41 
(m, 2 H), 7.32 – 7.25 (m, 6 H), 3.70 (d, J = 13.4 Hz, 1 H), 3.48 (d, J = 13.4 Hz, 1 H), 3.15 
(dd, J = 11.8, 3.2 Hz, 1 H), 2.98 (dd, J = 11.8 Hz, 3.2 Hz, 1 H), 2.72 – 2.68 (m, 2 H), 2.45 
– 2.39 (m, 2 H), 2.06 – 2.01 (m, 1 H), 1.91 – 1.84 (m, 1 H), 1.68 (s, 3 H), 0.31 (s, 9 H); 
13C-NMR (125 MHz, CDCl3) δ 136.0, 131.8, 131.2, 128.4, 128.1, 127.6, 126.8, 123.1, 
94.3, 85.2, 69.7, 52.4, 47.9, 45.3, 34.6, 27.3, 26.9, 24.9, 2.1; IR (thin film, NaCl) vmax cm-
1; [α]D22 = +36.5 (c 1.8 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3055, 2927, 2895, 2854, 
2736, 2708, 2231, 1946, 1598, 1489, 1471, 1462, 1275, 1254, 1167, 1097, 1054, 1003, 
910, 871, 808, 777, 756 cm-1; HRMS (ES) m/z (M+): Calculated for C25H32OS2Si: 
440.1664; observed: 440.1660. 
1H-NMR (500 MHz, CDCl3) δ 7.45 – 7.43 (m, 2 H), 7.32-7.31 (m, 3 H), 
4.35 (t, J = 5.9 Hz, 1 H), 2.97 (m, 2 H), 2.83 (t, J = 3.5, 1 H), 2.80 (t, J = 3.4 Hz, 1 H), 
2.18-2.07 (m, 3 H), 1.90 – 1.82 (m, 1 H), 1.61 (s, 3 H), 0.24 (s, 9 H); 13C-NMR (125 MHz, 
CDCl3) δ 131.4, 131.13, 128.3, 122.8, 92.5, 84.9, 68.8, 50.7, 43.0, 31.66, 30.8, 25.5, 1.8; 
f[α]D22 = -14.0 (c 1.1 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3421 (br), 2952, 2897, 
2086, 1635, 1489, 1442, 1423, 1371, 1276, 1248, 1168, 1118, 1053, 1010, 911, 841, 
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690, 584, 525, 450, 418 cm-1; HRMS (ES) m/z (M+): Calculated for 350.1194; observed: 
350.1209. 
 
1-6-b-4: Determination of Absolute Configuration of [1,2]-Addition 
 
 To a cooled solution of trimethylsilyl acetylene (278 µL, 2.01 
mmol, 1.0 eq) and (R)-Ph2BINOL (1.24) (176 mg, 0.402 mmol, 20 mol%) in THF (4 mL, 
0.5 M) under argon at -78 °C was added n-BuLi (1.15 mL, 1.4 equiv, 2.45 M) drop-wise.  
The reaction mixture was stirred for 1 h at -78 °C. In a separate flask, linchpin 1.29a (1 
equiv) was dissolved in THF (2 M) and added to the reaction mixture over a period of 10 
min. Once the addition was complete, the reaction was allowed to stir for an additional 2 
h at -78 °C.  Next, the flask was removed from the dry-ice acetone bath and allowed to 
warm to room temperature then quenched by the addition of sat. NH4Cl (10 mL). The 
phases were separated, and the aqueous phase extracted with Et2O (3 x 10 mL).  The 
organic phases were pooled, washed with brine, dried over MgSO4, and concentrated by 
rotary evaporation.  The crude product was purified by silica gel chromatography (1% 
EtOAc/Hex) to afford 1.34 as a colorless oil (279 mg, 40%). 1H-NMR (500 MHz, CDCl3) 
δ 4.25 (t, J = 5.8 Hz, 1 H), 2.94 – 2.89 (m, 2 H), 2.81 – 2.78 (m, 2 H), 2.10 – 2.05 (m, 1 
H), 2.03 (dd, J = 5.8, 1.7 Hz, 2 H), 1.89 – 1.80 (m, 1 H), 1.50 (s, 3 H), 0.20 (s, 9 H), 0.17 
(s, 9 H); 13C-NMR (125 MHz, CDCl3) δ 108.9, 89.4, 68.6, 50.3, 42.9, 31.3, 30.8, 30.7, 
25.4, 1.8, 0.4; [α]D22 = -13.1 (c 5.4 mg/mL, CHCl3); IR (thin film, NaCl) vmax 2956, 2897, 
2859, 2829, 2655, 2483, 2167, 1942, 1422, 1372, 1339, 1275, 1248, 1167, 1116, 1097, 
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1051, 1012, 953, 909, 842, 759, 699, 635, 608, 593, 580, 566, 525, 517 cm-1; HRMS 
(ES) m/z (M+) Calculated for C15H30OS2Si2: 346.1277; observed: 346.1270. 
 
 
 To a solution of 1.34 in ACN/H2O (30 mL, 0.027 M, 10:1 ACN:H2O) was 
added CaCO3 (1.2 g, 12.07 mmol, 15 eq) and MeI (750 µL, 12.07 mmol, 15 eq) and the 
mixture was heated to 60 °C for 5 h. The mixture was cooled to RT, filtered, extracted 
with Et2O (3 x 15 mL), washed with brine (20 mL), dried over MgSO4, and concentrated 
in vacuo. Crude material dissolved in MeOH (13 mL, 0.06 M) cooled to 0 °C, then NaBH4 
(152 mg, 4.03 mmol, 5 eq) was added. The mixture was allowed to warm to RT and stir 
for 3 h then quenched with NH4Cl and diluted. Extracted with Et2O (3 x 15 mL), washed 
with brine (20 mL), dried over MgSO4, and concentrated in vacuo to afford the crude 
alcohol product. Crude material dissolved in THF (4 mL, 0.2 M) and TBAF (1.6 mL, 1.61 
mmol, 2 eq) added. The reaction was stirred for 1 h at RT then diluted with sat. NaCl, 
extracted with Et2O (3 x 15 mL), dried over MgSO4, and concentrated in vacuo. Crude 
product purified by silica gel chromatography to afford 1.35 as a colorless oil (70 mg, 
76%). 1H-NMR (500 MHz, CDCl3) δ 4.19 (td, J = 10.7, 3.1 Hz, 1 H), 3.93 (dt, 11.0, 4.1 
Hz, 1 H), 3.77 (s, 1 H), 2.50 (s, 1 H), 2.00 (ddd, J = 14.6, 10.0, 4.3 Hz, 1 H), 1.83 (dt, J = 
14.6, 4.3 Hz, 1 H); 13C-NMR (125 MHz, CDCl3) δ 86.9, 71.9, 68.6, 60.7, 43.3, 30.6; [α]D22 
= -12.2 (c 1.0 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3450 (br), 3293, 2980, 2934, 
2110, 1654, 1232, 1133, 1053, 1015, 913, 847, 667, 558, 423, 418, 408 cm-1; HRMS 




1-6-b-5: General Procedure – Asymmetric ARC Protocol 
To a cooled solution of acetylene (1.0 equiv) and Ph2BINOL (10 mol%) in THF (0.5 M) 
under argon at -78 °C was added n-BuLi (1.2 equiv, 2.5 M in hexanes) dropwise.  The 
reaction mixture was stirred for 1 h at -78 °C. In a separate flask, linchpin 1.29a (1.0 
equiv) was dissolved in THF (2 M) and added to the reaction mixture over a period of 10 
min by carefully running the solution down the side of the flask (Note: 1/10th of the 
volume of the overall ketone solution was added every minute for 10 minutes – this 
prevents the amount of ketone from exceeding the amount of catalyst present for each 
addition). Once the addition was complete, the reaction was allowed to stir for an 
additional 2 h at -78 °C.  Next, electrophile (2.0 equiv) was added dropwise to the 
reaction mixture and the reaction vessel was immediately removed from the dry-ice 
acetone bath and allowed to warm to room temperature.  The reaction was allowed to 
stir at room temperature for 2 h.  Subsequently, the reaction mixture was quenched by 
the addition of sat. NH4Cl. The phases were separated, and the aqueous phase 
extracted 2 times with Et2O.  The organic phases were pooled, washed with brine, dried 
over MgSO4, and concentrated by rotary evaporation.  The crude product was dissolved 
in THF (0.2 M) and TBAF (1.0 equiv) was added dropwise.  The reaction was allowed to 
stir for approximately 1 h at room temperature, then brine was added.  The phases were 
separated, and the aqueous phase was extracted two times with Et2O.  Organic phases 
pooled, dried with MgSO4, and concentrated to provide the crude product; which is 
purified by silica gel chromatography. 
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 Following the general procedure using 4-
methoxyphenylacetylene (52 µL, 0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 
mmol), THF (800 µL), n-BuLi (200 µL, 0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 
mmol) in THF (200 µL), benzyl bromide (95 µL, 0.8 mmol), TBAF (400 µL, 0.4 mmol, 1 
M), and THF (2 mL). Purified by silica gel chromatography (40% Et2O/Hexanes) to afford 
1.37a (124 mg, 99:1 er, 78%) as a colorless oil. SFC ChiralPak® AD-H column, 12% 
MeOH/CO2, 4mL/min, 12 MPa, tmajor = 8.72 min, tminor = 11.34 min.  1H-NMR (500 MHz, 
CDCl3) δ 7.52 (d, J = 7.6 Hz, 2 H), 7.35 (d, J = 9.0 Hz, 2 H), 7.32-7.29 (m, 3 H), 6.81 (d, 
J = 9 Hz, 2 H), 4.74 (s, 1 H), 4.01 (d, J = 14 Hz, 1 H), 3.78 (s, 3 H), 3.48 (d, J = 14 Hz, 1 
H), 3.01 (t, J = 12.5 Hz, 1 H), 2.73 (t, J = 14.5 Hz, 2 H), 2.54 (d, J = 15.5 Hz, 1 H), 2.39 
(d, J = 15.5 Hz, 1 H), 2.11-2.08 (m, 1 H), 1.85 (q, J = 12.5 Hz, 1 H), 1.63 (s, 3 H); 13C-
NMR (125 MHz, CDCl3) δ 159.7, 135.2, 132.8, 131.6, 127.8, 127.1, 114.8, 114.0, 92.2, 
85.8, 67.5, 55.3, 52.2, 46.4, 45.3, 32.6, 27.3, 26.5, 24.4; [α]D22 = +211.8 (c 0.8 mg/mL, 
CHCl3); IR (thin film, NaCl) vmax 3419 (br), 3059, 3028, 2929, 2835, 2358, 2223, 1889, 
1670, 1604, 1569, 1509, 1495, 1453, 1440, 1423, 1367, 1286, 1249, 1173, 1157, 1135, 
1106, 1030, 937, 920, 99, 873, 832, 774, 749, 645 cm-1; HRMS (ES) m/z (M+): 
Calculated for C23H26O2S2: 398.1374; observed: 398.1385. 
 Following the general procedure using 4-
fluorophenylacetylene (46 µL, 0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), 
THF (800 µL),  n-BuLi (200 µL, 0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in 
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THF (200 µL), benzyl bromide (95 µL, 0.8 mmol), TBAF (400 µL, 0.4 mmol, 1 M), and 
THF (2 mL). Purified by silica gel chromatography (20% Et2O/Hexanes) to afford 1.37b 
(154 mg, 97:3 er, 53%) as a colorless oil. SFC ChiralPak® AD-H column, 12% 
MeOH/CO2, 4mL/min, 12 MPa, tmajor = 4.80 min, tminor = 6.56 min.  1H-NMR (500 MHz, 
CDCl3) δ 7.49 (d, J = 6.4 Hz, 2 H), 7.41 – 7.38 (m, 2 H), 7.34 – 7.29 (m, 3 H), 6.98 (t, J = 
8.7 Hz, 2 H), 4.78 (s, 1 H), 3.95 (d, J = 13.9 Hz, 1 H), 3.49 (d, J = 13.9 Hz, 1 H), 3.18 
(ddd, J = 13.0, 12.4, 3.0 Hz, 1 H), 3.01 (ddd, J = 13.0 12.4, 3.0 Hz, 1 H), 2.75 (tt, J = 
14.3, 3.9 Hz, 2 H), 2.54 (d, J = 15.4 Hz, 1 H), 2.40 (d, J = 15.4 Hz, 1 H), 2.19 – 2.07 (m, 
1 H), 1.91 – 1.82 (m 1 H), 1.64 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 162.5 (d, J = 
249.7 Hz), 135.1, 133.2 (d, J = 8.3 Hz), 131.5, 127.8, 127.2, 118.7 (d, J = 3.2 Hz), 115.6 
(d, J = 22.3 Hz), 93.4 (d, J = 1.1 Hz), 84.8, 67.4, 52.1, 46.4, 45.4, 32.5, 27.2, 26.5, 24.4; 
[α]D22 = +135.5 (c 1.4 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3419 (br) 3060, 3029, 
2980, 2929, 2348, 1600, 1506, 1453, 1436, 1368, 1277, 1220, 1155, 11136, 1092, 1043, 
1013, 920, 836, 786, 749, 702, 621, 581 cm-1; HRMS (ES) m/z (M+): Calculated for 
C22H23FOS2: 386.1174; observed: 386.1172. 
 Following the general procedure using 4-
(trifluoromethyl)-phenylacetylene (61 µL, 0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 
0.04 mmol), THF (800 µL),  n-BuLi (200 µL, 0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 
0.4 mmol) in THF (200 µL), benzyl bromide (95 µL, 0.8 mmol), TBAF (400 µL, 0.4 mmol, 
1 M), and THF (2 mL). Purified by silica gel chromatography (40% Et2O/Hexanes) to 
afford 1.37c (62 mg, 93:7 er, 36%) as a colorless oil. SFC ChiralPak® AD-H column, 
12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 3.11 min, tminor = 5.43 min.  1H-NMR (500 
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MHz, CDCl3) δ 7.57 – 7.51 (m, 4 H), 7.48 (d, J = 4.8 Hz, 2 H), 7.34 – 7.29 (m, 3 H), 4.38 
(s, 1 H), 3.90 (d, J = 13.9 Hz, 1 H), 3.49 (d, J = 13.9 Hz, 1 H), 3.17 (ddd, J = 14.4, 12.0, 
2.5 Hz, 1 H), 3.00 (ddd, J = 14.6, 11.8, 2.4 Hz, 1 H), 2.80 – 2.72 (m, 2 H), 2.55 (d, J = 
15.5 Hz, 1 H), 2.43 (d, J = 15.5 Hz, 1 H), 2.12 – 2.07 (m, 1 H), 1.91 – 1.83 (m, 1 H), 1.65 
(s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 135.0, 131.6, 131.4, 130.2 (d, J = 32.7 Hz), 
128.5, 127.9, 127.2, 126.4, 125.3 (d, J = 3.7 Hz), 96.2, 84.5, 67.5, 52.1, 46.6, 45.5, 32.4, 
27.3, 26.5, 24.3; [α]D22 = +54.9 (c 1.5 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3405 (br), 
3061, 3030, 2981, 2929, 2848, 2229, 1922, 1683, 1615, 1574, 1514, 1495, 1454, 1436, 
1425, 1405, 1368, 1323, 1277, 1249, 1167, 1128, 1105, 1066, 1015, 938, 921, 909, 873, 
842, 749 cm-1; HRMS (ES) m/z (M+): Calculated for C23H23F3OS2: 436.1142; observed: 
436.1155. 
Following the general procedure using trimethylsilyl acetylene (1.36di) 
(55 µL, 0.4 mmol), (R)-Ph2-BINOL-(1.24)  (17.5 mg, 0.04 mmol), THF (800 µL),  n-BuLi 
(200 µL, 0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), benzyl 
bromide (95 µL, 0.8 mmol), TBAF (400 µL, 0.4 mmol, 1 M), and THF (2 mL). Purified by 
silica gel chromatography (20% Et2O/Hexanes) to afford 1.37d (116 mg, 90:10 er, 73%) 
as a colorless oil. SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, 
tmajor = 3.30 min, tminor = 6.02 min.  1H-NMR (500 MHz, CDCl3) δ 7.46 (d, J = 7.1 Hz, 2 H), 
7.33 – 7.28 (m, 3 H), 4.75 (s, 1 H), 3.84 (d, J = 14.0 Hz, 1 H), 3.49 (d, J = 14.0 Hz, 1 H), 
3.14 (ddd, J = 14.6, 11.9, 2.3 Hz, 1 H), 3.14 (ddd, J = 14.6, 11.9, 2.3 Hz, 1 H), 2.72 (tt, J 
= 15.6, 3.4 Hz, 2 H), 2.68 (s, 1 H), 2.47 (d, J = 15.5 Hz, 1 H), 2.34 (d, J = 15.5 Hz, 1 H), 
2.11 – 2.05 (m, 1 H), 1.88 – 1.80 (m, 1 H), 1.57 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 
49 
 
135.1, 131.6, 127.8, 127.1, 88.5, 74.3, 66.9, 52.1, 46.3, 45.5, 32.6, 27.2, 26.6, 24.3; 
[α]D22 = +65.8 (c 4.6 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3419 (br), 3290, 3084, 
3060, 3028, 2980, 2929, 2852, 2829, 2107, 1953, 1888, 1716, 1652, 1602, 1583, 1532, 
1494, 1453, 1425, 1373, 1317, 1276, 1241, 1141, 1075, 917, 736, 701, 655, 583 cm-1; 
HRMS (ES) m/z (M+): Calculated for C16H20OS2: 292.0956; observed: 292.0970. 
 Following the general procedure using tert-butyldimethylsilyl 
acetylene (1.36dii) (75 µL, 0.4 mmol), (R)-Ph2-BINOL-(1.24)  (17.5 mg, 0.04 mmol), THF 
(800 µL),  n-BuLi (200 µL, 0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF 
(200 µL), benzyl bromide (95 µL, 0.8 mmol), TBAF (400 µL, 0.4 mmol, 1 M), and THF (2 
mL). Purified by silica gel chromatography (20% Et2O/Hexanes) to afford 1.37d (60 mg, 
72:28 er, 52%) as a colorless oil. SFC ChiralPak® AD-H column, 12% MeOH/CO2, 
4mL/min, 12 MPa, tmajor = 3.38 min, tminor = 6.12 min. [α]D22 = +13.1 (c 0.9 mg/mL, 
CHCl3); 1H-NMR / 13C-NMR / HRMS / IR same as reported for 16d with 15dii as 
acetylene. 
 Following the general procedure using cyclopropylacetylene (34 
µL, 0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL),  n-BuLi (200 
µL, 0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), benzyl 
bromide (95 µL, 0.8 mmol), TBAF (400 µL, 0.4 mmol, 1 M), and THF (2 mL). Purified by 
silica gel chromatography (20% Et2O/Hexanes) to afford 1.37e (133 mg, 91:9 er, 64%) 
as a colorless oil. SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, 
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tmajor = 2.84 min, tminor = 4.49 min.  1H-NMR (500 MHz, CDCl3) δ 7.47 (d, J = 6.9 Hz, 2 H), 
7.33 – 7.28 (m, 3 H), 4.58 (s, 1 H), 3.90 (d, J = 13.8 Hz, 1 H), 3.41 (d, J = 13.8 Hz, 1 H), 
3.16 (ddd, J = 14.5, 11.9, 2.4 Hz, 1 H), 2.97 (ddd, J = 14.5, 11.9, 2.4 Hz, 1 H), 2.7 (tt, 
12.8, 4.3 Hz, 2 H), 2.44 (d, J = 15.4 Hz, 1 H), 2.25 (d, J = 15.4 Hz, 1 H), 2.10 – 2.09 (m, 
1 H), 1.83 (qt, J = 12.4, 3.7 Hz, 1 H), 1.50 (s, 3 H), 1.32 – 1.26 (m, 1 H), 0.76 – 0.67 (m, 
4 H); 13C-NMR (125 MHz, CDCl3) δ 135.2, 131.5, 127.7, 127.1, 89.4, 79.9, 67.1, 52.2, 
46.3, 45.2, 32.8, 27.2, 26.4, 24.4, 7.8, 7.7, -0.4.; [α]D22 = +115.0 (c 0.6 mg/mL, CHCl3); 
IR (thin film, NaCl) vmax 3423 (br), 3085, 3060, 3027, 3007, 2978, 2927, 2849, 2236, 
1653, 1602, 1558, 1539, 1506, 1494, 1453, 1436, 1424, 1368, 1316, 1277, 1223, 1176, 
1141, 1120, 1093, 1074, 1050, 1030, 984, 936, 911, 872, 811, 749, 702, 631, 580, 544 
cm-1; HRMS (ES) m/z (M-H2O) Calculated for C19H24OS2: 314.1163; observed: 
314.1163. 
 
 Following the general procedure using hex-1-yne (46 µL, 
0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL),  n-BuLi (200 µL, 
0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), benzyl bromide 
(95 µL, 0.8 mmol), TBAF (400 µL, 0.4 mmol, 1 M), and THF (2 mL). Purified by silica gel 
chromatography (20% Et2O/Hexanes) to afford 1.37f (95 mg, 97:3 er, 68%) as a 
colorless oil. SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 
2.09 min, tminor = 2.70 min.  1H-NMR (500 MHz, CDCl3) δ 7.48 (d, J = 7.0 Hz, 2. H), 7.33 
– 7.28 (m, 3 H), 4.62 (s, 1 H), 3.94 (d, J = 13.8 Hz, 1 H), 3.43 (d, J = 13.9 Hz, 1 H), 3.17 
(ddd, 14.8, 12.0, 2.4 Hz, 1 H), 2.98 (ddd, J = 14.8, 12.0; 2.4 Hz, 1 H), 2.70 (tt, J = 14.3, 
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4.1 Hz, 2 H), 2.29 – 2.23 (m, 3 H), 2.10 – 2.05 (m, 1 H), 1.83 (qt, J = 11.7, 2.8 Hz, 1 H), 
1.52 (s, 3 H), 1.50 – 1.39 (m, 4 H), 0.88 (t, 7.3 Hz, 3 H); 13C-NMR (125 MHz, CDCl3) δ 
135.3, 131.5, 127.7, 127.1, 86.7, 84.7, 67.2, 52.2, 46.3, 45.2, 32.9, 30.4, 27.2, 26.4, 
24.4, 22.0, 18.5, 13.5; [α]D22 = +89.7 (c 4.1 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3433 
(br), 3060, 3028, 3586, 3566, 3433, 2234, 1171, 1733, 1717, 1699, 1684, 1653, 1646, 
1635, 1602, 1558, 1539, 1521, 1506, 1495, 1454, 1436, 1374, 1326, 1277, 1219, 1192, 
1140, 1073, 1031, 936, 910, 872, 748, 702, 580 cm-1; HRMS (ES) m/z (M-H2O) 
Calculated for C20H28OS2: 330.1476; observed: 330.1493. 
 Following the general procedure using benzyl propargyl 
ether (58 µL, 0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL),  n-
BuLi (200 µL, 0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), 
benzyl bromide (95 µL, 0.8 mmol), TBAF (400 µL, 0.4 mmol, 1 M), and THF (2 mL). 
Purified by silica gel chromatography (20% Et2O/Hexanes) to afford 1.37g (118 mg, 97:3 
er, 72%) as a colorless oil. SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 
12 MPa, tmajor = 5.48 min, tminor = 7.05 min.  1H-NMR (500 MHz, CDCl3) δ 7.46 (d, J = 6.4 
Hz, 2 H), 7.32 – 7.28 (m, 8 H), 4.68 (s, 1 H), 4.60 (d, J = 1.7 Hz, 2 H), 4.25 (s, 2 H), 3.83 
(d, J = 14.0 Hz, 1 H), 3.50 (d, J = 13.9 Hz, 1 H), 3.14 (ddd, J = 14.3, 11.8, 2.6 Hz, 1 H), 
3.00 (ddd, J = 14.3, 11.8, 2.6 Hz, 1 H), 2.73 (tt, J = 15.4, 4.3 Hz, 2 H), 2.49 (d, J = 15.4 
Hz, 1 H), 2.35 (d, J = 15.5 Hz, 1 H), 2.10 – 2.04 (m, 1 H), 1.84 (qt, J = 11.8, 3.2 Hz, 1 H), 
1.58 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 137.4 135.2, 131.5, 128.4, 128.0, 127.8, 
127.1, 91.0, 82.0, 71.7, 67.1, 57.6, 52.1, 46.6, 45.6, 32.6, 27.2, 26.6, 24.3; [α]D22 = -3.5 
(c 1.0 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3420 (br), 3085, 3060, 3028, 2925, 2853, 
52 
 
1954, 1683, 1602, 1495, 1453, 1436, 1355, 1276, 1214, 1091, 1074, 1028, 938, 909, 
848, 819, 748, 699 cm-1; HRMS (ES) m/z (M+): Calculated for C24H28O2S2: 412.1531; 
observed: 412.1526. 
 Following the general procedure using phenylacetylene (44 µL, 
0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL),  n-BuLi (200 µL, 
0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), BnBr (95 µL, 0.8 
mmol), TBAF (400 µL, 0.4 mmol, 1 M), and THF (2 mL). Purified by silica gel 
chromatography (20% Et2O/Hexanes) to afford 1.39a (88 mg, 97:3 er, 60%) as a 
colorless oil. SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 
5.74 min, tminor = 7.09 min.  1H-NMR (500 MHz, CDCl3) δ 7.52 (d, J = 7.4 Hz, 2 H), 7.44 – 
7.42 (m, 2 H), 7.34 – 7.29 (m, 6 H), 4.77 (s, 1 H), 4.00 (d, J = 13.9 Hz, 1 H), 3.49 (d, J = 
13.8 Hz, 1 H), 3.19 (t, J = 13.1 Hz, 1 H), 3.02 (t, J = 13.1 Hz, 1 H), 2.74 (t, J = 14.4 Hz, 2 
H), 2.55 (d, J = 15.5 Hz, 1 H), 2.42 (d, J = 15.4 Hz, 1 H), 2.09 (d, J = 13.8 Hz, 1 H), 1.86 
(q, J = 12.8 Hz, 1 H), 1.65 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 135.1, 131.6, 131.3, 
128.4, 128.3, 127.8, 127.1, 122.7, 93.6, 85.9, 67.5, 52.2, 46.4, 45.4, 32.5, 27.3, 26.5, 
24.4; [α]D22 = 1.9 (c 1.1 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3418 (br), 3082, 3059, 
3029, 2979 2929, 2829, 2336, 2225, 1952, 1882, 1810, 1752, 1675, 1597, 1572, 1489, 
1453, 1442, 1423, 1367, 1314, 1276, 1265, 1240, 1213, 1156, 1135, 1093, 1070, 1044, 
1031, 998, 937, 920, 873, 840, 816, 754, 701, 669, 622, 583, 571, 551, 523, 516, 502, 




 Following the general procedure using phenylacetylene (44 µL, 
0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL),  n-BuLi (200 µL, 
0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), allyl bromide (69 
µL, 0.8 mmol), TBAF (400 µL, 0.4 mmol, 1 M), and THF (2 mL). Purified by silica gel 
chromatography (20% Et2O/Hexanes) to afford 1.39b (83 mg, 97:3 er, 65%) as a 
colorless oil. SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 
4.31 min, tminor = 3.80 min.  1H-NMR (500 MHz, CDCl3) δ 7.41 – 7.40 (m, 2 H), 7.30 – 
7.29 (m, 3 H), 6.05 (dddd, J = 17.3, 10.1, 7.5, 7.5 Hz,  1 H), 5.22 (d, J = 27.7 Hz, 1 H), 
5.21 (s, 1 H), 4.85 (s, 1 H), 3.35 (dd, J = 14.8, 6.4 Hz, 1 H), 3.15 (ddd, J = 14.8, 12.8, 2.2 
Hz, 1 H), 3.05 (ddd, J = 14.8, 12.8, 2.2 Hz, 1 H), 2.97 (dd, J = 15.3, 8.9 Hz, 1 H), 2.78 – 
2.72 (m, 2 H), 2.64 (d, J = 15.4 Hz, 1 H), 2.41 (d, J = 15.3 Hz, 1 H), 2.14 – 2.09 (m, 1 H), 
1.88 (qt, J = 11.5, 2.8 Hz, 1 H), 1.62 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 132.2, 131.4, 
128.3, 122.7, 119.5, 93.3, 84.6, 67.2, 51.3, 47.0, 44.2, 32.7, 26.9, 26.3, 24.5; [α]D22 = 
+308.5 (c 1.3 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3399 (br), 3076, 2978, 2930, 2828, 
2250, 1489, 1472, 1441, 1424, 1374, 1277, 1251, 1139, 1089, 1070, 1047, 991, 918, 
818, 756, 691 cm-1; HRMS (ES) m/z (M+) Calculated for C18H22OS2: 318.1112; 
observed: 318.1122. 
 Following the general procedure using phenylacetylene (44 µL, 
0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL),  n-BuLi (200 µL, 
0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), 3-bromo-1-
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(trimethylsilyl)-propyne (131 µL, 0.8 mmol), TBAF (800 µL, 0.8 mmol, 1 M), and THF (2 
mL). Purified by silica gel chromatography (20% Et2O/Hexanes) to afford 1.39c (41 mg, 
98:2 er, 31%) as a colorless oil. SFC ChiralPak® AD-H column, 12% MeOH/CO2, 
4mL/min, 12 MPa, tmajor = 7.49 min, tminor = 6.25 min.  1H-NMR (500 MHz, CDCl3) δ 7.47 
– 7.45 (m, 2 H), 7.31 – 7.30 (m, 3 H), 4.53 (s, 1 H), 3.65 (dd, J = 17.1, 2.4 Hz, 1 H), 3.16 
– 3.03 (m, 3 H), 2.85 – 2.77 (m, 2 H), 2.68 (q, J = 14.4 Hz, 2 H), 2.25 (t, J = 2.6 Hz, 1 H), 
2.15 – 2.08 (m, 1 H), 1.96 – 1.88 (m, 1 H), 1.65 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 
131.7, 131.5, 128.3, 128.2, 92.6, 84.5, 78.9, 72.9, 67.3, 50.5, 46.9, 32.5, 31.4, 27.1, 
26.6, 24.3; [α]D22 = +117.0 (c 2.5 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3419 (br), 
3291, 3055, 2979, 2929, 2853, 2828, 2588, 2226, 2117, 1966, 1888, 1597, 1572, 1558, 
1539, 1533, 1521, 1516, 1489, 1442, 1423, 1367, 1289, 1277, 1242, 1158, 1139, 1100, 
1070, 1048, 1025, 936, 909, 872, 847, 817, 757, 735, 691, 647, 583, 560, 524 cm-1; 
HRMS (ES) m/z (M+) Calculated for C18H20OS2: 318.0955; observed: 316.0961. 
 Following the general procedure using phenylacetylene (44 µL, 0.4 
mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), n-BuLi (200 µL, 0.48 mmol, 2.4 M), 
linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), MeI (50 µL, 0.8 mmol), TBAF (400 
µL, 0.4 mmol, 1 M), and THF (2 mL). Purified by silica gel chromatography (20% 
Et2O/Hexanes) to afford 1.39d (106 mg, 98:2 er, 91%) as a colorless oil. SFC 
ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 8.75 min, tminor = 
5.71 min.  1H-NMR (500 MHz, CDCl3) δ 7.41 – 7.39 (m, 2 H), 7.30 – 7.29 (m, 3 H), 4.86 
(s, 1 H), 3.15 – 3.08 (m, 2 H), 2.77 – 2.71 (m, 3 H), 2.28 (d, J = 15.6 Hz, 1 H), 2.14 – 
2.10 (m, 1 H), 1.98 (s, 3 H), 1.86 (qt, J = 11.9, 2.5 Hz, 1 H), 1.62 (s, 3 H); 13C-NMR (125 
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MHz, CDCl3) δ 131.3, 128.2, 122.8, 93.3, 84.7, 67.4, 50.3, 47.5, 32.7, 29.3, 27.1, 26.9, 
24.3; [α]D22 = +91.2 (c 8.1 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3400 (br), 2978, 2929, 
2229, 1597, 1572, 1489 1442, 1423, 1373, 1276, 1240, 1144, 1077, 1046, 938, 907, 
870, 756, 691, 668, 659, 578, 550, 525, 508 cm-1; HRMS (ES) m/z (M+) Calculated for 
C16H20OS2: 292.0956; observed: 292.0955. 
 Following the general procedure using phenylacetylene (44 
µL, 0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL),  n-BuLi (200 
µL, 0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), 5-bromo-1-
pentene (95 µL, 0.8 mmol), TBAF (400 µL, 0.4 mmol, 1 M), and THF (2 mL). Purified by 
silica gel chromatography (20% Et2O/Hexanes) to afford 1.39e (36 mg, 98:2 er, 26%) as 
a colorless oil. SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor 
= 2.96 min, tminor = 2.73 min.  1H-NMR (500 MHz, CDCl3) δ 7.41 – 7.39 (m, 2 H), 7.30 – 
7.29 (m, 3 H), 5.75 – 5.67 (m, 1 H), 5.01 (s, 1 H), 4.88 (d, J = 25.6 Hz, 1 H), 4.87 (s, 1 
H), 3.16 (t, J = 14.3 Hz, 1 H), 3.04 (td, J = 14.5, 9.5 Hz, 1 H), 2.73 (tt, J = 13.8, 4.3 Hz, 2 
H), 2.67 (d, J = 15.4 Hz, 1 H), 2.53 – 2.50 (m, 1 H), 2.40 (d, J = 15.3 Hz, 1 H), 2.22 – 
2.11 (m, 1 H), 1.97 (q, J = 7.1 Hz, 2 H), 1.92 – 1.84 (m, 1 H), 1.78 – 1.68 (m, 2 H), 1.62 
(s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 138.2, 131.4, 128.2, 122.8, 114.8, 93.1, 84.1, 
67.2, 52.1, 46.5, 39.8, 33.8, 32.9, 26.9, 26.3, 24.8, 23.3; [α]D22 = +44.3 (c 3.2 mg/mL, 
CHCl3); IR (thin film, NaCl) vmax 3397 (br), 3075, 2977, 2929, 2848, 2247, 1489, 1472, 
1456, 1441, 1374, 1275, 1142, 910, 756, 691, 581 cm-1; HRMS (ES) m/z (M-H2O) 
Calculated for C20H26OS2: 328.1319; observed: 328.1336. 
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 Following the general procedure using phenylacetylene (44 µL, 
0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL),  n-BuLi (200 µL, 
0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), (R)-
epichlorohydrin (63 µL, 0.8 mmol). Silyl deprotection omitted for this entry. Purified by 
silica gel chromatography (10% EtOAc/89% Hexanes/1% PhMe) to afford 1.39f (128 
mg, >20:1 dr, 79%) as a colorless oil. 1H-NMR (500 MHz, CDCl3) δ 7.42 – 7.39 (m, 2 H), 
7.32 – 7.30 (m, 3 H), 3.35 – 3.31 (m, 1 H), 2.98 – 2.78 (m, 5 H), 2.62 – 2.49 (m, 5 H), 
2.00 – 1.92 (m, 2 H), 1.69 (s, 3 H), 0.25 (s, 9 H); 13C-NMR (125 MHz, CDCl3) δ 131.1, 
128.3, 128.2, 122.9, 93.5, 85.3, 69.3, 51.6, 51.3, 49.5, 47.2, 41.8, 33.9, 26.7, 26.6, 24.8, 
1.9; [α]D22 = +17.4 (c 2.3 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3048, 2953, 2829, 
2228, 1950, 1597, 1572, 1490, 1442, 1423, 1369, 1342, 1294, 1249, 1169, 1144, 1099, 
1069, 1000, 909, 841, 756, 737, 691, 586, 560, 538, 525, 518, 506, 501, 495, 488 cm-1; 
HRMS (ES) m/z (M+) Calculated for C21H30O2S2Si: 406.1457; observed: 406.1448. 
 Following the general procedure using phenylacetylene 
(44 µL, 0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL),  n-BuLi 
(200 µL, 0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), (S)-(+)-
benzyl glycidyl ether (123 µL, 0.8 mmol). Silyl deprotection omitted for this entry. Purified 
by silica gel chromatography (15% EtOAc/Hexanes) to afford 1.39g (76 mg, >20:1 dr, 
37%) as a colorless oil. 1H-NMR (500 MHz, CDCl3) δ 7.42 – 7.40 (m, 2 H), 7.33 (d, J = 
4.5 Hz, 4 H), 7.31 – 7.27 (m, 4 H), 4.54 (s, 2 H), 4.37 – 4.32 (m, 1 H), 3.48 (dd, J = 9.7, 
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4.4 Hz, 1 H), 3.42 (dd, J = 9.3 Hz, 6.4 Hz, 1 H), 3.34 (d, J = 3.4 Hz, 1 H), 2.96 – 2.89 (m, 
3 H), 2.84 – 2.79 (m, 1 H), 2.65 (d, J = 15.1 Hz, 1 H), 2.56 (d, J = 15.3 Hz, 1 H), 2.54 (d, 
J = 15.3 Hz, 1 H), 2.42 (dd, J = 15.3, 2.2 Hz, 1 H), 1.99 – 1.96 (m, 2 H), 1.70 (s, 3 H), 
0.23 (s, 9 H); 13C-NMR (125 MHz, CDCl3) δ 138.3, 131.2, 128.33, 128.31, 128.2, 127.2, 
127.5, 123.0, 93.8, 85.4, 74.7, 73.3, 69.7, 68.2, 51.6, 42.2, 33.8, 26.9, 26.8, 24.8, 2.1; 
[α]D22 = +3.5 (c 1.1 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3440 (br), 3061, 3030, 2918, 
2757, 2359, 2340, 1952, 1733, 1597, 1490, 1453, 1442, 1365, 1249, 1206, 1169, 1100, 
1027, 909, 842, 756, 692, 668, 653, 609, 549, 514, 507, 434 cm-1; HRMS (ES) m/z 
(M+H): Calculated for C28H38O3S2Si: 514.2032, observed: 514.2045. 
 Following the general procedure using phenylacetylene (44 µL, 
0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL),  n-BuLi (200 µL, 
0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), (S)-propylene 
oxide (56 µL, 0.8 mmol). Silyl deprotection omitted for this entry. Purified by silica gel 
chromatography (10% EtOAc/Hexanes) to afford 1.39h (95 mg, >20:1 dr, 58%) as a 
colorless oil. 1H-NMR (500 MHz, CDCl3) δ 7.42 – 7.40 (m, 2 H), 7.32 – 7.32 (m, 3 H), 
4.28 – 4.22 (m, 1 H), 3.95 (d, J = 3.4 Hz, 1 H), 2.89 – 2.81 (m, 3 H), 2.71 (d, J = 15.2 Hz, 
1 H), 2.58 (d, J = 15.2 Hz, 1 H), 2.49 (dd, J = 14.8, 9.4 Hz, 1 H), 2.36 (d, J = 15.2 Hz, 1 
H), 2.00 – 1.95 (m, 2 H), 1.17 (d, J = 6.2 Hz, 3 H), 0.30 (s, 3 H); 13C-NMR (125 MHz, 
CDCl3) δ 131.1, 129.5, 128.4, 122.9, 93.1, 85.6, 69.9, 64.3, 51.5, 50.1, 47.0, 34.6, 26.9, 
26.6, 25.0, 24.8, 2.0; [α]D22 = +267.0 (c 5.3 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3465 
(br), 2958, 2929, 2829, 2228, 1490, 1472, 1442, 1418, 1399, 1369, 1339, 1312, 1294, 
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1274, 1249, 1169, 1138, 1076, 1050, 1000, 975, 909, 872, 842, 756, 691 cm-1; HRMS 
(ES) m/z (M+) Calculated for C21H32O2S2Si: 408.1613; observed: 408.1641. 
 Following the general procedure using phenylacetylene (44 µL, 
0.4 mmol), (R)-Ph2-BINOL (1.24) (17.5 mg, 0.04 mmol), THF (800 µL), n-BuLi (200 µL, 
0.48 mmol, 2.4 M), linchpin 1.29a (100 mg, 0.4 mmol) in THF (200 µL), benzaldehyde 
(82 µL, 0.8 mmol). Purified by silica gel chromatography (10% EtOAc/Hexanes) to afford 
1.39i (111 mg, 99:1 er, 1.5:1 dr, 73%) as a colorless oil. SFC ChiralPak® AD-H column, 
12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 6.01 min, tminor = 4.92 min. 1H-NMR (500 
MHz, CDCl3) δ 7.68 – 7.66 (m, 3.5 H), 7.58 – 7.55 (m, 2 H), 7.46 – 7.41 (m, 6 H), 7.38 – 
7.30 (m, 18.6 H), 5.56 (s, 1.7 H), 5.39 (s, 1 H), 4.32 (s, 1 H), 4.23 (s, 1.7 H), 3.83 (s, 1.7 
H), 3.61 (s, 1 H), 3.10 – 3.04 (m, 1 H), 2.93 – 2.71 (m, 11.5 H), 2.50 (d, J = 15.6 Hz, 1.7 
H), 2.37 (d, J = 15.7 Hz, 1.7 H), 2.05 – 1.91 (m, 6.6 H), 1.64 (s, 5.3 H), 1.61 (s, 3 H); 13C-
NMR (125 MHz, CDCl3) δ 137.9, 137.7, 131.43, 131.40, 130.8, 128.9, 128.8, 128.5, 
128.3, 128.28, 128.24, 128.1, 127.9, 127.5, 127.4, 127.0, 126.4, 122.83, 122.80, 94.0, 
93.3, 85.4, 84.4, 75.9, 74.3, 67.2, 66.9, 57.8, 57.4, 48.8, 47.7, 33.0, 32.8, 30.3, 27.1, 
26.2, 26.0, 24.1; [α]D22 = +62.1 (c 4.7 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3355 (br), 
3031, 2979, 2928, 2348, 1489, 1442, 13374, 1276, 1133, 1026, 757, 735, 692 cm-1; 
HRMS (ES) m/z (M+) Calculated for C22H24O2S2: 384.1218; observed: 384.1207. 
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 Following the general procedure using phenylacetylene (44 µL, 
0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL),  n-BuLi (200 µL, 
0.48 mmol, 2.4 M), linchpin 1.42a (94 mg, 0.4 mmol) in THF (200 µL), BnBr (95 µL, 0.8 
mmol), TBAF (400 µL, 0.4 mmol, 1 M), and THF (2 mL). Purified by silica gel 
chromatography (10% EtOAc/Hexanes) to afford 1.43 (105 mg, 71:29 er, 74%) as a 
colorless oil. SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 
6.60 min, tminor = 5.87 min. 1H-NMR (500 MHz, CDCl3) δ 7.45-7.43 (m, 2 H), 7.38 (d, J = 
6.9 Hz, 2 H), 7.34-7.28 (m, 6 H), 5.11-5.10 (m, 1 H), 3.33 (q, J = 14.0 Hz, 2 H), 3.2 (d, J 
= 3.3 Hz, 1 H), 3.05 (dd, J = 10.4, 2.7 Hz, 1 H), 2.96 (dd, J = 10.4, 2.7 Hz, 1 H), 2.85-
2.79 (m, 2 H), 2.61 (dd, J = 15.4, 8.2 Hz, 1 H), 2.41 (dd, J = 15.4, 3.1 Hz, 1 H), 2.08-2.03 
(m, 1 H), 1.95-1.88 (m, 2 H); 13C-NMR (125 MHz, CDCl3) δ 134.9, 131.7, 131.6, 131.3, 
128.4, 128.3, 128.2, 127.9, 127.2, 122.5, 89.6, 85.0, 60.8, 52.0, 45.9, 44.5, 26.7, 26.4, 
24.5; [α]D22 = -18.3 (c 1.5 mg/mL, CHCl3); IR (thin film, NaCl) vmax 3430 (br), 3059, 3029, 
2973, 2900, 1975, 1684, 1598, 1570, 1490 1442, 1422, 1382, 1349, 1250, 1151, 1114, 
1070, 1029, 843, 757, 692, 566, 446 cm-1; HRMS (ES) m/z (M+) Calculated for 
C21H22OS2: 354.1112; observed: 354.1122. 
 Following the general procedure using phenylacetylene (44 µL, 
0.4 mmol), (R)-Ph2-BINOL-(1.24) (17.5 mg, 0.04 mmol), THF (800 µL),  n-BuLi (200 µL, 
0.48 mmol, 2.4 M), linchpin 1.42b (111 mg, 0.4 mmol) in THF (200 µL), BnBr (95 µL, 0.8 
mmol), TBAF (400 µL, 0.4 mmol, 1 M), and THF (2 mL). Purified by silica gel 
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chromatography (10% EtOAc/Hexanes) to afford 1.43 (94 mg, 71:29 er, 66%) as a 
colorless oil. SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 
6.52 min, tminor = 5.80 min. [α]D22 = -18.2 (c 1.9 mg/mL, CHCl3); Spectroscopic data 





1-6-b-6: Catalyst Loading Experiments: Silyl Acetylene Nucleophiles 
 
Each experiment followed General Procedure for ARC Protocol to couple a silyl 
acetylene (1.0 eq), ketone linchpin (1.0 eq), and BnBr (2.0 eq). Stoichiometry varied only 
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with respect to the amount of catalyst (R or S)-1.24 (0-100 mol%) and n-BuLi used (1-3 
equivalents). In some cases the crude product was subjected to SFC analysis without 
purification. 
 
1-6-b-7: Synthesis of Difluoromethylene Linchpins 
1-6-b-7-a: General Procedure – Acylation of Oxazolidinone 
 
To a solution of oxazolidinone (1.0 eq) in THF (0.2 M) at -78 °C was added n-BuLi (1.05 
eq) dropwise. After 30 mins at -78 °C, a solution of propionyl chloride (1.1 eq) in THF 
(1.8 M) was added to the reaction mixture. The reaction mixture was allowed to 
gradually warm to RT and stir overnight. The reaction was quenched with saturated 
NaHCO3, extracted three times with EtOAc, washed with saturated NaCl, dried over 
MgSO4, and concentrated to afford crude product. The crude was product purified by 
silica gel chromatography. 
 
 Performed following the general procedure using (S)-4-isopropyl-5,5-
dimethyloxazolidin-2-one (7.10 g, 45.2 mmol) in THF (230 mL), n-BuLi (19.4 mL, 47.5 
mmol), and propionyl chloride (4.4 mL, 49.7 mmol) to afford 1.55a (9.13 g, 95%). 1H-
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NMR (500 MHz, CDCl3) δ 4.15 (d, J = 3.42 Hz, 1 H), 3.05-2.89 (m, 2 H), (septet of 
doublets, J = 7.01, 3.27 Hz, 1 H), 1.51 (s, 3 H), 1.38 (s, 3 H), 1.19 (t, 7.37 Hz, 3 H), 1.02 
(d, J = 7.27 Hz, 3 H), 0.94 (d, J = 6.87 Hz, 3 H); 
 
 Performed following the general procedure using (S)-4-
phenyloxazolidin-2-one (2.0 g, 12.3 mmol) in THF (62 mL), n-BuLi (5.4 mL, 12.9 mmol, 
2.4 M), and butyryl chloride (1.4 mL, 13.5 mmol) to afford 1.55b (2.62 g, 91%).1H-NMR 
(500 MHz, CDCl3) δ 7.40-7.31 (m, 2 H), 7.30-7.28 (m, 3 H), 5.42 (dd, J = 8.6, 3.6 Hz, 1 
H), 4.68 (t, J = 8.9 Hz, 1 H), 4.27 (dd, J = 8.9, 3.7 Hz, 1 H), 2.96-2.86 (m, 2 H), 1.67-1.60 
(m, 2 H), 0.92 (t, J = 7.3 Hz, 3 H); 13C-NMR (125 MHz, CDCl3) δ 172.8, 153.9, 139.3, 
129.3, 128.8, 126.0, 70.1, 57.7, 37.5, 17.7, 13.7;  
 
Performed following the general procedure using (S)-4-isopropyl-
5,5-dimethyloxazolidin-2-one (3.88 g, 24.7 mmol) in THF (124 mL), n-BuLi (10.8 mL, 
25.9 mmol, 2.4 M), and 4-pentenoyl chloride (3.0 mL, 27.2 mmol) to afford 1.55c (3.9 g, 
66%). 1H-NMR (500 MHz, CDCl3) δ 5.86 (ddt, J = 16.9, 10.2, 6.6 Hz, 1 H), 5.05 (dq, J = 
17.0, 1.42 Hz, 1 H), 5.01 (dq, J = 21.7, 1.4 Hz, 1 H), 4.15 (d, J = 3.3 Hz, 1 H), 3.12 (ddd, 
J = 16.7, 7.8, 6.8 Hz, 1 H), 3.00 (dt, J = 16.7, 7.3 Hz, 1 H), 2.49-2.38 (m, 2 H), 2.14 
(septet of doublets, J = 6.8, 3.5 Hz, 1 H), 1.51 (s, 3 H), 1.38 (s, 3 H), 1.02 (d, J = 7.9 Hz, 
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3 H), 0.94 (d, J = 6.9 Hz, 3 H); 13C-NMR (125 MHz, CDCl3) δ 173.2, 153.7, 136.9, 115.8, 
83.0, 66.4, 34.8, 29.7, 28.9, 28.7, 21.6, 21.5, 17.2; 
 
 Performed following the general procedure using (S)-4-isopropyl-
5,5-dimethyloxazolidin-2-one (5.00 g, 31.8 mmol) in THF (160 mL), n-BuLi (13.9 mL, 
33.4 mmol, 2.4 M), and crotonyl chloride (3.4 mL, 35.0 mmol) to afford 1.55d (4.5 g, 
63%). 1H-NMR (500 MHz, CDCl3) δ 7.30 (dtd, J = 15.27, 1.66, 1.51 Hz, 1 H), 7.16-7.09 
(m, 1 H), 4.19 (d, J = 3.46, 1 H), 2.14 (septet of doublets, J = 6.77, 3.47 Hz, 1 H), 1.94 
(dd, J = 6.92, 1.62 Hz, 3 H), 1.49 (s, 3 H), 1.36 (s, 3 H), 1.01 (d, J = 6.93 Hz, 3 H), 0.93 
(d, J = 6.78 Hz, 3 H); 13C-NMR (125 MHz, CDCl3) δ 165.7, 153.7, 146.7, 122.0, 82.8, 
66.4, 29.8, 28.9, 21.5, 21.5, 18.6, 17.2; 
 
 Performed following the general procedure using (S)-4-
phenyloxazolidin-2-one (2.0 g, 12.3 mmol) in THF (62 mL), n-BuLi (5.4 mL, 12.9 mmol, 
2.4 M), and phenylacetyl chloride (1.8 mL, 13.5 mmol) to afford 1.55e (3.46 g, 78%). 1H-
NMR (500 MHz, CDCl3) δ 7.36-7.21 (m, 10 H), 5.41 (dd, J = 8.7, 3.8 Hz, 1 H), 4.64 (t, J 
= 8.9 Hz, 1 H), 4.30 (s, 3 H), 4.23 (dd, J = 9.0, 3.9 Hz, 1 H); 13C-NMR (125 MHz, CDCl3) 




1-6-b-7-b: General Procedure – α-silyldifluoromethylation  
 
To a solution of oxazolidinone (1.0 eq) in THF (1.0 M) at -78 °C was added LiHMDS (1.0 
eq). After the reaction mixture was stirred at -78 °C for 1 h, MeLi (1.0 eq) was added 
dropwise. The reaction mixture was stirred at -78 °C for an additional 10 mins, then 
TMS-CF3 (3.0 eq) was added. The reaction mixture was stirred at -78 °C, then quenched 
by the addition of a 1:1 mixture of dH2O/EtOAc. The phases were separated, and the 
aqueous phase was extracted three times with EtOAc, washed with brine, dried over 
MgSO4, and concentrated in vacuo to afford the crude product. The crude product was 
purified by silica gel chromatography.  
 
 Performed following the general procedure using oxazolidinone 
1.55a (9.0 g, 42.2 mmol), THF (42  mL), LiHMDS (42.2 mL, 42.2 mmol), MeLi (26.3 mL, 
42.2 mmol), and TMS-CF3 (18.7 mL, 126.6 mmol) to afford 1.56a (7.61 g, 54%). 1H-NMR 
(400 MHz, CDCl3) δ 4.69 (d, J = 25.9, 7.1 Hz, 1 H), 4.23 (d, J = 2.4 Hz, 1 H), 2.16-2.11 
(m, 1 H), 1.51 (s, 3 H), 1.36 (s, 3 H), 1.26 (d, J = 7.1 Hz, 3 H), 1.03 (d, J = 7.0 Hz, 3 H), 
0.98 (d, J = 6.8 Hz, 3 H), 0.25 (s, 9 H); 13C-NMR (100 MHz, CDCl3) δ 172.1 (dd, J = 8.1, 
3.9 Hz), 153.5, 129.2 (dd, J = 264.5, 269.0 Hz), 82.7, 66.6, 43.2 (t, J = 20.7 Hz), 30.0, 
29.0, 21.4 (d, J = 4.2 Hz), 16.8 (d, J = 1.2 Hz), 11.9 (t, J = 6.3 Hz), -3.4 (t, J = 2.6 Hz); 
19F-NMR (376 MHz, CDCl3) δ -109.0 (dd, J = 319.5, 6.3 Hz), -118.2 (dd, J = 320.0, 25.4 
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Hz); 19F-NMR (1H decoupled) (376 MHz, CDCl3) δ  -109.0 (d, J = 319.5), -118.2 (d, J = 
320.0); IR (thin film, NaCl) vmax 3534, 3383, 2975, 1773, 1703, 1376, 1312, 1069, 1041, 
90, 852, 788, 718, 641, 613 cm-1; [α]D22 = (+)-1.56 (c 5.0 mg/mL, CHCl3). 
 
 Performed following the general procedure using oxazolidinone 
1.55b (2.62 g, 11.23 mmol), THF (11.2 mL), LiHMDS (11.2 mL, 11.2 mmol), MeLi (7.0 
mL, 11.2 mmol), and TMS-CF3 (8.3 mL, 15.16 mmol) to afford 1.56b (1.55 g, 39%). 1H-
NMR (500 MHz, CDCl3) δ 7.38-7.35 (m, 2 H), 7.33-7.29 (m, 3 H), 5.47 (dd, J = 8.8, 4.4 
Hz, 1 H), 4.71-4.62 (m, 2 H), 4.24 (dd, J = 8.9,  4.5 Hz, 1 H), 2.00-1.86 (m, 1 H), 1.67-
1.59 (m, 1 H), 0.93 (t, J = 7.4 Hz, 3 H), 0.07 (s, 9 H); 13C-NMR (125 MHz, CDCl3) δ 170.6 
(dd, J = 9.4 3.6 Hz), 153.7, 138.7, 129.2 (t, J = 266.8 Hz), 129.2, 128.8, 127.1, 69.8, 
58.3, 51.1 (t, J = 19.8 Hz), 20.3 (t, J = 5.3 Hz), 12.2, -3.6 (d, J = 2.3 Hz). 
 
Performed following the general procedure using oxazolidinone 
1.55c (1.05 g, 4.39 mmol), THF (4.4 mL), LiHMDS (4.4 mL, 4.4 mmol), MeLi (2.9 mL, 4.4 
mmol), and TMS-CF3 (2.6 mL, 17.5 mmol) to afford 1.56c (900 mg, 57%). 1H-NMR (400 
MHz, CDCl3) δ 5.70-5.61 (m, 1 H), 5.00 (d, J = 16.8 Hz, 1 H), 4.95 (d, J = 10.1 Hz, 1 H), 
4.86 (dddd, J = 27.5, 11.8, 5.9, 2.9 Hz, 1 H), 4.15 (d, J = 2.7 Hz, 1 H), 2.66 (td, J = 13.4, 
8.8 Hz, 1 H), 2.26 (d, J = 14.0 Hz, 1 H), 2.07 (septet of doublets, J = 6.9, 2.5 Hz, 1 H), 
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1.43 (s, 3 H), 1.26 (s, 3 H), 0.96 (d, J = 7.1 Hz, 3 H), 0.89 (d, J = 6.9 Hz, 3 H), 0.20 (s, 9 
H); 13C-NMR (100 MHz, CDCl3) δ 170.3 (dd, J = 9.9, 1.1 Hz), 153.4, 134.2, 128.8 (dd, J 
= 270.9, 261.9 Hz), 117.7, 82.5, 66.4, 48.12 (t, J = 19.5 Hz), 31.2 (t, J = 5.4 Hz), 29.8, 
28.5, 21.4, 21.1, 16.6, -3.6 (t, J = 2.41 Hz). 
 
 Performed following the general procedure using oxazolidinone 
1.55d (3.60 g, 16.0 mmol, 1.0 eq), THF (16 mL), LiHMDS (16 mL, 16.0 mmol), MeLi (10 
mL, 16.0 mmol), and TMS-CF3 (9.5 mL, 64.0 mmol) to afford 1.56d (3.3 g, 59%). 1H-
NMR (400 MHz, CDCl3) δ 5.97 (ddd, J = 17.3, 9.8, 9.6 Hz, 1 H), 5.45-5.31 (m, 3 H), 4.19 
(d, J = 2.7 Hz, 1 H), 2.12 (septet of doublets, 6.9, 2.5 Hz, 1 H), 1.49 (s, 3 H), 1.32 (s, 
3H), 1.02 (d, J = 7.0 Hz, 3 H), 0.95 (d, J = 6.8 Hz, 3 H), 0.21 (s, 9 H); 13C-NMR (100 
MHz, CDCl3) δ 169.1 (dd, J = 7.6, 3.9 Hz), 153.4, 130.6 (dd, J = 7.9, 5.4 Hz), 128.2 (dd, 
J = 271.1, 265.8 Hz), 122.1, 82.9, 86.7, 53.1 (dd, J = 21.2, 18.8 Hz), 29.9, 28.9, 21.5, 
21.3, 16.7 (d, J = 0.96 Hz), -3.5 (d, J = 2.2 Hz); 19F-NMR (376 MHz, CDCl3) δ -109.0 (dd, 
J = 322.4, 4.6 Hz), -117.8 (dd, J = 322.2, 27.1 Hz); 19F-NMR (1H decoupled) (376 MHz, 
CDCl3) δ -109.0 (d, J = 322.4 Hz), -117.8 (d, J = 322.2 Hz). 
 
 Performed following the general procedure using oxazolidinone 
1.55e (2.69 g, 9.56 mmol), THF (9.6 mL), LiHMDS (9.6 mL, 9.6 mmol), MeLi (6.0 mL, 9.6 
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mmol), and TMS-CF3 (7.1 mL, 47.8 mmol) to afford 1.56e (2.59 g, 67%). 1H-NMR (500 
MHz, CDCl3) δ 7.55 (s, 2 H), 7.42-7.39 (m, 2 H), 7.36-7.32 (m, 6 H), 5.96 (dd, J = 26.6, 
8.8 Hz, 1 H), 5.38 (dd, J = 8.8, 4.0 Hz, 1 H), 4.59 (t, J = 9.0 Hz, 1 H), 4.23 (dd, J = 8.8, 
4.1 Hz, 1 H), -0.10 (s, 9 H); 13C-NMR (400 MHz, CDCl3) δ 168.0, 153.7, 138.7, 131.4, 
131.2 (d, J = 8.4 Hz), 129.3, 128.8 (d, J = 7.5 Hz), 128.6, 128.1, (dd, J = 274.7, 266.4 
Hz), 126.2, 69.7, 58.3, 52.9 (dd, J = 20.5, 18.2 Hz), -4.21 (t, J = 2.4 Hz). 
 
1-6-b-7-c: Reductions of oxazolidinones 
 To a suspension of LiAlH4 (861 mg, 22.7 mmol, 1.3 eq) in Et2O (36 mL, 
0.62 M) at 0 °C was added dropwise a solution of oxazolidinone 1.56a (5.88 g, 17.52 
mmol, 1.0 eq) in Et2O (21 mL, 0.85 M). The reaction mixture was stirred at 0 °C for 2 h, 
then quenched by the addition of a saturated solution of sodium potassium tartrate. The 
quenched reaction mixture was stirred for 5 h then the phases were separated, the 
aqueous phase was extracted three times with Et2O, dried over MgSO4, and 
concentrated in vacuo to provide the crude product. The crude product was purified by 
silica gel chromatography to afford 1.57a as a colorless oil (2.96 g, 93%). 1H-NMR (400 
MHz, CDCl3) δ 3.84 (dd, J = 10.8, 5.4 Hz, 1 H), 3.60 (dd, J = 9.9, 5.1 Hz, 1 H), 2.24-2.06 
(m, 1 H), 1.91 (s, 1 H), 1.05 (d, J = 6.8 Hz, 3 H), 0.19 (s, 9 H); 13C-NMR (100 MHz, 
CDCl3) δ 132.0 (dd, J = 362.89, 260.1 Hz), 62.7 (t, J = 7.5 Hz), 42.7 (t, J = 18.6 Hz), 10.9 
(dd, J = 8.7, 5.4 Hz), -3.6 (t, J = 2.5 Hz); 19F-NMR (376 MHz, CDCl3) δ -114.3 (dd, J = 
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322.7 Hz, 14.1 Hz), -119.22 (dd, J = 318.9, 14.6 Hz); 19F-NMR (1H decoupled) (376 
MHz, CDCl3) δ -114.3 (d, J = 322.7 Hz), -119.22 (d, J = 318.9 Hz).  
 
To a solution of fluoro-oxazolidinone 1.56b (1.5 g, 4.22 mmol) in THF/H2O 
(3:1 THF:H2O, 40 mL, 0.1 M) at 0 °C was added NaBH4 (640 mg, 16.9 mmol, 4.0 eq) in 
quarter portions over a period of 15 minutes. The reaction mixture was allowed to stir for 
10 h at 0 °C, then quenched with saturated NH4Cl. The phases were separated, and the 
aqueous phase was extracted three times with Et2O, washed with brine, dried over 
MgSO4, and concentrated in vacuo to afford the crude product. The crude product was 
purified by silica gel chromatography to afford 1.57b as a colorless oil (294 mg, 36%). 
1H-NMR (400 MHz, CDCl3) δ 3.86-3.78 (m, 2 H), 1.96-1.80 (m, 1 H), 1.65-1.55 (m, 2 H), 
1.50-1.38 (m, 1 H), 1.01 (t, J = 7.4 Hz, 3 H), 0.20 (s, 9 H); 13C-NMR (100 MHz, CDCl3) δ 
132.7 (t, J = 263.9 Hz), 59.7 (t, J = 7.1 Hz), 49.4 (t, J = 17.6 Hz), 17.9 (dd, J = 7.3, 5.1 
Hz), 12.2, -3.5 (t, J = 2.6 Hz); 19F-NMR (376 MHz, CDCl3) δ -111.6 (dt, J = 322.6, 13.9 
Hz), -116.1 (dd, J – 322.5, 4.1 Hz); 19F-NMR (1H decoupled) (376 MHz, CDCl3) δ -111.6 
(dd, J = 322.6, 12.5 Hz), -116.1 (dd, J = 322.5, 4.1 Hz); IR (thin film, NaCl) vmax 3408 
(br), 2971, 1637, 1465, 1413, 1324, 1254, 1143, 1107, 1050, 950, 844, 756, 700, 628 
cm-1. HRMS (EI) m/z (M+): Calculated for C12H16OF2Si: 196.109, observed: (CH3)3Si: 





 Performed procedure as described for 1.57a using LiAlH4 (65 mg, 1.7 
mmol), Et2O (2.7 mL), oxazolidinone 1.56c (472 mg, 1.31 mmol), Et2O (1.5 mL) to afford 
1.57c as a colorless oil (190 mg, 70%).  1H-NMR (400 MHz, CDCl3) δ 5.84 (dddd, J = 
16.9, 10.1, 7.6, 6.0 Hz, 1 H), 5.15-5.07 (m, 2 H), 3.83-3.75 (m, 2 H), 2.41-2.36 (m, 1 H), 
2.22-2.00 (m, 2 H), 1.62 (t, J = 2.7 H, 1 H), 0.22 (s, 9 H); 13C-NMR (100 MHz, CDCl3) δ 
136.2, 131.9 (t, J = 267.8 Hz), 60.2 (t, J = 6.9 Hz), 47.6 (t, J = 18.0 Hz), 29.5 (t, J = 6.4 
Hz), -3.5 (t, J = 2.7 Hz); 19F-NMR (376 MHz, CDCl3) δ  -113.8 (dd, J = 322.6, 18.9  Hz), -
115.0 (dd, J = 324.8, 19.9 Hz); 19F-NMR (1H decoupled) (376 MHz, CDCl3) δ  -113.8 (d, 
J = 322.6 Hz), -115.0 (d, J = 324.8 Hz) ; IR (thin film, NaCl) vmax 3441 (br), 3080, 2963, 
1878, 1779, 1697, 1643, 1470, 1445, 1416, 1395, 1375, 1314, 1253, 1218, 1176, 1114, 
1044, 994, 918, 844, 757, 701, 627 cm-1. 
 
 Performed procedure as described for 1.57a using LiAlH4 (23 mg, 0.60 
mmol), Et2O (1 mL), oxazolidinone 1.56d (160 mg), Et2O (0.5 mL) to afford 1.57d as a 
colorless oil (89 mg, 75%).  1H-NMR (400 MHz, CDCl3) δ 5.72 (dd, J = 17.2, 10.0 Hz, 1 
H), 5.34 (d, J = 10.6 Hz, 1 H), 5.30 (d, J = 17.6 Hz, 1 H), 3.98 (dd, J = 11.1, 4.9 Hz, 1 H), 
3.66 (dd, J = 11.1, 7.7 Hz, 1 H), 2.74 (dqd, J = 26.7, 8.5, 4.9 Hz, 1 H), 1.70 (s, 1 H), 0.16 
(s, 9 H); 13C-NMR (100 MHz, CDCl3) δ 133.0 (dd, J = 9.9, 3.2 Hz), 130.2 (dd, J = 264.7, 
263.3 Hz), 121.4, 60.0 (t, J = 8.7 Hz), 53.9 (t, J = 18.4 Hz), -3.7 (t, J = 2.3 Hz); 19F-NMR 
(376 MHz, CDCl3) δ -113.7 (dd, J = 322.6, 7.7 Hz), -121.6 (dd, J = 322.6, 9.1 Hz); 19F-
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NMR (1H decoupled) (376 MHz, CDCl3) δ -113.7 (d, J = 322.6 Hz), -121.6 (d, J = 322.6 
Hz). 
 
Performed procedure as described for 1.57b using fluoro-oxazolidinone 
1.56e (5.9 g, 17.3 mmol), THF/H2O (3:1 THF:H2O, 173 mL) and NaBH4 (2.6 g, 69.2 
mmol) to afford 1.57e as a colorless oil (973 mg, 23%). 1H-NMR (400 MHz, CDCl3) δ 
7.35-7.32 (m, 5 ), 4.32 (ddd, J = 11.6, 7.3, 5.6 Hz, 1 H), 3.97 (ddd, J = 11.2, 7.9, 5.4 Hz, 
1 H), 3.29 (dtd, J = 30.9, 7.9, 5.6 Hz, 1 H), 1.54 (ddd, J = 7.3, 5.6, 1.9 Hz, 1 H), 0.11 (s, 
9 H); 13C-NMR (100 MHz, CDCl3) δ 135.6 (d, J = 11.5 Hz), 130.9 (dd, J = 268.0, 261.8 
Hz), 130.1 (d, J = 2.2 Hz), 128.9, 128.2, 61.8 (dd, J = 10.2, 6.6 Hz), 54.9 (dd, J = 19.4, 
18.1 Hz), -4.2 (t, J = 2.1 Hz); 19F-NMR (376 MHz, CDCl3) δ -109.6 (dd, J = 319.0, 7.0 
Hz), -122.6 (dd, J = 318.9, 31.1 Hz); 19F-NMR (1H decoupled) (376 MHz, CDCl3) δ -109.6 
(d, J = 319.0 Hz), -122.6 (d, J = 318.9 Hz). 
 
1-6-b-7-d: General Procedure – Oxidations to Obtain Linchpins 
 To a suspension of Dess-Martin periodinane (13.3 g, 31.3 mmol, 1.25 eq) 
in CH2Cl2 (235 mL, 0.08 M) at 0 °C was added drop-wise a solution of alcohol 1.57a 
(4.58 g, 25.1 mmol, 1.0 eq) in CH2Cl2 (235 mL, 0.08 M). The reaction mixture was stirred 
at 0 °C for 2 h, then quenched by pouring the reaction mixture into a 1:1 mixture of 
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NaHCO3/Na2S2O3 and allowing the biphasic mixture to stir for approximately 20 mins at 
RT. The phases were separated, and the aqueous phase was extracted three times with 
CH2Cl2. The organic phases were combined, and washed with NaHCO3 twice, then dried 
with MgSO4 and concentrated in vacuo to afford 1.58a as a colorless oil. Crude product 
purified by Kügelrohr distillation (75 °C, 70 torr) to obtain pure 1.58a as a colorless oil 
(3.43 g, 75%). 1H-NMR (500 MHz, CDCl3) δ 9.82 (s, 1 H), 2.91-2.79 (m, 1 H), 1.19 (d, J 
= 7.15 Hz, 3 H), 0.20 (s, 9 H); 13C-NMR (125 MHz, CDCl3) δ 200.8 (t, J = 8.3 Hz), 129.7 
(dd, J = 265.3, 263.2 Hz), 53.4 (t, J = 19.1 Hz), 8.0 (t, J = 6.5 Hz), -3.8 (t, J = 2.5 Hz); 
19F-NMR (376 MHz, C6D6) δ -113.0 (dd, J = 329.9, 17.4 Hz), -114.7 (dd, J = 329.9, 20.4 
Hz); 19F-NMR (1H decoupled) (376 MHz, C6D6) δ -113.0 (d, J = 329.9 Hz), -114.7 (d, J = 
329.9 Hz). 
 
 Performed procedure as described for 1.58a using Dess-Martin 
periodinane (466 mg, 1.1 mmol), CH2Cl2 (20 mL), alcohol 1.57b (200 mg, 1.0 mmol), 
and CH2Cl2 (20 mL) to afford 1.58b as a colorless oil (179 mg, 90%). 1H-NMR (400 MHz, 
CDCl3) δ 9.70 (d, J = 3.5 Hz, 1 H), 2.69-2.56 (m, 1 H), 1.92-1.71 (m, 2 H), 0.94 (t, J = 7.5 
Hz, 3 H), 0.18 (s, 9 H); 13C-NMR (100 MHz, CDCl3) δ 281.0 (t, J = 7.8 Hz), 129.2 (dd, J = 
266.0, 263.2), 60.8 (t, J = 18.5 Hz), 16.3 (t, J = 6.3 Hz), 12.0, -3.9 (t, J = 2.3 Hz); 19F-
NMR (376 MHz, CDCl3) δ -112.2 (dd, J = 332.8, 18.2 Hz), -114.2 (dd, J = 332.9, 17.3 
Hz); 19F-NMR (1H decoupled) (376 MHz, CDCl3) δ -112.2 (d, J = 332.8 Hz), -114.2 (d, J 




 Performed procedure as described for 1.58a using Dess-Martin 
periodinane (302 mg, 0.712 mmol, 1.1 eq), CH2Cl2 (13 mL, 0.05 M), alcohol 1.57c (135 
mg, 0.648 mmol, 1.0 eq), and CH2Cl2 (13 mL, 0.05 M) to afford 1.58c as a colorless oil 
(129 mg, 97%). 1H-NMR (400 MHz, CDCl3) δ 9.66-9.65 (m, 1 H), 5.72 (ddt, J = 17.1, 
10.2, 7.0 Hz, 1 H), 5.12-5.05 (m, 1 H), 2.90-2.77 (m, 1 H), 2.67-2.58 (m, 1 H), 2.52-2.46 
(m, 1 H), 0.19 (s, 9 H); 13C-NMR (100 MHz, CDCl3) δ 200.4 (t, J = 7.5 Hz), 134.2, 128.9 
(t, J = 266.06 Hz), 117.8, 58.6 (t, J = 18.8 Hz), 27.1 (t, J = 6.6 Hz), -3.9 (t, J = 2.4 Hz); 
19F-NMR (376 MHz, CDCl3) δ -113.4 (t, J = 18.8 Hz); 19F-NMR (1H decoupled) (376 MHz, 
CDCl3) δ -113.3, -113.4. HRMS (ES) m/z (M+): Calculated for C9H16F2OSi: 207.1017, 
observed: 207.1029. 
 
 Performed procedure as described for 1.58a using Dess-Martin 
periodinane (946 mg, 2.23 mmol, 1.1 eq), CH2Cl2 (42 mL, 0.05 M), alcohol 1.57d (404 
mg, 2.08 mmol, 1.0 eq), and CH2Cl2 (42 mL, 0.05 M) to afford 1.58d as a colorless oil 




 Performed procedure as described for 1.58a using Dess-Martin 
periodinane (174 mg, 0.41 mmol), CH2Cl2 (7.5 mL), alcohol 1.57e (92 mg, 0.37 mmol), 
and CH2Cl2 (7.5 mL) to afford 1.58e as a colorless oil (74 mg, 81%). 1H-NMR (500 MHz, 
CDCl3) δ 10.06 (d, J = 2.5 Hz, 1 H), 7.39-7.35 (m, 5 H), 3.91 (ddd, J = 29.7, 9.9, 2.3 Hz, 
1 H), 0.04 (s, 9 H); 13C-NMR (125 MHz, CDCl3) δ 197.6 (dd, J = 9.7, 6.3 Hz), 130.6 (d, J 
= 2.3 Hz), 130.4 (d, J = 10.7 Hz), 130.1 (dd, J = 269.3, 263.6 Hz), 129.2, 128.8, 64.4 
(dd, J = 20.2, 18.5 Hz), -4.3 (t, J =1.7 Hz); HRMS (ES) m/z (M+): Calculated for 
C12H16OF2Si: 242.0939, observed: 242.0945. 
 
1-6-b-8: Stepwise Evaluation of ARC Sequence 
 
To a solution of aldehyde 1.58a (302 mg, 1.68 mmol) in Et2O (8.4 mL, 0.2 M) at -78 °C 
was added n-BuLi (700 µL, 1.68 mmol, 1.0 eq, 2.4 M in hexanes). The reaction mixture 
was stirred for 30 mins then quenched by the addition of HCl (1.68 mL, 3.36 mmol, 2 eq, 
2.0 M in Et2O) at -78 °C. After stirring for approximately 10 mins at -78 °C, the reaction 
mixture was warmed to RT and a saturated solution of NH4Cl was added. The phases 
were separated, and the aqueous phase was extracted three times with Et2O. The 
pooled organic phases were washed with saturated NaCl, dried over MgSO4, and 
concentrated in vacuo to afford the crude product as a mixture of 1.59a and 1.59b. The 
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crude product was purified by silica gel chromatography to afford 1.59a (292 mg, 73%) 
and 1.59b (32 mg, 8%) as individually isolated diastereomers.  
1H-NMR (400 MHz, CDCl3) δ 4.09 (t, J = 4.2 Hz, 1 H), 2.01-1.85 (m, 1 
H), 1.73 (d, J = 2.5 Hz, 1 H), 1.61-1.52 (m, 1 H), 1.44-1.22 (m, 5 H), 1.01 (d, J = 7.2 Hz, 
3 H), 0.90 (t, J = 4.0 Hz, 3 H), 0.19 (s, 9 H); 13C-NMR (100 MHz, CDCl3) δ 132.9 (dd, J = 
262.4, 261.2 Hz), 69.0 (t, J = 6.3 Hz), 44.3 (t, J = 17.8 Hz), 34.7, 28.5, 22.8, 14.1, 6.4 
(dd, J = 8.2, 5.0 Hz), -3.5 (t, J = 2.5 Hz); 19F-NMR (376 MHz, CDCl3) δ -112.8 (dd, J = 
319.3, 16.7 Hz), -117.0 (dd, J = 319.0, 24.2 Hz); 19F-NMR (1H decoupled) (376 MHz, 
CDCl3) δ -112.8 (d, J = 319.3 Hz), -117.0 (d, J = 319.0 Hz); IR (thin film, NaCl) vmax 
3619, 3470 (br), 2958, 2861, 1949, 1880, 1463, 1409, 1381, 1309, 1254, 1207, 1142, 
1091, 1029, 1002, 933, 8444, 788, 757, 700, 620, 503, 470 cm-1; [α]D22 = (-)-1.02 (c 5.0 
mg/mL, CHCl3). 
 
1H-NMR (400 MHz, CDCl3) δ 3.86 (ddd, J = 8.7, 6.3, 2.5 Hz, 1 H), 
2.20-2.04 (m, 1 H), 1.62-1.57 (m, 1 H), 1.51-1.31 (m, 5 H), 0.98 (d, J = 7.2 Hz, 3 H), 0.92 
(t, J = 6.9 Hz, 3 H), 0.20 (s, 9 H); 13C-NMR (100 MHz, CDCl3) δ 70.9 (t, J = 17.8 Hz), 
33.5, 27.7, 22.7, 14.1, 9.3 (dd, J = 8.1, 6.5 Hz), -3.4 (t, J = 2.5 Hz); 19F-NMR (376 MHz, 
CDCl3) δ -113.4 (dd, J = 322.5, 15.0 Hz), -116.0 (dd, J = 322.5, 22.6 Hz); 19F-NMR (1H 
decoupled) (376 MHz, CDCl3) δ -113.4 (d, J = 322.5 Hz), -116.0 (d, J = 322.5 Hz); IR 
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(thin film, NaCl) vmax 3425 (br), 2958, 2929, 2860, 2359, 1465, 1254, 1118, 994, 936, 
846, 756, 629, 488, 478, 470, 453, 426 cm-1; [α]D22 = (-)-17.49 (c 1.0 mg/mL, CHCl3). 
 
 
To a solution of alcohol 1.59a (32 mg, 0.134 mmol, 1.0 eq) in Et2O (670 µL, 0.2 M) at -78 
°C was added n-BuLi (56 µL, 0.134 mmol, 1.0 eq, 2.4 M in hexanes) and the reaction 
mixture was stirred at -78 °C for 10 mins. Next, a solution of benzaldehyde (28 µL, 0.268 
mmol, 2.0 eq) in Et2O/HMPA (270 µL, 1:1 Et2O/HMPA, 1 M) was added dropwise at -78 
°C. The reaction mixture was stirred at -78 °C for 1 min, then removed from the dry-ice 
acetone cooling bath and rapidly warmed to RT. The reaction was quenched by the 
addition of a saturated NH4Cl solution. The phases were separated, and the aqueous 
phase was extracted three times with Et2O. The pooled organic phases were washed 
with saturated NaCl, dried over MgSO4, and concentrated in vacuo to afford the crude 
product. The crude product was purified by silica gel chromatography to afford 1.60a as 
a colorless oil (26 mg, 1:1 dr, 72%). 1H-NMR (400 MHz, CDCl3) δ 7.46-7.44 (m, 2 H), 
7.39-7.36 (m, 3 H), 4.93 (ddd, J = 22.1, 18.9, 5.5 Hz, 1 H), 4.43 (bs, 0.43 H), 4.13-4.09 
(m, 1 H), 3.32 (bs, 0.46 H), 2.87 (bs, 0.48 H), 2.29-2.15 (m, 1 H), 2.10 (bs, 0.46 H), 1.61-
1.55 (m, 1 H), 1.47-1.23 (m, 5 H), 1.13-1.10 (m, 3 H), 0.93-0.89 (m, 3 H); 13C-NMR (100 
MHz, CDCl3) δ 136.7 (d, J = 10.3 Hz), 128.7 (d, J = 5.7 Hz), 128.3 (d, J = 7.8 Hz), 128.0, 
124.3 (dd, J = 253.3, 246.6 Hz), 123.4 (dd, J = 254.0, 245.9 Hz), 74.3 (dd, J = 32.9, 26.4 
Hz), 72.6 (dd, J = 33.3, 25.2 Hz), 69.6-69.5 (m), 44.0 (t, J = 22.5 Hz), 42.5 (t, J = 21.7 
Hz), 34.6, 34.4, 28.6, 28.5, 22.7, 22.6, 14.1, 7.1-7.0 (m); 19F-NMR (376 MHz, CDCl3) δ -
103.3 (dd, J = 258.7, 16.3 Hz), -107.3 (dd, J = 254.1, 20.7 Hz), -113.7 (dd, J = 227.0, 9.8 
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Hz), -114.4 (dd, J = 231.9, 10.0 Hz); 19F-NMR (1H decoupled) (376 MHz, CDCl3) δ -
103.3 (d, J = 258.7 Hz), -107.3 (d, J = 254.1 Hz), -113.7 (d, J = 227.0 Hz), -114.4 (d, J = 
231.9 Hz); IR (thin film, NaCl) vmax 3344 (br), 3066, 3034, 2931, 2871, 1952, 1700, 1494, 
1456, 1383, 1198, 1090, 1057, 970, 916, 835, 742, 699, 605, 568, 513, 485, 472, 445, 





To a solution of aldehyde 1.58a (99 mg, 0.55 mmol, 1.0 eq) in Et2O (2.75 mL, 0.2 M) at -
78 °C was added n-BuLi (254 µL, 0.61 mmol, 1.1 eq, 2.4 M in hexanes). The reaction 
mixture was stirred for 30 mins, then a solution of benzaldehyde (112 µL, 1.10 mmol, 2.0 
eq) in Et2O/HMPA (1.1 mL, 1:1 Et2O/HMPA, 1.0 M) was added dropwise at -78 °C. The 
reaction mixture was stirred at -78 °C for 1 min, then removed from the dry-ice acetone 
cooling bath and rapidly warmed to RT. The reaction was quenched by the addition of a 
saturated NH4Cl solution. The phases were separated, and the aqueous phase was 
extracted three times with Et2O. The pooled organic phase was washed three times with 
a saturated solution of CuSO4, washed with saturated NaCl, dried over MgSO4, and 
concentrated in vacuo to afford the crude product. The crude product was purified by 




1-6-b-9: Mosher Esters 
MTPA esters were prepared following the procedure described by Hoye et al (Nat Protoc 
2, 2451-2458, 2007). 
1H-NMR (400 MHz, CDCl3) δ 7.57 (t, J = 3.5 Hz, 2 H), 7.40-7.37 
(m, 3 H), 5.60 (td, J = 6.8, 1.7 Hz, 1 H), 3.54 (s, 3 H), 2.18-2.06 (m, 1 H), 1.80-1.73 (m, 1 
H), 1.65-1.57 (m, 1 H), 1.39-1.31 (m, 2 H), 1.28-1.22 (m, 2 H), 1.03 (d, J = 7.2 Hz, 3 H), 
0.89 (t, J = 6.9 Hz, 3 H), 0.18 (s, 9 H). 
1H-NMR (400 MHz, CDCl3) δ 7.56 (t, J = 3.5 Hz, 2 H), 7.39-7.38 
(m, 3 H), 5.59 (t, J = 6.9 Hz, 1 H), 3.55 (s, 3 H), 2.17-2.08 (m, 1 H), 1.72-1.65 (m, 1 H), 
1.53-1.48 (m, 1 H), 1.32-1.27 (m, 2 H), 1.23-1.17 (m, 2 H), 1.04 (d, J = 7.2 Hz, 3 H), 0.86 
(t, J = 7.28 Hz), 0.20 (s, 9 H). 
 




To a solution of linchpin (1.0 eq) in Et2O (0.2 M) at -78 °C was added n-BuLi (1.0 eq, 2.4 
M in hexanes) dropwise and the reaction mixture was stirred at -78 °C for 30 mins. Next, 
a solution of the electrophile (2 eq) in a 1:1 mixture of HMPA/Et2O (1.0 M) was added to 
the reaction mixture at -78 °C. The reaction mixture was stirred for 1 min at -78 °C, then 
the reaction vessel was removed from the cryogenic bath and warmed to RT. After 1 h at 
RT, a saturated solution of NH4Cl was added. The phases were separated, and the 
aqueous phase was extracted three times with Et2O. The pooled organic phase was 
washed three times with a saturated solution of CuSO4, washed with saturated NaCl, 
dried over MgSO4, and concentrated in vacuo to afford the crude three-component 
adduct. The crude product was dissolved in THF (0.2 M) and TBAF (1.0 equiv) was 
added dropwise. The reaction was allowed to stir for approximately 1 h at room 
temperature, then brine was added. The phases were separated, and the aqueous 
phase was extracted two times with Et2O. Organic phases pooled, dried with MgSO4, 
and concentrated to provide the crude product; which is purified by silica gel 
chromatography. 
 
 Reaction performed as described in the general procedure using 
linchpin 1.58a (124 mg, 0.688 mmol), Et2O (3.4 mL), n-BuLi (286 µL, 0.688 mmol, 2.4 M 
in hexanes), benzaldehyde (140 µL, 0.X mmol, 2 eq), HMPA/Et2O (1.38 mL, 1.0 M), THF 
(3.4 mL), and TBAF (690 µL, 1.0 M). Purified by silica gel chromatography to afford 




 Reaction performed as described in the general procedure 
using linchpin 1.58a (141 mg, 0.782 mmol), Et2O (3.9 mL), n-BuLi (326 µL, 0.782 mmol, 
2.4 M in hexanes), cinnamaldehyde (196 µL, 1.56 mmol), HMPA/Et2O (1.56 mL, 1.0 M), 
THF (3.9), and TBAF (782 µL). Purified by silica gel chromatography to afford 1.60b 
(177 mg, 76%). 1H-NMR (400 MHz, CDCl3) δ 7.42-7.40 (m, 2 H), 7.35-7.25 (m, 3 H), 
6.76 (dd, J = 16.0, 6.4 Hz, 1 H), 6.33 (ddd, J = 15.9, 6.4, 3.0 Hz), 4.61-4.51 (m, 1 H), 
4.10 (ddd, J = 18.6, 8.1, 3.8 Hz, 1 H), 2.33-2.20 (m, 1 H), 1.63-1.56 (m, 1 H), 1.44-1.25 
(m, 5 H), 1.13-1.10 (m, 3 H), 0.93-0.90 (m, 3 H); 13C-NMR (100 MHz, CDCl3) δ 136.3 (d, 
J = 1.2 Hz), 134.6, 133.8, 128.7 (d, J = 3.1 Hz), 128.2, 126.8 (d, J = 4.2 Hz), 124.5 (dd, J 
= 250.6, 246.8 Hz), 124.2 (t, J = 3.4 Hz), 123.9 (dd, J = 251.8, 246.2 Hz), 123.7 (t, J = 
2.9 Hz), 122.1, 121.4, 73.4 (dd, J = 32.3, 28.8 Hz), 71.5 (dd, J = 33.3, 26.4 Hz), 69.4-
69.3 (m), 43.9 (t, J = 22.2 Hz), 42.9 (t, J = 21.6 Hz), 34.5, 34.2, 22.6 (d, J = 1.4 Hz), 
14.1, 7.1-6.8 (m); 19F-NMR (376 MHz, CDCl3) δ -104.7 (dd, J = 257.6, 17.9 Hz), -106.8 
(dd, J = 254.3, 16.9 Hz), -112.6 (ddd, J = 256.5, 11.1, 11.0 Hz), -114.1 (ddd, J = 257.4, 
9.8, 9.6 Hz); 19F-NMR (1H decoupled) (376 MHz, CDCl3) δ -104.7 (d, J = 257.6 Hz), -
106.8 (d, J = 254.3 Hz), -112.6 (d, J = 256.5 Hz), -114.1 (d, J = 257.4); IR (thin film, 
NaCl) vmax 3344 (br), 3083, 3059, 3028, 2956, 2871, 2305, 1950, 1880, 1805, 1657, 
1599, 1578, 1495, 1464, 1385, 1266, 1202, 1054, 969, 914, 895, 866, 736, 702, 547 cm-




 Reaction performed as described in the general procedure using 
linchpin 1.58a (142 mg, 0.787 mmol), Et2O (4 mL), n-BuLi (328 µL, 0.787 mmol, 2.4 M in 
hexanes), allyl bromide (135 µL, 1.57 mmol), HMPA/Et2O (1.57 mL), THF (4 mL), and 
TBAF (787 µL). Purified by silica gel chromatography to afford 1.60c (35 mg, 23%). 1H-
NMR (400 MHz, CDCl3) δ 5.87-5.76 (m, 1 H), 5.23-5.20 (m, 2 H), 4.07 9dd, J = 8.0, 4.6 
Hz, 1 H),, 2.81-2.58 (m, 2 H), 2.02-1.88 (m, 1 H), 1.60 (bs, 1 H), 1.55 (ddd, J = 12.5, 8.5, 
4.1 Hz, 1 H), 1.45-1.24 (m, 5  H), 1.03 (d, J = 7.2 Hz, 3 H), 0.91 (t, J = 7.1 Hz, 3 H); 13C-
NMR (100 MHz, CDCl3) δ 129.6 (dd, J = 6.6, 5.3 Hz), 126.4 (t, J = 244.5 Hz), 120.3, 69.1 
(t, J = 4.2 Hz), 43.2 (t, J = 21.6 Hz), 39.7 (t, J = 26.1 Hz), 34.9, 28.5, 22.7, 14.2, 6.6 (t, J 
= 4.7 Hz); 19F-NMR (376 MHz, CDCl3) δ -99.9 - -100.7 (m,), -101.8 - -102.6 (m); 19F-
NMR (1H decoupled) (376 MHz, CDCl3) δ -100.3 (d, J = 246.5 Hz), -102.2 (d, J = 246.5 
Hz); IR (thin film, NaCl) vmax 3447, 3082, 2932, 2861, 1600, 1465, 1431, 1382, 1346, 
1198, 1134, 1081, 971, 880 cm-1; [α]D22 = (-)-2.82 (c 5.0 mg/mL, CHCl3). HRMS (ES) m/z 
(M-H): Calculated for C11H20F2O: 205.1404, observed: 205.1424. 
 
 Reaction performed as described in the general procedure using 
linchpin 1.58a (100 mg, 0.55 mmol), Et2O (2.8 mL), n-BuLi (230 µL, 0.55 mmol, 2.4 M in 
hexanes), benzyl bromide (130 µL, 1.10 mmol), HMPA/Et2O (1.1 mL), THF (2.8 mL), and 
TBAF (550 µL). Purified by silica gel chromatography to afford 1.60d (59 mg, 42%). 1H-
NMR (400 MHz, CDCl3) δ 7.35-7.27 (m, 5 H), 4.11 (ddd, J = 8.4, 4.6, 1.1, 1 H), 3.35-3.11 
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(m, 3 H), 1.97-1.83 (m, 1 H), 1.63-1.51 (m, 2 H), 1.43-1.21 (m, 5 H), 1.09 (d, J = 7.2 Hz, 
3 H), 0.89 (t, J = 7.1 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 133.3 (dd, J = 5.3, 3.8 Hz), 
130.5, 128.6, 127.4, 126.3 (t, J = 244.6 Hz), 69.3 (dd, J = 5.1, 3.4 Hz), 43.2 (t, J = 21.6 
Hz), 41.2 (t, J = 25.9 Hz), 34.9, 28.5, 22.7, 6.86 (t, J = 4.7 Hz); 19F-NMR (376 MHz, 
CDCl3) δ -99.4 (dddd, J = 245.6, 28.1, 20.8, 12.7 Hz), -101.1 (dtd, J = 246.3, 18.2, 11.3 
Hz); 19F-NMR (1H decoupled) (376 MHz, CDCl3) δ -99.4 (d, J = 245.6 Hz), -101.1 (d, J = 
246.3 Hz); IR (thin film, NaCl) vmax 3435, 2956, 2933, 2860, 1637, 1497, 1456, 1434, 
1383, 1353, 1246, 1227, 1195, 1137, 1080, 1031, 998, 970 cm-1; [α]D22 = (-)-5.15 (c 5.0 
mg/mL, CHCl3). HRMS (ES) m/z (M-H2O): Calculated for C15H22F2O: 238.1638, 
observed: 238.1522. 
 
 Reaction performed as described in the general procedure using 
linchpin 1.58a (86 mg, 0.48 mmol), Et2O (2.4 mL), n-BuLi (200 µL, 0.48 mmol, 2.4 M in 
hexanes), methyl iodide (60 µL, 0.96 mmol), HMPA/Et2O (960 µL), THF (2.4 mL), and 
TBAF (480 µL). Purified by silica gel chromatography to afford 1.60e (64 mg, 74%). 1H-
NMR (400 MHz, CDCl3) δ 4.02 (dd, J = 7.6, 4.4 Hz, 1 H), 1.99-1.86 (m, 1 H), 1.63 (t, J = 
19.4 Hz, 3 H), 1.57-1.51 (m, 2 H), 1.46-1.24 (m, 4 H), 1.09 (d, J = 7.2 Hz, 3 H), 0.91 (t, J 
= 7.1 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 126.7 (t, J = 240.4 Hz), 69.4 (dd, J = 5.6, 
3.6 Hz), 44.9 (t, J = 22.1 Hz), 35.2, 28.4, 22.7, 21.9 (t, J = 27.9 Hz), 14.2, 7.0 (t, J = 4.7 
Hz); 19F-NMR (376 MHz, CDCl3) δ  -91.3 (dqd, J = 242.8, 17.3, 10.8 Hz), -94.8 (dp, J = 
242.8, 18.3 Hz); 19F-NMR (1H decoupled) (376 MHz, CDCl3) δ -91.3 (d, J = 242.8 Hz), -
94.8 (d, J = 242.8 Hz); IR (thin film, NaCl) vmax 3436, 2932, 2861, 1668, 1394, 1307, 




 Reaction performed as described in the general procedure 
using linchpin 1.58a (48 mg, 0.266 mmol), Et2O (1.3 mL), n-BuLi (110 µL, 0.266 mmol, 
2.4 M in hexanes), (R,E)-N-benzylidene-2-methylpropane-2-sulfinamide (111 mg, 0.532 
mmol), HMPA/Et2O (530 µL), THF (1.3 mL), and TBAF (266 µL). Purified by silica gel 
chromatography to afford 1.60f (53 mg, 53%). 1H-NMR (400 MHz, CDCl3) δ 7.42-7.31 
(m, 5 H), 4.75 (ddd, J = 15.5, 11.9, 8.5 Hz, 1 H), 4.04 (dd, J = 8.3, 3.4 Hz, 1 H), 3.84 (d, 
J = 8.5 Hz, 1 H), 2.12-1.99 (m, 1 H), 1.88 (bs, 1 H), 1.55-1.48 (m, 1 H), 1.29-1.24 (m, 4 
H), 1.22 (s, 9 H), 1.16-1.09 (m, 1 H), 1.05 (d, J = 7.1 Hz, 3 H), 0.85 (t, J = 7.0 Hz, 3 H); 
13C-NMR (100 MHz, CDCl3) δ 136.3 (d, J = 3.4 Hz), 129.0, 128.9, 128.5, 125.3 (t, J = 
246.5 Hz), 68.9 (t, J = 3.8 Hz), 62.2 (dd, J = 26.9, 24.1 Hz), 56.9, 41.2 (t, J = 20.9 Hz), 
34.6, 28.3, 22.6, 22.5, 19.1, 6.2 (t, J = 4.9 Hz); 19F-NMR (376 MHz, CDCl3) δ -109.2 (dt, 
J = 254.1, 13.9 Hz), -110.9 (dt, J = 254.1, 15.5 Hz);; 19F-NMR (1H decoupled) (376 MHz, 
CDCl3) δ -109.2 (d, J = 254.1 Hz), -110.9 (d, J = 254.1 Hz);; IR (thin film, NaCl) vmax 
3229 (br), 3065, 3032, 2928, 2691, 1958, 1705, 1494, 1456, 1381, 1365, 1349, 1299, 
1119, 1051, 914, 844, 794, 757, 700, 553, 531 cm-1; [α]D22 = (-)-38.22 (c 5.0 mg/mL, 
CHCl3). 
 
 Reaction performed as described in the general procedure 
using linchpin 1.58a (107 mg, 0.59 mmol), Et2O (3.0 mL), n-BuLi (246 µL, 0.59 mmol, 
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2.4 M in hexanes), (S,E)-N-benzylidene-2-methylpropane-2-sulfinamide (246 mg, 1.18 
mmol), HMPA/Et2O (1.2 mL), THF (3.0 mL), and TBAF (590 µ). Purified by silica gel 
chromatography to afford 1.60g (91 mg, 41%). 1H-NMR (400 MHz, CDCl3) δ 7.41-7.33 
(m, 5 H), 4.73 (ddd, J = 18.1, 10.3, 7.8 Hz, 1 H), 4.10 (ddd, J = 8.8, 4.3, 1.2 Hz, 1 H), 
3.76 (d, J = 7.6 Hz, 1 H), 1.93-1.75 (m, 1 H), 1.54-1.46 (m, 1 H), 1.40-1.36 (m, 5 H), 1.22 
(s, 9 H), 0.99 (d, J = 7.2 Hz, 3 H), 0.86 (t, J = 7.1 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 
136.5 (d, J = 5.5 Hz), 129.2, 129.1, 128.8, 128.7, 128.6, 128.4 (d, J = 1.5 Hz), 125.6 (dd, 
J = 253.7, 250.1 Hz), 69.0 (dd, J = 4.7, 3.1 Hz), 62.5 (t, J = 23.5 Hz), 57.0, 41.6 (t, J = 
20.7 Hz), 34.5, 29.8, 28.5, 22.7, 14.1, 6.9 (dd, J = 5.8, 3.4 Hz); 19F-NMR (376 MHz, 
CDCl3) δ -110.2 (ddd, J = 252.4, 21.3, 10.1 Hz), -112.1 (ddd, J = 250.6, 17.5, 10.5 Hz); 
19F-NMR (1H decoupled) (376 MHz, CDCl3) δ -110.2 (d, J = 252.4 Hz), -112.1 (d, J = 
250.6 Hz); IR (thin film, NaCl) vmax 3398 (br), 2956, 2927, 2859, 2360, 1456, 1381, 1364, 
1183, 1118, 1058, 889, 700, 487, 470, 456, 450, 437 cm-1; [α]D22 = (+)-26.42 (c 5.0 
mg/mL, CHCl3). 
 
 Reaction performed as described in the general procedure 
using linchpin 1.58a (80 mg, 0.44 mmol), Et2O (2.2 mL), n-BuLi (183 µL, 0.44 mmol, 2.4 
M in hexanes), (R)-2-methyl-N-((1Z,2E)-3-phenylallyldiene)propane-2-sulfinamide (207 
mg, 0.88 mmol), HMPA/Et2O (880 µL), THF (2.2 mL), and TBAF (440 µL). Purified by 
silica gel chromatography to afford 1.60h (109 mg, 62%). 1H-NMR (400 MHz, CDCl3) δ 
7.42-7.39 (m, 2 H), 7.35-7.29 (m, 2 H), 7.27-7.23 (m, 1 H), 6.82 (d, J = 15.9 Hz, 1 H), 
6.28 (dd, J = 16.1, 7.3 Hz, 1 H), 4.37 (sextet, J = 8.2 Hz, 1 H), 4.12 (dd, J = 7.2, 4.9 Hz, 
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1 H), 3.64 (d, J = 9.3 Hz, 1 H), 2.28-2.15 (m, 1 H), 1.69 (bs, 1 H), 1.62-1.55 (m, 2 H), 
1.30-1.22 (m, 13 H), 1.08 (d, J = 7.2 Hz, 3 H), 0.88 (t, J = 7.2 Hz, 3 H); 13C-NMR (100 
MHz, CDCl3) δ 136.1, 135.9, 128.8, 128.7, 128.4, 127.0, 126.7, 125.5 (t, J = 250.8 Hz), 
123.4 (t, J = 3.5 Hz,), 69.0 (t, J = 3.7 Hz), 61.6 (dd, J = 29.2, 25.6 Hz), 57.0, 41.1 (t, J = 
21.2 Hz), 34.7, 28.5, 22.7, 22.6, 14.1, 6.6 (dd, J = 5.5, 4.0 Hz); 19F-NMR (376 MHz, 
CDCl3) δ -110.6 (ddd, J = 253.2, 20.3, 7.0 Hz), -112.1 (dt, J = 253.2, 14.2 Hz); 19F-NMR 
(1H decoupled) (376 MHz, CDCl3) δ -110.6 (d, J = 253.2 Hz), -112.1 (d, J = 253.2 Hz); IR 
(thin film, NaCl) vmax 3241 (br), 3060, 3027, 2957, 2929, 2869, 1951, 1705, 1607, 1577, 
1495, 1456, 1381, 1365, 1309, 1182, 1118, 1057, 973, 894, 844, 793, 748, 694, 599 cm-
1; [α]D22 = (-)-26.63 (c 5.0 mg/mL, CHCl3). 
 
Reaction performed as described in the general procedure using 
linchpin 1.58a (95 mg, 0.526 mmol), Et2O (2.6 mL), PhLi (276 µL, 0.526 mmol, 1.9 M 
Bu2O), methyl iodide (65 µL, 1.052 mmol), HMPA/Et2O (1.1 mL), THF (2.6 mL), and 
TBAF (526 µL). Purified by silica gel chromatography to afford 1.62a (60 mg, 57%). 1H-
NMR (400 MHz, CDCl3) δ 7.39-7.35 (m, 4 H), 7.31-7.26 (m, 1 H), 5.28 (s, 1 H), 2.25-2.12 
(m, 1 H), 2.00 (bs, 1 H), 1.71 (t, J = 19.5 Hz, 3 H), 0.96 (d, J = 7.2 Hz, 3 H); 13C-NMR 
(100 MHz, CDCl3) δ 143.0, 128.4, 127.4, 126.5 (t, J = 241.0 Hz), 71.6 (dd, J = 6.9, 3.6 
Hz), 47.8 (t, J = 22.3 Hz), 21.9 (t, J = 4.3 Hz), 6.5 (t, J = 4.3 Hz); 19F-NMR (376 MHz, 
CDCl3) δ -90.0 - -90.1 (m), -90.6 - -90.8 (m), -94.3 - -94.5 (m,), -95.0 - -95.2 (m); 19F-
NMR (1H decoupled) (376 MHz, CDCl3) δ -90.4 (d, J = 240.4 Hz), -94.8 (d, J = 242.8 
Hz); IR (thin film, NaCl) vmax 3608, 3450 (br), 3087, 3063, 3028, 2988, 2949, 2921, 2850, 
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2336, 2222, 1954, 1887, 1812, 1682, 1602, 1491, 1453, 1393, 1361, 1322, 1284, 1236, 
1199, 1139, 1110, 1079, 1029, 985, 937, 915, 829, 758, 738, 701, 634 cm-1; [α]D22 = (-)-
35.68 (c 5.0 mg/mL, CHCl3). 
 
Bromo-styrene (101 µL, 0.79 mmol, 1.0 eq) was dissolved in Et2O 
(2.0 mL, 0.4 M) and cooled to -78 °C. Next, t-BuLi (930 µL, 1.58 mmol, 2.0 eq, 1.7 M) 
was added dropwise, and the solution was stirred at -78 °C for 30 mins, after which time 
the reaction was warmed to 0 °C. After 1 h at 0 °C, the reaction mixture was cooled to -
78 °C, and a solution of linchpin 1.58a (143 mg, 0.79 mmol, 1.0 eq) in Et2O (2.0 mL, 0.4 
M) was added dropwise. The reaction mixture was stirred at -78 °C for 30 mins, then a 
solution of methyl iodide (99 µL, 1.58 mmol, 2.0 eq) in HMPA/Et2O (1.6 mL, 1.0 M, 1:1 
HMPA/Et2O) was added dropwise. The reaction mixture was stirred at -78 °C for 
approximately 1 min, then warmed to room temperature. The reaction was worked up as 
previously described. Crude TBAF deprotection employed: TBAF (790 µL) and THF (4 
mL). Crude product was purified by silica gel chromatography to obtain 1.62b as a 
colorless oil (98 mg, 55%). 1H-NMR (400 MHz, CDCl3) δ -7.41-7.38 (m, 2H), 7.36-7.31 
(m, 2 H), 7.28-7.24 (m, 1 H), 6.66 (dd, J = 16.0, 1.2 Hz, 1 H), 6.22 (dd, J = 16.0, 5.6 Hz, 
1 H), 4.76 (d, J = 1.5 Hz, 1 H), 2.20-2.08 (m, 1 H), 1.81 (t, J = 2.6 Hz, 1 H), 1.69 (t, J = 
19.4 Hz, 3 H), 1.11 (d, J = 7.2 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 136.7, 130.7, 
130.3, 128.8, 127.9, 126.6, 126.3 (t, J = 240.3 Hz), 70.4 (dd, J = 6.6, 2.9 Hz), 45.9 (t, J = 
22.5 Hz), 21.9 (t, J = 27.7 Hz), 7.7 (t, J = 4.5 Hz); 19F-NMR (376 MHz, CDCl3) δ -90.0 - -
90.2 (m), -90.7 - -90.9 (m), -94.1 (dp, J = 242.8, 18.8 Hz); 19F-NMR (1H decoupled) (376 
MHz, CDCl3) δ -90.4 (d, J = 242.8 Hz), -94.1 (d, J = 242.8 Hz); IR (thin film, NaCl) vmax 
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3600 (br), 3437 (br), 3082, 3059, 3026, 2985, 2948, 2916, 1950, 1880, 1752, 1657, 
1599, 1577, 1495, 1462, 1449, 1393, 1331, 1267, 1237, 1150, 1114, 1073, 1028, 967, 
912, 848, 826, 808, 739, 695 cm-1; [α]D22 = (-)-10.38 (c 5.0 mg/mL, CHCl3). 
 
Phenylacetylene (82 µL, 0.749 mmol, 1.0 eq) was dissolved in Et2O 
(1.9 mL, 0.4 M) and cooled to -78 °C, then n-BuLi (312 µL, 0.749 mmol, 1.0 eq, 2.4 M in 
hexanes) was added. The reaction was allowed to stir for 1 h at -78 °C, then a solution 
of linchpin 1.58a (135 mg, 0.749 mmol, 1.0 eq) in Et2O (1.9 mL, 0.4 M) was added 
dropwise. The resultant mixture was stirred at -78 °C for 30 mins, then a solution of 
methyl iodide (93 µL, 1.50 mmol, 2.0 eq) in HMPA/Et2O (1.5 mL, 1.0 M, 1:1 HMPA/Et2O) 
was added dropwise. The reaction mixture was stirred at -78 °C for approximately 1 min, 
then warmed to room temperature. The reaction was worked up as previously described. 
Crude TBAF deprotection employed: TBAF (750 µL) and THF (3.8 mL). Crude product 
was purified by silica gel chromatography to obtain 1.62c as a colorless oil (132 mg, 
79%). 1H-NMR (400 MHz, CDCl3) δ 7.44-7.42 (m, 2 H), 7.35-7.29 (m, 3 H), 5.02 (s, 1 H), 
2.40-2.28 (m, 1 H), 1.99 (bs, 1 H), 1.69 (t, J = 19.5 Hz, 3 H), 1.29 (d, J = 7.2 Hz, 3 H); 
13C-NMR (100 MHz, CDCl3) δ 131.8, 128.8, 128.5, 125.6 (t, J = 241.1 Hz), 122.4, 88.3, 
85.6, 62.0 (dd, J = 8.2, 4.3 Hz), 46.6 (t, J = 23.1 Hz), 21.7 (t, J = 27.4 Hz), 8.6 (t, J = 4.4 
Hz); 19F-NMR (376 MHz, CDCl3) δ -89.2 - -89.4 (m), -89.8 - -90.0 (m), -93.3 (ddtd, J = 
242.9, 19.7, 19.1, 14.7 Hz); 19F-NMR (1H decoupled) (376 MHz, CDCl3) δ -89.6 (d, J = 
242.6 Hz), -93.3 (d, J = 242.9 Hz); IR (thin film, NaCl) vmax 3421 (br), 2986, 2916, 2848, 
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2201, 1598, 1490, 1444, 1394, 1236, 1144, 1105, 1080, 1028, 972, 915, 757, 691 cm-1; 
[α]D22 = (-)-26.78 (c 5.0 mg/mL, CHCl3). 
 
To a solution of 1,3-dithiane (57 mg, 0.472 mmol, 1.0 eq) in Et2O (1.2 
mL, 0.4 M), was added n-BuLi (197 µL, 0.472 mmol, 1.0 eq) at 0 °C and stirred for 1 h. 
Next, the solution was cooled to -78 °C, and a solution of linchpin 1.58a (85 mg, 0.472 
mmol, 1.0 eq) in Et2O (1.2 mL, 0.4 M) was added dropwise. The reaction mixture was 
stirred for 30 mins at -78 °C, then a solution of methyl iodide (59 µL, 0.944 mmol, 2.0 eq) 
in Et2O/HMPA (950 µL, 1:1 Et2O/HMPA, 1.0 M) was added dropwise. The resultant 
mixture was stirred at -78 °C for approximately 1 min, then warmed to room temperature. 
The reaction was worked up as previously described. Crude TBAF deprotection 
employed: TBAF (480 µL) and THF (2.4 mL). Crude product was purified by silica gel 
chromatography to obtain 1.62d as a colorless oil (70 mg, 61%). 1H-NMR (400 MHz, 
CDCl3) δ 4.24 (d, J = 9.9 Hz, 1 H), 3.58 (d, J = 9.9 Hz, 1 H), 3.03-2.91 (m, 2 H), 2.80-
2.69 (m, 2 H), 2.64-2.58 (m, 2 H), 2.07-2.01 (m, 2 H), 1.66 (t, J = 19.5 Hz, 3 H), 1.00 (d, 
J = 7.2 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 126.4 (t, J = 240.6 Hz), 67.4 (dd, J = 7.9, 
3.7 Hz), 47.8, 41.7 (d, J = 24.2 Hz), 26.1, 25.5, 21.1 (t, J = 27.6 Hz), 6.8 (dd, J = 5.8, 3.1 
Hz); 19F-NMR (376 MHz, CDCl3) δ -88.6 - -88.8 (m), -89.3 - -89.5 (m), -92.6 - -92.8 (m), -
93.3 - -93.5 (m); 19F-NMR (1H decoupled) (376 MHz, CDCl3) δ -89.1 (d, J = 242.6 Hz), -
93.0 (d, J = 239.8 Hz); IR (thin film, NaCl) vmax 3466 (br), 2978, 2913, 1624, 1462, 1424, 
1394, 1321, 1274, 1241, 1148, 1117, 1077, 1048, 981, 934, 912, 886, 834, 797, 763, 




Reaction performed as described in the general procedure using 
linchpin 1.58b (157 mg, 0.81 mmol), Et2O (4.1 mL), n-BuLi (340 µL, 0.81 mmol, 2.4 M in 
hexanes), methyl iodide (100 µL, 0.1.62 mmol), HMPA/Et2O (1.62 mL), THF (4.1 mL), 
and TBAF (810 µL). Purified by silica gel chromatography to afford 1.63a (157 mg, 63%). 
1H-NMR (400 MHz, CDCl3) δ 3.97 (dd, J = 8.5, 2.8 Hz, 1 H), 1.77-1.26 (m, 9 H), 1.64 (t, 
J = 19.9 Hz, 3 H), 1.04 (t, J = 7.5 Hz, 3 H), 0.91 (t, J = 7.1 Hz, 3 H); 13C-NMR (100 MHz, 
CDCl3) δ 127.1 (t, J = 241.5 Hz), 70.3 (dd, J = 5.9, 4.4 Hz), 52.2 (t, J = 20.7 Hz), 35.4, 
28.7, 22.7, 22.3 (t, J = 27.8 Hz), 16.7 (t, J = 3.8 Hz), 14.6, 14.2; 19F-NMR (376 MHz, 
CDCl3) δ -88.9 (ddtd, J = 246.6, 20.6, 20.3, 14.6 Hz), -91.1 (dp, J = 246.5, 17.5 Hz); 19F-
NMR (1H decoupled) (376 MHz, CDCl3) δ -88.9 (d, J = 246.6 Hz), -91.1 (d, J = 246.5 
Hz); IR (thin film, NaCl) vmax 3430 (br), 2917, 2849, 1712, 1462, 1393, 1259, 1153, 1019, 
912, 805, 729, 539 cm-1; [α]D22 = (+)-2.31 (c 5.0 mg/mL, CHCl3). 
 
Reaction performed as described in the general procedure using 
linchpin 1.58c (102 mg, 0.37 mmol), Et2O (1.9 mL), n-BuLi (154 µL, 0.37 mmol, 2.4 M in 
hexanes), methyl iodide (46 µL, 0.74 mmol), HMPA/Et2O (740 µL), THF (1.9 mL), and 
TBAF (370 µL). Purified by silica gel chromatography to afford 1.63b (42 mg, 55%). 1H-
NMR (400 MHz, CDCl3) δ 5.92-5.82 (m, 1 H), 5.12-5.00 (m, 2 H), 4.01 (ddd, J = 8.3, 4.2, 
1.3 Hz, 1 H), 2.43-2.24 (m, 2 H), 2.01-1.90 (m, 1 H), 1.65 (t, J = 19.5 Hz, 3 H), 1.59-1.53 
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(m, 1 H), 1.50-1.28 (m, 5 H), 0.91 (t, J = 7.2 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 
138.0, 126.6 (t, J = 241.9 Hz), 116.1, 70.1 (dd, J = 5.6, 3.9 Hz), 50.3 (t, J = 21.1 Hz), 
35.3, 29.8, 28.6, 28.3 (t, J = 4.3 Hz), 22.7 (t, J = 13.4 Hz), 14.1; 19F-NMR (376 MHz, 
CDCl3) δ -89.1 (dtdd, J = 246.3, 22.7, 20.8, 14.1 Hz), -91.8 (ddt, J = 242.6, 35.4, 20.3 
Hz); 19F-NMR (1H decoupled) (376 MHz, CDCl3) δ -89.1 (d, J = 246.3 Hz), -91.8 (d, J = 
242.6 Hz); IR (thin film, NaCl) vmax 3413, 2917, 2849, 1731, 1462, 1378, 1118, 915, 729 
cm-1; [α]D22 = (+)-0.95 (c 5.0 mg/mL, CHCl3). 
 
Reaction performed as described in the general procedure using 
linchpin 1.58d (123 mg, 0.64 mmol), Et2O (3.2 mL), n-BuLi (270 µL, 0.64 mmol, 2.4 M in 
hexanes), methyl iodide (80 µL, 1.28  mmol), HMPA/Et2O (1.3 mL), THF (3.2 mL), and 
TBAF (640 µL). Purified by silica gel chromatography to afford 1.63c (65 mg, 53%). 1H-
NMR (400 MHz, CDCl3) δ 5.88 (dt, J = 17.2, 10.3, 1 H), 5.37 (d, J = 10.2 Hz, 1 H), 5.23 
(dd, J = 17.1, 1.5 Hz, 1 H), 4.12 (dd, J = 3.6, 2.0 Hz, 1 H), 2.40 (dtd, J = 20.2, 9.8, 1.5 
Hz, 1 H), 1.74 (t, J = 4.0 Hz, 1 H), 1.62 (t, J = 19.4 Hz, 3 H), 1.54-1.47 (m, 1 H), 1.42-
1.25 (m, 5 H), 0.90 (t, J = 7.2 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 130.8 (dd, J = 5.6, 
3.6 Hz), 125.4 (t, J = 242.4 Hz), 122.0, 69.0 (dd, J = 5.2, 2.6 Hz), 56.4 (t, J = 22.3 Hz), 
35.1, 28.0, 22.9 (t, J = 27.5 Hz), 22.7, 14.2; 19F-NMR (376 MHz, CDCl3) δ -90.5 (dtdd, J 
= 243.1, 20.7, 17.5, 7.3 Hz), -95.6 (dp, J = 238.8, 18.4 Hz); 19F-NMR (1H decoupled) 
(376 MHz, CDCl3) δ -90.5 (d, J = 243.1 Hz), -95.6 (d, J = 238.8 Hz); IR (thin film, NaCl) 
vmax 3448, 2917, 2849, 1694, 1462, 1377, 1260, 1118, 805, 700 cm-1; [α]D22 = (+)-4.23 (c 




Reaction performed as described in the general procedure using 
linchpin 1.58e (74 mg, 0.305 mmol), Et2O (1.5 mL), n-BuLi (130 µL, 0.305 mmol, 2.4 M 
in hexanes), methyl iodide (38 µL, 0.61 mmol), HMPA/Et2O (610 µL), THF (1.5 mL), and 
TBAF (310 µ). Purified by silica gel chromatography to afford 1.63d (47 mg, 64%). 1H-
NMR (400 MHz, CDCl3) δ 7.38-7.30 (m, 5 H), 4.40 (d, J = 3.3 Hz, 1 H), 2.97 (ddd, J = 
24.1, 8.9, 3.0 Hz, 1 H), 1.76 (t, J = 3.7 Hz, 1 H), 1.50 (t, J = 19.0 Hz, 3 H), 1.43-1.26 (m, 
6 H), 0.87 (t, J = 7.4 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 134.9 (d, J = 7.5 Hz), 130.7 
(d, J = 1.5 Hz), 128.6, 127.9, 125.8 (dd, J = 244.0, 241.9 Hz), 69.6 (t, J = 3.2 Hz), 57.9 
(dd, J = 23.3, 21.6 Hz), 35.3, 28.2, 23.8 (t, J = 27.5 Hz), 22.7, 14.2; 19F-NMR (376 MHz, 
CDCl3) δ -87.6 (ddtd, J = 243.0, 20.1, 17.4, 10.5 Hz), -95.6 (dp, J = 239.2, 20.0 Hz); 19F-
NMR (1H decoupled) (376 MHz, CDCl3) δ -87.6 (d, J = 243.0 Hz), -95.6 (d, J = 239.2 
Hz); IR (thin film, NaCl) vmax 3457 (br), 3090, 3063, 3029, 2931, 2861, 1954, 1886, 1728, 
1684, 1602, 1583, 1495, 1455, 1386, 1350, 1231, 1180, 1120, 1077, 966, 915, 844, 814, 
794, 755, 738, 702, 608, 581, 516 cm-1; [α]D22 = (+)-13.01 (c 5.0 mg/mL, CHCl3). 
 
1-6-b-11: Synthesis of Difluorocyclopentyl Ketal 
 To a solution of diol 1.60a (14 mg, 0.051 mmol, 1.0 eq) in CH2Cl2 (2.6 
mL, 0.02 M) at room temperature was added MnO2 (44mg, 0.51 mmol, 10.0 eq). The 
reaction mixture was stirred for 24 h at room temperature, then filtered through celite, 
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and concentrated by rotary evaporation to afford 1.61 (13.5 mg, 97%). 1H-NMR (400 
MHz, CDCl3) δ 7.61-7.57 (m, 2 H), 7.40-7.38 (m, 3 H), 4.46-4.33 (m, 1 H), 3.26-2.54 (m, 
2 H), 1.69-1.33 (m, 7 H), 1.08 (d, J = 7.7 Hz, 3 H), 0.97 (t, J = 6.9 Hz, 3 H); 13C-NMR 
(100 MHz, CDCl3) δ 138.3, 137.2 (dd, J = 1.1 Hz), 129.3, 129.2, 128.2, 128.1, 127.0, 
126.8, 125.1 (dd, J = 265.4, 251.8 Hz), 100.5 (dd, J = 33.6, 23.0 Hz), 79.9 (dd, J = 4.7, 
2.1 Hz), 78.0 (d, J = 8.8 Hz), 41.2 (dd, J = 23.2, 20.0 Hz), 31.6, 31.0, 29.8, 29.5, 28.3, 
28.4, 22.9, 22.8, 14.2, 14.1, 8.03 (d, J = 5.4 Hz), 6.5 (d, J = 7.9 Hz); 19F-NMR (376 MHz, 
CDCl3) δ -104.3 (dd, J = 232.3, 14.5 Hz), -117.3 (dd, J = 22.8.7, 26.5 Hz), -122.3 (d, J = 
232.3 Hz), -123.4 (dd, J = 227.3, 10.0 Hz); 19F-NMR (1H decoupled) (376 MHz, CDCl3) δ 
-104.3 (d, J = 232.3 Hz), -117.3 (d, J = 228.7 Hz), -122.3 (d, J = 232.3 Hz), -123.4 (d, J = 
227.3 Hz); IR (thin film, NaCl) vmax 3396 (br), 3065, 2929, 2858, 1450, 1364, 1294, 1234, 
1182, 1145, 1085, 1057, 1025, 997, 960, 932, 901, 764, 700, 652, 584, 485, 470, 458, 
440, 423, 408 cm-1; [α]D22 = (+)-61.04 (c 5.0 mg/mL, CHCl3). 
 
1-6-b-12: Mechanistic Studies 
1-6-b-12-a: TEMPO Trapping Experiment 
No TEMPO. To a solution of alcohol 1.59a (35.5 mg, 0.15 mmol) in Et2O (750 µL) at -
78 °C was added n-BuLi (63 µL, 0.15 mmol) and the reaction mixture was stirred at -78 
°C for 10 mins. Next, a solution of benzaldehyde (31 µL, 0.30 mmol) in Et2O/HMPA (300 
µL) was added dropwise at -78 °C. The reaction mixture was stirred at -78 °C for 1 min, 
then removed from the dry-ice acetone cooling bath and rapidly warmed to RT. Reaction 
worked up as previously described. The crude product was purified by silica gel 
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chromatography to afford 1.60a as a colorless oil (33 mg, 1:1 dr, 81%). Analytical data 
matches previously reported data. 
 
With TEMPO. To a solution of alcohol 9a (34.4 mg, 0.14 mmol) in Et2O (700 µL) at -78 
°C was added n-BuLi (60 µL, 0.14 mmol) and the reaction mixture was stirred at -78 °C 
for 10 mins. Next, a solution of benzaldehyde (29 µL, 0.28 mmol) and TEMPO (44 mg, 
0.28 mmol) in Et2O/HMPA (280 µL) was added dropwise at -78 °C. The reaction mixture 
was stirred at -78 °C for 1 min, then removed from the dry-ice acetone cooling bath and 
rapidly warmed to RT. Reaction worked up as previously described. The crude product 
was purified by silica gel chromatography to afford 1.60a as a colorless oil (24 mg, 1:1 
dr, 63%). Analytical data matches previously reported data. 
 
1-6-b-12-b: Silyl Adduct Isolation 
 
Reaction performed as described in the general procedure using linchpin 1.59a (48 mg, 
0.266 mmol), Et2O (1.3 mL), n-BuLi (110 µL, 0.266 mmol, 2.4 M in hexanes), (R,E)-N-
benzylidene-2-methylpropane-2-sulfinamide (111 mg, 0.532 mmol), HMPA/Et2O (530 
µL). Reaction was not treated with TBAF prior to purification. Purified by silica gel 
chromatography to afford 1.65 (50 mg, 42%).  1H-NMR (500 MHz, CDCl3) δ 7.39-7.31 
(m, 5 H), 4.67 (ddd, J = 20.0, 10.8, 9.2 Hz, 1 H), 3.99 (t, J = 6.6 Hz, 1 H), 3.69 (d, J = 8.8 
Hz, 1 H), 2.14-2.04 (m, 1 H), 1.47-1.40 (m, 1 H), 1.37-1.30 (m, 1 H), 1.27-1.18 (m, 11 H), 
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1.16-1.10 (m, 1 H), 1.05 (d, J = 7.0 Hz, 3 H), 1.02-0.95 (m, 1 H), 0.84 (t, J = 7.3 Hz, 3 H), 
0.09 (s, 9H); 13C-NMR (125 MHz, CDCl3) δ 136.6 (d, J = 2.5 Hz), 129.0, 128.7, 128.6, 
124.6 (t, J = 251.7 Hz), 69.7 (t, J = 3.5 Hz), 62.8 (dd, J = 27.8, 24.0 Hz), 56.9, 40.9 (t, J = 





















SYNTHESIS OF A RECYCLABLE POLYMER-SUPPORTED SILOXANE 
TRANSFER AGENT FOR TRANSITION METAL-MEDIATED CROSS-
COUPLING REACTIONS OF ORGANOLITHIUMS 
 
2-1: Introduction to Siloxane Transfer Agents: From Anion Relay Chemistry 
(ARC) to Transition Metal Catalyzed Cross-Coupling Reactions (CCRs) 
 Transition-metal catalyzed cross-coupling reactions (CCRs) have become an 
invaluable tool for the modern synthetic chemist in the construction of C – C bonds.  
Facile methods for the forging of such bonds are of critical importance to the synthesis of 
biologically active molecules, fine chemicals, and materials.  Many CCR methods have 
been developed, including Suzuki (organoboron), Stille (organotin), and Negishi 
(organozinc) reactions.  However, these methods all require prefunctionalized 
organometallic reagents.1 Organolithium reagents clearly represent an ideal 
organometallic coupling component, as they can be generated from commercially 
available organohalides, and are in many cases used in the synthesis of other 
organometallic reagents. However, these reagents are often overlooked in synthesis due 
to their strong basicity, nucleophilicity, and tendency to afford homo-coupling products in 
transition metal catalyzed CCRs.2   
In connection with the evolution of Anion Relay Chemistry (ARC), the Smith 
group has demonstrated that oxasilole species, referred to as siloxanes, are competent 
alternatives to accessing the Type II ARC manifold.3 Nucleophilic addition of an 
organolithium reagent to the electrophilic silicon of siloxane 2.1 affords an alkoxide 
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intermediate (2.3) which is in equilibirum with a hypervalent silicate species (2.4) (Figure 
2-1). Addition of a polar solvent additive, such as HMPA, can trigger the [1,4]-Brook 
rearrangement and permit electrophile capture to afford 2.5. Alternatively, the addition of 
CuI, Pd0, and an aryl iodide with the polar additive, rather than an ordinary electrophile, 
afforded aryl-aryl bond formation adduct 2.6.  Recognizing the similarities between this 
pathway and organosilicon cross-coupling methods, such as those developed by 
Hiyama4 and Takeda,5 it was reasoned that these CCR pathways could be intersected at 
the hypervalent silicate intermediate generated by nucleophilic addition to siloxane 2.1, 
thereby permitting indirect cross-coupling of organolithium reagents via a siloxane 
“transfer agent”. Treatment of siloxane 2.1 with PhLi in THF, followed by the addition of 
CuI/Pd0/4-iodoanisole afforded the desired cross-coupling product 2.7 in good yield and 
recovery of 2.1, thus validating the CCR mediated by a silicon transfer agent.   
Figure 2-1: Transition from Anion Relay Chemistry to Cross-Coupling Reactions 
Ch2Fig 1  
 
Organosilicon-based cross-coupling reactions, pioneered by Hiyama, have 
received increasing attention due to the abundance and low-toxicity of silicon.  Although 
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Denmark, Tamao, and many others have made significant contributions to Hiyama 
coupling methods, only Hiyama and Smith have disclosed recyclable silicon-based 
transfer agents.  The siloxane transfer agents allow the cross-coupling of aryl or alkenyl 
halides and organolithium reagents via the in situ generation of a hypervalent silicate. 
This manifold is initiated by nucleophilic addition to the organometallic reagent on the 
siloxane transfer reagent 2.8, resulting in the formation of the hypervalent silicate (2.9) 
(Figure 2-2).  Subsequently, the silicate species undergoes transmetalation to the Pd(II) 
species (2.10), generated by oxidative addition of the aryl halide to Pd(0), to afford 2.11.  
The transmetalation step transfers the organic portion of the organometallic to palladium 
and regenerates the siloxane transfer agent. The catalytic cycle is completed by the 
reductive elimination of Pd(II) complex 2.11 to Pd(0) and formation of the desired cross-
coupling product (2.12).  Formation of the hypervalent silicate (2.9), with significantly 
reduced basicity and nucleophilicity with respect to the organolithium species permits 
high functional group tolerance, with respect to the electrophile, in CCRs.   
Figure 2-2: Mechanism of Siloxane-Mediated CCR of Organolithium Reagents  




2-2: Design, Synthesis, and Application of Polymer-Supported Silicon-
Transfer Agents for Cross-Coupling Reactions with Organolithium 
Reagents 
(This work was conducted in collaboration with Dr. Minh Nguyen and published in 
Nguyen, M. H.; O’Brien, K. T.; Smith, A. B., III. J. Org. Chem. 2017, 82, 11056.) 
Continued research in the area of siloxane mediated cross-coupling reactions 
has led to the development of several novel siloxanes over the years (Figure 2-3). Initial 
siloxane transfer agent 2.13 demonstrated that an organolithium cross coupling reaction 
could be achieved, validating the concept, but the recoverability of the transfer agent 
was less than ideal. Siloxane 2.13 streaks on silica gel, thus hindering the recovery and 
often co-eluting with the cross-coupling product, requiring Fleming-Tamao oxidation to 
achieve pure product.  
Thus, a second generation of siloxane transfer agent was developed (2.14).6 
Here a Lewis basic pyridine moiety was incorporated into the siloxane to allow recovery 
of the transfer agent prior to column chromatography. Thus, the siloxane could be 
separated from the crude reaction product via acid/base extraction. In cases where the 
products were stable to such extraction conditions this siloxane proved effective.  
While acid/base extraction as a method to purify the siloxane was an 
improvement, an ideal transfer agent could be recovered without the need for 
chromatography or chemical manipulations. Therefore, our attention was turned to the 
development of a polymer supported transfer agent that could be precipitated via neutral 
solvent solubility. Accordingly, a variety of polynorbornene based transfer agents were 
developed, synthesized, and evaluated. It was found that the 200-unit polymer (2.15) 
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was ideal for permitting cross-coupling and could be recovered in high yield.7 Repeated 
use of this polymer in iterative cross-coupling reactions lead to a decrease in yield. 
Furthermore, when two different nucleophiles were used in iterative reactions, some of 
the nucleophile used in the first reaction was identified as active in the next reaction. 
Despite the improvements in recovery observed with siloxane 2.15, efficiency and cross-
coupling integrity issues were exhibited.  
Figure 2-3: Improvements in Design for Recovery of Siloxane Transfers Agents 
Ch2Fig 3  
 
 The problems associated with the first polymer supported siloxane transfer agent 
(2.15) were reasoned to be attributable to intramolecular cross-linking of alkoxide 
intermediates and unreacted siloxanes during the course of the reaction, thus 
diminishing efficiency and causing product contamination. To avoid intramolecular cross-
linking of the alkoxide intermediate, we desired a greater distance between functional 
siloxane units and a more rigid, cross-linked polymer support (Figure 2-4). To achieve 
this, use of an inert co-monomer in the polymerization process would provide greater 
spacing between each of the functional siloxane units. Additionally, a saturated 
polymeric structure was sought, to avoid any thermal or chemical degradation that may 
occur with an olefin containing support. On the basis of these factors, a cross-linked 




Figure 2-4: Design Features of Polystyrene Supported Siloxane Transfer Agent 
Ch2Fig 4  
 
Initially, we envisioned preparing the polymer supported siloxane transfer agent 
(2.17) via functionalization of a commercially available resin (2.18 or 2.19). However, 
attempts to install the siloxane moiety onto commercially available functionalized resin 
by SN2 were unsuccessful using either the polymer or the siloxane as the electrophile 
(2.21) or the nucleophile (2.20), likely a result of side reactivity with the siloxane moiety. 
Scheme 2-1: Failed Attempts to Synthesize Polystyrene Siloxane via SN2 
Ch2_S cheme 1  
 
Thus, we turned our attention to a de novo preparation of the polystyrene 
supported siloxane transfer agent via suspension co-polymerization.8 We envisioned first 
preparing a styrene-containing siloxane monomer which could be subjected to co-
polymerization with styrene and a suitable cross-linker. By this approach, the siloxane 
loading and swelling properties of the polymer could be controlled by selecting the 
100 
 
appropriate ratio. Thus, we began the synthesis of siloxane monomer 2.26 from 
commercially available 2-bromobenzaldehyde (2.22) with allylmagnesium chloride to 
afford benzyl alcohol 2.23. Employing a one-pot three-step reaction sequence, alcohol 
2.23 is converted to siloxane 2.24. Hydroboration of 2.24 with 9-BBN, followed in turn by 
a Suzuki cross-coupling reaction with p-dibromobenzene afforded 2.25. Another Suzuki 
cross-coupling with vinyltrifluoroborate afforded siloxane monomer 2.26. Suspension co-
polymerization of 2.26 with styrene and cross-linker 2.27 (12:87:1 ratio), initiated by 
benzoyl peroxide, proceeded to afford the 1% cross-linked polystyrene-supported 
transfer agent 2.28 as well-defined beads. Upon addition to THF the beads exhibited 
excellent swelling properties, appearing as a gel type resin. The siloxane loading of the 
polymer was reasoned to be approximately equivalent to the silicon loading, the latter of 
which was determined by elemental analysis. 
Scheme 2-2: Synthesis of Polystyrene-Supported Siloxane Transfer Agent (2.28) 




 Siloxane polymer 2.28 was evaluated employing conditions analogous to those 
used with previous siloxane (2.15), to permit cross-coupling of 4-iodoanisole (2.29) and 
PhLi to afford biaryl product (2.30). In this case, the best results were obtained with 
stoichiometry of the organolithium and siloxane of 2.5 equiv and 3.0 equiv respectively. It 
is important to note that the efficiency remained the same after six consecutive CCR 
iterations with this polymer, thereby highlighting the advantages of the newly designed 
polymer. Another key advantage of the polystyrene polymer (2.28), over the norbornene 
based polymer (2.15), is the ease of recovery. Whereas the norbornene based polymer 
(2.15) was recovered by precipitation, the polystyrene based polymer (2.28) requires 
only filtration of the crude product and a washing/drying sequence to afford quantitative 
recovery before use in iterative cross-coupling reactions.  
Figure 2-5: Recyclability of Siloxane Transfer Agent 2.28 in Iterative CCRs 
Ch2Fig 5  
 
 With the validated siloxane polymer 2.28 in hand, we began to evaluate the 
substrate scope of this cross-coupling reaction with repeated reactions employing 
different nucleophiles and electrophiles. A variety of nucleophiles, including aryl- and 
vinyllithium species were tolerated. Aryl bromides and iodides were both amenable in 
the CCR. Significantly, aryl and vinyl iodide electrophiles were well tolerated, even with 
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electrophilic ketone (2.31h) and nitrile substituents (2.31f), highlighting the functional 
group tolerance of this method. Furthermore, no nucleophile cross-contamination 
products were detected in this series of reactions. Once more, nearly quantitative 
recovery of polymer supported siloxane transfer agent 2.28 was observed between each 
of the sequential cross-coupling experiments. 
Figure 2-6: Siloxane CCR Employing Recycled Transfer Agent 




 To highlight the utility of this polymer supported siloxane transfer agent (2.28), a 
second batch of polymer was prepared according to the same synthetic scheme 
(Scheme 2-2). In this case, the silicon loading was found to be 0.57 mmol/g, as 
compared to the previously observed 0.74 mmol/g. Adjusting the conditions only to 
account for this difference in silicon loading permitted effective iterative use in the same 
manner. Here, the substrate scope was evaluated with an emphasis on heterocyclic 
species (Figure 2-9). To this end, electrophilic coupling partners comprising imidazole 
(2.31j) and all regioisomers of iodopyridine (2.31i, 2.31l, and 2.31m) proceeded 
efficiently. It is worth mentioning that trifluoromethyl substitution was also well tolerated 
in both electrophilic (2.31k) and nucleophilic (2.31r) components. A variety of heteroaryl 
and hindered aryllithiums were suitable in the cross-coupling reaction. We were 
particularly interested in cross-coupling reactions of 2-substituted heterocycle 2.31o, 
given the inherently unstable and/or challenging to access 2-heterocyclic cross-coupling 
surrogates. Pleasingly, the direct cross-coupling of 2-lithiopyridine was permitted 
employing 2.28, alleviating the need for preconstruction of 2-pyridyl N-
methyliminodiacetic acid (MIDA) boronates.9 Furthermore, cross-couplings of 2-
thienyllithium and 2-benzofuryllithium were successful, providing good yield of desired 
products (2.31n and 2.31q), while the latter access via a direct o-lithiation/cross-coupling 
sequence of benzofuran. Importantly, a single batch of polymer was used and recovered 
nearly quantitatively following each reaction in this series of experiments. 
Polystyrene supported siloxane transfer agent 2.28 has proven to be the most 
effective transfer agent to date and the features that enable this success were a result of 
improvement upon the design of pre-existing transfer agents. This polymer support in 
turn greatly simplifies purification of the product and recovery of the transfer agent while 
104 
 
maintaining the efficiency of the cross-coupling reaction over consecutive reaction 
cycles. Moreover, sensitive functional groups such as nitrile and esters are tolerated in 
this organolithium cross-coupling reaction. Thus, the direct use of organolithium 
reagents in cross-coupling reactions has been achieved without the need for the 
generation of stoichiometric waste by-products.  
Figure 2-7: Expanded Siloxane CCR Employing Recycled Transfer Agent 





We have reported here the development of a polystyrene supported siloxane 
transfer agent for use in transition metal-catalyzed cross-coupling reactions of 
organolithium reagents with aryl halides. The rational design of this polymer, inspired by 
the shortcomings observed in previous generations of transfer agents developed by our 
group, permitted us to arrive at a transfer agent suitable for iterative cross-coupling 
reactions with high efficiency and recovery with only a simple filtration and rinsing 
sequence required. This method holds the promise of wide application in that the direct 
use of organolithium reagents permits CCRs without the generation of stoichiometric 
waste products, such as zinc or boron, which are currently the gold standard nucleophilic 
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2-5: Experimental Section 
 1-6-a: General 
 All reactions were performed in flame- or oven-dried (120 °C) glassware under 
an atmosphere of nitrogen or argon. All aqueous work-ups were performed open to air 
and all organic solutions were dried over magnesium sulfate prior to filtration through a 
cotton plug and rotary evaporation. Reactions were magnetically stirred unless otherwise 
stated. Tetrahydrofuran (THF) and diethyl ether (Et2O) were dried by passage through 
alumina in a Pure SolveTM PS-400 solvent purification system.  Subsequently THF and 
Et2O were distilled from sodium/benzophenone prior to use. Unless otherwise stated, 
solvents and reagents were used as received. Thin layer chromatography (TLC) was 
performed on pre-coated silica gel 60 F-254 plates (40-55 micron, 230-400 mesh) and 
visualized by UV light or staining with p-anisaldehyde (acetic acid, sulfuric acid, and 
methanol) and heating. Yields refer to chromatographically and spectroscopically pure 
compounds unless otherwise noted. 1H-NMR and 13C-NMR spectra were recorded at 
500 MHz/125MHz on a Bruker Avance III 500 MHz spectrometer at 300 K, `H-NMR, 13-
CNMR and 19F-NMR spectra were also recorded at 400 MHz/100 MHz/76 MHz on a 
Bruker NEO-400 NMR. Chemical shifts are reported in parts per million with the residual 
chloroform solvent peak (δ 7.26) as an internal standard. 1H-NMR spectra are tabulated 
in the following manner: chemical shift (multiplicity, coupling constant, integration). The 
following abbreviations were used to explain the multiplicities: s=singlet, d=doublet, 
t=triplet, q=quartet, dd=doublet of doublets, ddd=doublet of doublet of doublets, 
dt=doublet of triplets, td=triplet of doublets, tt=triplet of triplets, qt=quartet of triplets, 
m=multiplet. 13C-NMR spectra are tabulated by observed peak. Supercritical Fluid 
Chromatography (SFC) analyses were performed with a JASCO system equipped with a 
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Chiralcel® AD-H column (5 µm, 4.6 mm x 250 mm), a PU-280-CO2 plus CO2 Delivery 
System, a CO-2060 plus Intelligent Column Thermostat, an HC-2068-01 Heater 
Controller, a BP-2080 plus Automatic Back Pressure Regulator, an MD-2018 plus 
Photodiode Array Detector (200-648 nm), and PU-2080 plus Intelligent HPLC Pumps. 
High-resolution mass spectra (HRMS) were acquired on a Waters LC-TOF mass 
spectrometer (model LCT-XE Premier) at the University of Pennsylvania. 
1-6-b: Synthesis of Polystyrene Supported Siloxane Tranfer Agent (2.28) 
 
Allylmagnesium chloride (2.0 M in THF, 52.20 mL, 104.47 mmol) was added 
slowly to a stirred solution of 2-bromobenzaldehyde (16.11 g, 87.05 mmol) in 250 
mL THF at room temperature. The obtained solution was stirred for 15 h and was 
quenched with saturated aqueous NH4Cl (50 mL). The organic layer was 
collected and the aqueous layer was extracted with Et2O (2 x 50 mL). The 
combined organic layers were washed with brine, dried with MgSO4, and 
concentrated in vacuo. The crude product was purified by flash chromatography 
on silica gel (10% EtOAc/Hexanes) to afford the desired alcohol 2.23 as a pale 
yellow oil (18.73 g, 82.88 mmol, 95%). 1H NMR (500 MHz, CDCl3) δ 7.59-7.55 
(m, 1 H), 7.52 (d, J = 7.9 Hz, 1 H), 7.34 (t, J = 7.5 Hz, 1 H), 7.16-7.11 (m, 1 H), 
5.93-5.83 (m, 1 H), 5.24-5.16 (m, 2 H), 5.14-5.09 (m, 1 H), 2.69-2.62 (m, 1 H), 
2.40-2.32 (m, 1 H), 2.14 (d, J = 3.4 Hz, 1 H); 13C NMR (125 MHz, CDCl3) δ 
142.8, 134.4, 132.8, 129.0, 127.8, 127.5, 121.9, 118.9, 72.0, 42.3; IR (neat, cm–1) 
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3389, 3073, 2979, 2912, 1639, 1568, 1468, 1439, 1023, 917, 754; HRMS (CI+) 
m/z (M-C3H5)+: Calcd for C7H6OBr: 184.9602, found: 184.9608. 
 
 
A solution of n-BuLi (2.55 M in hexanes, 62.10 mL, 158.30 mmol) was added 
dropwise to a stirred solution of benzyl alcohol 2.23 (16.33 g, 71.95 mmol) in 250 
mL THF at –78 oC. The obtained solution was stirred for 1 h, followed by addition 
of Me2SiHCl (17.20 mL, 158.30 mmol) in one portion at –78 oC. The resulting 
reaction mixture was allowed to warm to rt and was stirred overnight. After 14 h, 
the reaction mixture was quenched by addition of d.i. H2O (100 mL) and stirred 
for 4 h. Note slow evolution of hydrogen gas (caution!). The organic layer was 
collected and the aqueous layer was extracted with hexanes (2 x 50 mL). The 
combined organic layers were washed with brine, dried with MgSO4, and 
concentrated in vacuo. Kugelrohr distillation (50 – 140 oC, 0.025 mmHg), 
followed by flash chromatography on water-washed silica gel (1% Et2O/Hexanes) 
afforded the desired siloxane 2.24 as a colorless oil (6.60 g, 32.35 mmol, 45%). 
1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 7.1 Hz, 1 H), 7.42-7.37 (m, 1 H), 7.31 
(t, J = 7.1 Hz, 1 H), 7.24 (d, J = 7.7 Hz, 1 H), 5.87-5.76 (m, 1 H), 5.30 (dd, J = 
3.9, 7.0 Hz, 1 H), 5.14-5.04 (m, 2 H), 2.73-2.65 (m, 1 H), 2.47-2.39 (m, 1 H), 0.38 
(d, J = 15.5 Hz, 6 H); 13C NMR (125 MHz, CDCl3) δ 152.5, 135.9, 134.7, 131.0, 
129.7, 127.2, 122.5, 117.7, 81.2, 43.5, 1.5, 0.7; IR (neat, cm–1) 3072, 3001, 2966, 
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2931, 2899, 2868, 1642, 1595, 1443, 1329, 1076, 1049, 988, 897, 825, 790; 
HRMS (CI+) m/z (M-CH3)+: Calcd for C11H13OSi: 189.0736, found: 189.0733. 
 
 
A solution of 9-BBN (0.5 M in THF, 12.15 mL, 6.08 mmol) was added dropwise to 
a flask containing siloxane 2.24 (826.3 mg, 4.05 mmol) while stirring at room 
temperature. The obtained solution was stirred for 3 h. A screw-cap vial was 
charged with 1,4-dibromobenzene (2.87 g, 12.15 mmol), Pd(dppf)Cl2.DCM (165.4 
mg, 0.203 mmol), K3PO4 (1.72 g, 8.10 mmol), and the mixture was suspended in 
10 mL DMF. The obtained mixture was stirred for 15 min at room temperature, 
followed by addition of the above solution containing siloxane 2.24/9-BBN adduct 
via cannula (rinsed with 0.5 mL DMF). The obtained vial was capped and heated 
to 50 oC for 16 h. The reaction mixture was then cooled to room temperature and 
quenched with d.i. H2O (10 mL). The resulting mixture was extracted with Et2O (2 
x 25 mL). The combined organic layers were washed with brine, dried with 
MgSO4, and concentrated in vacuo. The crude oil was then taken up in THF (10 
mL), followed by addition of solid NaBO3.4H2O (3.12 g, 20.25 mmol), and d.i. 
H2O (10 mL) for oxidation of borane byproducts to facilitate purification. The 
mixture was then stirred vigorously at room temperature, open to air, for 2 h. The 
aqueous layer was then extracted with hexanes (2 x 25 mL). The combined 
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organic layers were washed with brine, dried with MgSO4, and concentrated in 
vacuo. Purification by column chromatography afforded the desired aryl bromide 
2.25 as pale yellow oil (1.25 g, 3.46 mmol, 85%). 1H NMR (500 MHz, CDCl3) δ 
7.54 (d, J = 7.1 Hz, 1 H), 7.41-7.35 (m, 3 H), 7.29 (t, J = 7.1 Hz, 1 H), 7.15 (d, J = 
7.7 Hz, 1 H), 7.03 (d, J = 8.3 Hz, 2 H), 5.25 (dd, J = 3.3, 7.4 Hz, 1 H), 2.68-2.53 
(m, 2 H), 1.98-1.90 (m, 1 H), 1.82-1.59 (m, 3 H), 0.37 (d, J = 4.8 Hz, 6 H); 13C 
NMR (125 MHz, CDCl3) δ 153.0, 141.5, 135.7, 131.4, 131.0, 130.3, 129.8, 127.1, 
122.3, 119.5, 81.5, 38.3, 35.3, 26.5, 1.5, 0.7; IR (neat, cm–1) 3058, 2942, 2860, 
1593, 1487, 1252, 1077, 876, 818, 790; HRMS (CI+) m/z (M)+: Calcd for 
C18H21OBrSi: 360.0545, found: 360.0529. 
 
 
A solution of potassium vinyltrifluoroborate (336.6 mg, 2.51 mmol), PdCl2 (6.9 
mg, 0.039 mmol), PPh3 (30.4 mg, 0.116 mmol), Cs2CO3 (1.89 g, 5.80 mmol), and 
aryl bromide 2.25 (698.5 mg, 1.93 mmol) in THF/H2O (9:1, 4.1 mL) was heated at 
85 oC in a screw-cap vial. The reaction mixture was stirred at 85 oC for 19 h, then 
cooled to room temperature and diluted with H2O (5 mL), followed by extraction 
with dichloromethane (2 x 10 mL). The combined organic layers were washed 
with brine, dried with MgSO4, and concentrated in vacuo. Purification via flash 
chromatography on water-washed silica gel (1% Et2O/Hexanes) afforded the 
desired styrene 2.26 as a colorless oil (536.7 mg, 1.74 mmol, 90%). 1H NMR 
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(500 MHz, CDCl3) δ 7.54 (d, J = 7.1 Hz, 1 H), 7.40-7.35 (m, 1 H), 7.33-7.26 (m, 3 
H), 7.16 (d, J = 7.7 Hz, 1 H), 7.12 (d, J = 7.9 Hz, 2 H), 6.69 (dd, J = 10.9, 17.6 
Hz, 1 H), 5.70 (d, J = 17.6 Hz, 1 H), 5.26 (dd, J = 3.2, 7.3 Hz, 1 H), 5.18 (d, J = 
10.9 Hz, 1 H), 2.72-2.57 (m, 2 H), 2.01-1.90 (m, 1 H), 1.84-1.59 (m, 3 H), 0.38 (d, 
J = 7.1 Hz, 6 H); 13C NMR (125 MHz, CDCl3) δ 153.1, 142.3, 136.9, 135.7, 135.2, 
131.0, 129.7, 128.7, 127.0, 126.3, 122.3, 113.0, 81.6, 38.4, 35.6, 26.5, 1.5, 0.7; 
IR (neat, cm–1) 3055, 3001, 2941, 2858, 1629, 1511, 1442, 1252, 1085, 876, 823, 
790; HRMS (CI+) m/z (M)+: Calcd for C20H24OSi: 308.1596, found: 308.1581. 
 
 
A solution of acacia gum (3.2 g) and NaCl (2.0 g) in H2O (85 mL) was placed in a 
100 mL- reaction flask equipped with a mechanical stirrer and deoxygenated by 
purging with N2 for 30 min. A solution of monomer 2.26 (433 mg, 1.40 mmol), 
styrene (1.20 mL, 10.47 mmol), cross-linker 2.27 (34.9 mg, 0.119 mmol), and 
benzoyl peroxide (20.0 mg, 0.083 mmol) in chlorobenzene (2.0 mL) was injected 
to the rapidly stirred aqueous solution. This mixture was heated at 85 oC for 17 h. 
The crude polymer was collected by filtration and washed sequentially with 
MeOH/H2O (3:1, 4 x 50 mL), MeOH (2 x 50 mL), THF (2 x 25 mL), Et2O (2 x 25 
mL), hexanes (2 x 25 mL), followed by drying in vacuo to provide the desired 
polymer 2.28 as white beads (724 mg) and a Si loading of 1.49 mmol/g was 
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determined by inductively coupled plasma optical emission spectrometry (ICP-
OES). The yield was 77% based on Si incorporation. IR (KBr, cm–1) 3026, 2914, 
1943, 1721, 1492, 1448, 1372, 1329, 1249, 1082, 1026, 743, 698. 
 
1-6-c: Procedure for Recyclability of Siloxane Transfer Agent in Iterative 
CCRs 
To a cooled suspension of siloxane polymer 2.28 (1.49 mmol/g, 500 mg, 0.745 mmol) 
swelling in THF (20 mL) at -78 °C was added PhLi in Bu2O (1.8 M, 345 µL, 0.621 mmol) 
dropwise. The reaction mixture was allowed to warm to room temperature and was 
stirred for 3 h. A solid mixture of PdCl2 (1.3 mg, 7.4 µmol), CuI (4.7 mg, 25 µmol), and 
dpca (3.7 mg, 9.9 µmol) was combined and added to the reaction flask, followed by 
addition of 4-iodoanisole (58.0 mg, 0.248 mmol). The obtained reaction mixture was 
stirred vigorously at room temperature for 18 h. The reaction mixture was then quenched 
with sat. aq. NH4Cl (5 mL), followed by addition of deionized H2O (5 mL), and stirred for 
an hour at room temperature. The obtained mixture was filtered through a fritted filter to 
remove polymer. The filtered polymer was then washed with Et2O (4 x 50 mL). The 
combined filtrate was washed with brine, dried with MgSO4, and concentrated in vacuo, 
followed by purification via flash chromatography (1% Et2O/hex) to provide the desired 
cross-coupling product 4-phenylanisole 2.30 as a white solid (43.8 mg, 0.238 mmol, 
96%). 1H NMR (500 MHz, CDCl3) δ 7.57-7.53 (m, 4 H), 7.42 (t, J = 7.6 Hz, 2 H), 7.31 (t, 
J = 7.4 Hz, 1 H), 6.99 (d, J = 8.7 Hz, 2 H), 3.86 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 
159.3, 141.0, 133.9, 128.9, 128.3, 126.9, 126.8, 114.3, 55.5; HRMS (CI+) m/z (M+H)+: 
Calcd for C13H13O: 185.0966, found: 185.0963. Following filtration, the polymer was 
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further washed sequentially with a MeOH/H2O solution (1:1, 2 x 50 mL), MeOH (2 x 25 
mL), CH2Cl2 (2 x 25 mL), Et2O (2 x 25 mL), hexanes (2 x 25 mL), and dried in vacuo to 
provide near quantitative recovery of siloxane polymer. The obtained polymer was re-
used 5 more times employing the same procedure above and showed no loss in cross-
coupling efficiency. 
 
1-6-d: General Procedure for Siloxane CCR Multiple Nucleophiles and 
Electrophiles 
To a cooled suspension of siloxane polymer 2.28 (3.0 equiv) swelling in THF (25 
mL) at –78 oC was added the organolithium solution (2.5 equiv) dropwise. The 
reaction mixture was allowed to warm to room temperature and was stirred for 3 
h. A solid mixture of PdCl2 (3 mol %), CuI (10 mol %), and dpca (4 mol %) was 
combined and added to the reaction flask, followed by addition of the aryl or 
alkenyl halide (1.0 equiv). The obtained reaction mixture was stirred vigorously at 
room temperature for 18 h. The reaction mixture was then quenched with sat. aq. 
NH4Cl (5 mL), followed by addition of dH2O (5 mL), and stirred for an hour at 
room temperature. The obtained mixture was filtered through a fritted filter to 
remove polymer. The filtered polymer was then washed with Et2O (4 x 50 mL). 
The combined filtrate was washed with brine, dried with MgSO4, and 
concentrated in vacuo, followed by purification via flash chromatography to 
provide the desired cross-coupling product. Following filtration, the polymer was 
further washed sequentially with MeOH/H2O solution (1:1, 2 x 50 mL), MeOH (2 x 
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25 mL), CH2Cl2 (2 x 25 mL), Et2O (2 x 25 mL), hexanes (2 x 25 mL), and dried in 
vacuo to provide near quantitative recovery of siloxane polymer, which was 
employed in the next cross-coupling cycle. 
 
Following general procedure, using 2.28 (750 mg, 0.555 
mmol), (4-(tert-butyl)phenyl)lithium (926 µL, 0.50 M, 0.463 mmol), PdCl2 (1.0 mg,  5.6 
µmol), dpca (2.7 mg, 7.4 µmol), CuI (3.5 mg, 18.5 µmol) and 4-iodoanisole (42.0 mg, 
0.180 mmol). The product was purified by chromatography on SiO2 (1% Et2O/ hexanes) 
to afford 2.31a (41.2 mg, 0.172 mmol, 95%) as a colorless solid. 1H NMR (500 MHz, 
CDCl3) δ 7.57-7.49 (m, 4 H), 7.48-7.44 (m, 2 H), 6.98 (d, J = 8.7 Hz, 2 H), 3.86 (s, 3 H), 
1.38 (s, 9 H); 13C NMR (125 MHz, CDCl3) δ 159.1, 149.8, 138.1, 133.8, 128.1, 126.5, 
125.8, 114.3, 55.5, 34.6, 31.5; HRMS (CI+) m/z (M+H)+: Calcd for C17H21O: 241.1592, 
found: 241.1603. 
 
Following general procedure, using 2.28 (720 mg, 0.533 mmol), 
PhLi (234 µL, 1.9 M, 0.444 mmol), PdCl2 (0.9 mg, 5.3 µmol), dpca (2.6 mg, 7.1 µmol), 
CuI (3.4 mg, 17.8 µmol) and 4-iodoanisole (41.6 mg, 0.178 mmol). The product was 
purified by chromatography on SiO2 (1% Et2O/ hexanes) to afford 2.31 (31.8 mg, 0.173  
mmol, 97%) as a colorless solid. 1H NMR (500 MHz, CDCl3) δ 7.57-7.53 (m, 4 H), 7.42 
(t, J = 7.6 Hz, 2 H), 7.31 (t, J = 7.4 Hz, 1 H), 6.99 (d, J = 8.7 Hz, 2 H), 3.86 (s, 3 H); 13C 
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NMR (125 MHz, CDCl3) δ 159.3, 141.0, 133.9, 128.9, 128.3, 126.9, 126.8, 114.3, 55.5; 
HRMS (CI+) m/z (M+H)+: Calcd for C13H13O: 185.0966, found: 185.0963. 
 
Following general procedure, using 2.28 (702 mg, 0.519 
mmol), (4-(methoxy)phenyl)lithium  (1.2 mL, 0.36 M, 0.433 mmol), PdCl2 (0.9 mg, 5.2 
µmol), dpca (2.6 mg, 7.0 µmol), CuI (3.3 mg, 17.3 µmol) and (E)-(4-iodobut-3-en-1-
yl)benzene (44.7 mg, 0.173 mmol). The product was purified by chromatography (0.5 % 
Et2O/ hexanes) to afford 2.31c (37 mg, 0.155 mmol, 90%) as a colorless solid. 1H NMR 
(500 MHz, CDCl3) δ 7.57 (d, J = 8.3 Hz, 2 H), 7.39 (d, J = 8.3 Hz, 2 H), 7.31 (t, J = 7.5 
Hz, 2 H), 7.25 - 7.18 (m, 3 H), 6.46 - 6.35 (m, 2 H), 2.81 (t, J = 7.7 Hz, 2 H), 2.64 - 2.52 
(m, 2 H); 13C NMR (125 MHz, CDCl3) δ 142.3, 141.4, 134.4, 132.5, 129.2, 128.6, 128.6, 
126.6, 126.2, 119.2, 110.3, 35.6, 35.0; HRMS (CI+) m/z (M)+: Calcd for C17H15N: 
233.1204, found: 233.1200. 
 
Following general procedure, using 2.28 (686 mg, 0.508 mmol), 
(E)-hept-1-en-1-yllithium (1.14 mL, 0.37 M, 0.423 mmol), PdCl2 (0.9 mg, 5.1 µmol), dpca 
(2.5 mg, 6.8 µmol), CuI (3.2 mg, 16.9 µmol) and 4-iodoanisole (39.6 mg, 0.169 mmol). 
The product was purified by chromatography on SiO2 (0-0.5 % Et2O/ hexanes) to afford 
2.31d (25.5 mg, 0.125 mmol, 74%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.28 
(dd, J = 2.0, 6.5 Hz, 2 H), 6.84 (dd, J = 2.1, 6.6 Hz, 2 H), 6.32 (d, J = 15.7 Hz, 1 H), 6.09 
(dt, J = 7.2, 15.8 Hz, 1 H), 3.80 (s, 3 H), 2.18 (m, 2 H), 1.46 (m, 2 H), 1.40-1.37 (m, 4 H), 
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0.90 (t, J = 7.1 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 158.6, 131.2, 129.6, 129.5, 
127.1, 114.2, 55.7, 33.5, 31.4, 29.5, 22.7, 14.1; HRMS (CI+) m/z (M+H)+: Calcd for 
C14H21O: 205.1592, found: 205.1621. 
 
Following general procedure, using 2.28 (662 mg, 0.490 
mmol), (E)-(3-((trimethylsilyl)oxy)prop-1-en-1-yl)lithium (1.4 mL, 0.30 M, 0.408 mmol), 
PdCl2 (0.9 mg, 4.9 µmol), dpca (2.4 mg, 6.5 µmol), CuI (3.1 mg, 16.3 µmol) and (E)-(4-
iodobut-3-en-1-yl)benzene (42.1 mg, 0.163 mmol). The crude was taken up in THF (3 
mL) and treated with TBAF (0.65 mmol, 4.0 equiv, 1.0 M in THF). The reaction mixture 
was stirred at rt for 4 h, quenched with sat. aq. NH4Cl (5 mL), followed by addition of d.i. 
H2O (5 mL). The organic layer was collected and the aqueous layer was extracted with 
Et2O (2 x 10 mL). The combined organic layers were washed with brine, dried with 
MgSO4, and concentrated in vacuo. The product was purified by chromatography on 
SiO2 (20 % Et2O/ hexanes) to afford 2.31e (22.0 mg, 0.117 mmol, 72%) as a colorless 
oil. 1H NMR (500 MHz, CDCl3) δ 7.31 - 7.26 (m, 2 H), 7.22 - 7.16 (m, 3 H), 6.22 (dd, J = 
10.5, 15.1 Hz, 1 H), 6.09 (dd, J = 10.5, 15.1 Hz, 1 H), 5.79 - 5.70 (m, 2 H), 4.17 (d, J = 
3.8 Hz, 2 H), 2.71 (t, J = 7.8 Hz, 2 H), 2.42 (q, J = 7.4 Hz, 2 H), 1.30 (bs, 1 H); 13C NMR 
(125 MHz, CDCl3) δ 141.8, 134.6, 132.0, 130.1, 130.0, 128.6, 128.5, 126.0, 63.7, 35.8, 
34.6; HRMS (CI+) m/z (M-OH)+: Calcd for C13H15: 171.1174, found: 171.1182. 
 
Following general procedure, using 2.28 (660 mg, 0.488 mmol), 
PhLi (214 µL, 1.9 M, 0.407 mmol), PdCl2 (0.9 mg, 4.9 µmol), dpca (2.4 mg, 6.5 µmol), 
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CuI (3.1 mg, 16.3 µmol) and 4-iodobenzonitrile (37.3 mg, 0.163 mmol). The product was 
purified by chromatography on SiO2 (2% Et2O/ hexanes) to afford 2.31f (26.8 mg, 0.150 
mmol, 92%) as a colorless solid. 1H NMR (500 MHz, CDCl3) δ 7.73 (d, J = 8.3 Hz, 2 H), 
7.69 (d, J = 8.4 Hz, 2 H), 7.59 (d, J = 7.4 Hz, 2 H), 7.49 (t, J = 7.2 Hz, 2 H), 7.43 (t, J = 
7.3 Hz, 1 H); 13C NMR (125 MHz, CDCl3) δ 145.8, 139.3, 132.8, 129.3, 128.8, 127.9, 
127.4, 119.1, 111.1; HRMS (CI+) m/z (M+H)+: Calcd for C13H10N: 180.0813, found: 
180.0813. 
 
Following general procedure, using 2.28 (650 mg, 0.481 
mmol), PhLi (211 µL, 1.9 M, 0.401 mmol), PdCl2 (0.9 mg, 4.8 µmol), dpca (2.4 mg, 6.4 
µmol), CuI (3.0 mg, 16.0 µmol) and 4-(5-iodopyridin-2-yl)morpholine (46.4 mg, 0.160 
mmol). The product was purified by chromatography on SiO2 (20% Et2O/ hexanes) to 
afford 2.31g (34.9 mg, 0.145 mmol, 91%) as a colorless solid. 1H NMR (500 MHz, 
CDCl3) δ 8.47 (d, J = 2.2 Hz, 1 H), 7.75 (dd, J = 2.5, 8.8 Hz, 1 H), 7.53 (d, J = 7.4 Hz, 2 
H), 7.43 (t, J = 7.5 Hz, 2 H), 7.32 (t, J = 7.4 Hz, 1 H), 6.71 (d, J = 8.8 Hz, 1 H), 3.85 (app 
t, J = 4.9 Hz, 4 H), 3.56 (app t, J = 4.9 Hz, 4 H); 13C NMR (125 MHz, CDCl3) δ 158.9, 
146.3, 138.4, 136.3, 129.1, 127.0, 126.9, 126.4, 106.8, 66.9, 45.8; HRMS (CI+) m/z 
(M+H)+: Calcd for C15H17N2O: 241.1341, found: 241.1344. 
 
Following general procedure, using 2.28 (620 mg, 0.459 mmol), 
PhLi (201 µL, 1.9 M, 0.382 mmol), PdCl2 (0.8 mg, 4.6 µmol), dpca (2.3 mg, 6.1 µmol), 
119 
 
CuI (2.9 mg, 15.3 µmol) and 4-iodoacetophenone (36.5 mg, 0.148 mmol). The product 
was purified by chromatography on SiO2 (5% Et2O/ hexanes) to afford 2.31h (23.8 mg, 
0.121 mmol, 82%) as a colorless solid. 1H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 8.3 Hz, 
2 H), 7.69 (d, J = 8.1 Hz, 2 H), 7.63 (d, J = 7.3 Hz, 2 H), 7.48 (t, J = 7.5 Hz, 2 H), 7.41 (t, 
J = 7.3 Hz, 1 H), 2.64 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 197.9, 145.9, 140.0, 136.0, 
129.1, 129.0, 128.4, 127.4, 127.4, 26.8; HRMS (CI+) m/z (M)+: Calcd for C14H12O: 
196.0888, found: 196.0888. Preparation of 2.31h from 4-bromoacetophenone was 
carried out in a similar fashion. 
 
Following general procedure, using 2.28 (699 mg, 0.390 mmol), PhLi 
(176 µL, 1.85 M, 0.325 mmol), PdCl2 (0.7 mg, 4.0 µmol), dpca (2.0 mg, 5.2 µmol), CuI 
(2.6 mg, 13.0 µmol) and 4-iodopyridine (26.7 mg, 0.13 mmol). The product was purified 
by chromatography on SiO2 (40% EtOAc/ hexanes, Rf = 0.27) to afford 2.31i (15.6 mg, 
0.100 mmol, 77%) as a colorless liquid. 1H NMR (500 MHz, CDCl3) δ 8.67 (s, 2H), 7.65 
(dd, J = 7.2, 1.8 Hz, 2H), 7.52 – 7.42 (m, 5H); 13C NMR (125 MHz, CDCl3) δ 150.2, 
148.3, 138.2, 129.1, 129.0, 127.0, 121.7; HRMS (EI+): Calcd for C11H9N: 155.0734, 
found: 155.0735. 
 
Following general procedure, using 2.28 (684 mg, 0.390 mmol), PhLi 
(176 µL, 1.85 M, 0.325 mmol), PdCl2 (0.7 mg, 4.0 µmol), dpca (2.0 mg, 5.2 µmol), CuI 
(2.6 mg, 13.0 µmol) and 4-iodo-1-methyl-1H-imidazole (27.0 mg, 0.13 mmol). The 
product was purified by chromatography on SiO2 (40% EtOAc/ hexanes, Rf = 0.23) to 
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afford 2.31j (16.6 mg, 0.105 mmol, 81%) as a colorless solid. 1H NMR (500 MHz, CDCl3) 
δ 7.76 (s, 1H), 7.60 (s, 1H), 7.47 (d, J = 7.6 Hz, 2H), 7.36 (t, J = 7.6 Hz, 2H), 7.22 (t, J = 
7.4 Hz, 1H), 3.94 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 136.7, 132.6, 128.8, 126.9, 
126.3, 125.5, 123.2, 39.0; HRMS (EI+) m/z (M)+: Calcd for C10H10N2: 158.0844, found: 
158.0833. 
 
Following general procedure, using 2.28 (652 mg, 0.371 mmol), 
PhLi (167 µL, 1.85 M, 0.309 mmol), PdCl2 (0.7 mg, 4.0 µmol), dpca (2.0 mg, 5.2 µmol), 
CuI (2.5 mg, 12.0 µmol) and 1-iodo-4-(trifluoromethyl)benzene (33.7 mg, 0.124 mmol). 
The product was purified by chromatography on SiO2 (100% hexanes, Rf = 0.54) to 
afford 2.31k (25.1 mg, 0.114 mmol, 92%) as a colorless solid. 1H NMR (500 MHz, 
CDCl3) δ 7.70 (s, 4H), 7.61 – 7.60 (m, 2H), 7.48 (t, J = 7.6 Hz, 2H), 7.41 (t, J = 7.3 Hz, 
1H); 13C NMR (125 MHz, CDCl3) δ 144.7, 139.8, 129.5, 129.0, 128.2, 127.4, 127.3, 
125.7 (q, JCF = 3.7 Hz), 123.2; HRMS (EI+) m/z (M)+: Calcd for C13H9F3: 222.0656, found: 
222.0663. 
 
Following general procedure, using 2.28 (645 mg, 0.367 mmol), PhLi 
(167 µL, 1.85 M, 0.310 mmol), PdCl2 (0.6 mg, 3.6 µmol), dpca (1.8 mg, 4.8 µmol), CuI 
(2.3 mg, 12.0 µmol) and 3-iodopyridine (24.6 mg, 0.12 mmol). The product was purified 
by chromatography on SiO2 (40% EtOAc/ hexanes, Rf = 0.32) to afford 2.31l (15.6 mg, 
0.101 mmol, 84%) as a colorless liquid:36 1H NMR (500 MHz, CDCl3) δ 8.86 (d, J = 2.3 
Hz, 1H), 8.59 (dd, J = 4.7, 1.6 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.1 Hz, 2H), 
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7.48 (t, J = 7.6 Hz, 2H), 7.41 (t, J = 7.4 Hz, 1H), 7.37 (dd, J = 7.9, 4.8 Hz, 1H).; 13C NMR 
(125 MHz, CDCl3) δ 148.4, 148.3, 137.8, 136.6, 134.4, 129.1, 128.1, 127.1, 123.5; 
HRMS (EI+) m/z (M+H)+: Calcd for C11H9N: 155.0727, found: 155.0735. 
 
Following general procedure, using 2.28 (640 mg, 0.364 mmol), PhLi 
(169 µL, 1.80 M, 0.303 mmol), PdCl2 (0.6 mg, 3.6 µmol), dpca (1.8 mg, 4.8 µmol), CuI 
(2.3 mg, 12.0 µmol) and 2-iodopyridine (24.6 mg, 0.12 mmol). The product was purified 
by chromatography on SiO2 (40% EtOAc/ hexanes, Rf = 0.31) to afford 2.31m (16.3 mg, 
0.106 mmol, 88%) as a colorless liquid. 1H NMR (500 MHz, CDCl3) δ 8.70 (d, J = 4.5 Hz, 
1H), 7.99 (d, J = 6.9 Hz, 2H), 7.77 – 7.72 (m, 2H), 7.48 (t, J = 7.3 Hz, 2H), 7.42 (t, J = 
7.3 Hz, 1H), 7.23 (td, J = 4.8, 2.3 Hz, 1H).; 13C NMR (125 MHz, CDCl3) δ 157.5, 149.7, 
139.4, 136.7, 128.9, 128.7, 126.9, 122.1, 120.5; HRMS (EI+) m/z (M)+: Calcd for C11H9N: 
155.0735, found: 155.0717. 
 
Following general procedure, using 2.28 (638 mg, 0.360 mmol), 2-
thienyllithium (714 µL, 0.42 M, 0.30 mmol), PdCl2 (0.6 mg, 3.6 µmol), dpca (1.8 mg, 4.8 
µmol), CuI (2.3 mg, 12.0 µmol) and 4-iodoanisole (27.5 mg, 0.12 mmol). The product 
was purified by chromatography on SiO2 (1% EtOAc/ hexanes, Rf = 0.31) to afford 2.31n 
(16.2 mg, 0.114 mmol, 71%) as a colorless solid. 1H NMR (500 MHz, CDCl3) δ δ 7.54 (d, 
J = 8.7 Hz, 2H), 7.21 (d, J = 5.2 Hz, 1H), 7.20 (d, J = 3.5 Hz, 1H), 7.05 (dd, J = 5.1, 3.6 
Hz, 1H), 6.92 (d, J = 8.7 Hz, 2H), 3.84 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 159.2, 
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144.3, 127.9, 127.3, 127.2, 123.8, 122.1, 114.3, 55.4; HRMS (EI+) m/z (M)+: Calcd for 
C11H10OS: 190.0452, found: 190.0436. 
 
Following general procedure, using 2.28 (616 mg, 0.351 mmol), 2-
pyridyllithium (572 µL, 0.51 M, 0.292 mmol), PdCl2 (0.7 mg, 4.0 µmol), dpca (1.9 mg, 5.0 
µmol), CuI (2.3 mg, 12.0 µmol) and 4-iodoanisole (26.8 mg, 0.117 mmol). The product 
was purified by chromatography on SiO2 (20% EtOAc/ hexanes, Rf = 0.37) to afford 
2.31o (19.2 mg, 0.104 mmol, 89%) as a colorless solid. 1H NMR (500 MHz, CDCl3) δ 
8.65 (d, J = 3.9 Hz, 1H), 7.95 (d, J = 8.8 Hz, 2H), 7.71 (td, J = 7.7, 1.8 Hz, 1H), 7.67 (d, J 
= 8.0 Hz, 1H), 7.17 (t, J = 5.9 Hz, 2H), 7.00 (d, J = 8.8 Hz, 1H), 3.87 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 160.4, 157.1, 149.5, 136.7, 132.0, 128.1, 121.4, 119.8, 114.1, 55.3; 
HRMS (EI+) m/z (M)+: Calcd for C12H11NO: 185.0836, found: 185.0841. 
 
Following general procedure, using 2.28 (552 mg, 0.310 mmol), 
naphthalen-1-yllithium (456 µL, 0.57 M, 0.260 mmol), PdCl2 (0.5 mg, 3.0 µmol), dpca 
(1.5 mg, 4.0 µmol), CuI (1.9 mg, 10.0 µmol) and 4-iodoanisole (22.9 mg, 0.10 mmol). 
The product was purified by chromatography on SiO2 (1% EtOAc/ hexanes, Rf = 0.25) to 
afford 2.31p (15.0 mg, 0.064 mmol, 64%) as a colorless solid. 1H NMR (500 MHz, 
CDCl3) δ 7.94 – 7.90 (m, 2H), 7.84 (d, J = 8.2 Hz, 1H), 7.53 – 7.48 (m, 2H), 7.45 – 7.40 
(m, 4H), 7.04 (d, J = 8.6 Hz, 2H), 3.90 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 158.9, 
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139.9, 133.8, 133.1, 131.8, 131.1, 128.2, 127.3, 126.9, 126.1, 125.9, 125.7, 125.4, 
113.7, 55.4; HRMS (EI+) m/z (M)+: Calcd for C17H14O: 234.1048, found: 234.1045. 
 
Following general procedure, using 2.28 (524 mg, 0.300 
mmol), benzofuran-2-yllithium (694 µL, 0.36 M, 0.25 mmol), PdCl2 (0.5 mg, 3.0 µmol), 
dpca (1.5 mg, 4.0 µmol), CuI (1.9 mg, 10.0 µmol) and 4-iodoanisole (22.9 mg, 0.10 
mmol). The product was purified by chromatography on SiO2 (1% EtOAc/ hexanes, Rf = 
0.18) to afford 2.31q (16.4 mg, 0.073 mmol, 73%) as a colorless solid. 1H NMR (500 
MHz, CDCl3) δ 7.80 (d, J = 8.8 Hz, 2H), 7.56 (d, J = 7.4 Hz, 1H), 7.50 (d, J = 7.6 Hz, 
1H), 7.30 – 7.19 (m, 2H), 6.98 (d, J = 8.8 Hz, 2H), 6.89 (s, 1H), 3.87 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 159.9, 156.0, 154.7, 129.5, 125.4, 123.7, 123.3, 122.8, 120.5, 
114.2, 111.0, 99.6, 55.3; HRMS (EI+) m/z (M)+: Calcd for C15H12O2: 224.0837, found: 
224.0834. 
 
Following general procedure, using 2.28 (480 mg, 0.270 
mmol), (4-(trifluoromethyl)phenyl)lithium (437 µL, 0.53 M, 0.230 mmol), PdCl2 (0.5 mg, 
3.0 µmol), dpca (1.5 mg, 4.0 µmol), CuI (1.7 mg, 9.0 µmol) and 4-iodoanisole (20.6 mg, 
0.09 mmol). The product was purified by chromatography on SiO2 (1% EtOAc/ hexanes, 
Rf = 0.23) to afford 2.31r (17.9 mg, 0.071 mmol, 79%) as a colorless solid. 1H NMR (500 
MHz, CDCl3) δ 7.68-7.64 (m, 4H), 7.55 (d, J = 8.7 Hz, 2H), 7.01 (d, J = 8.7 Hz, 2H), 3.87 
(s, 3H); 13C NMR (125 MHz, CDCl3) δ 159.8, 144.3, 132.2, 128.5, 126.9, 125.6 (q, J = 
124 
 










































































































































































































































































































































































































































































































































SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 8.72 min, 
tminor = 11.34 min 
 
 





SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 4.80 min, 
tminor = 6.56 min.   
 
 





SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 3.11 min, 
tminor = 5.43 min.  
 
 




 TMS acetylene nucleophile used. SFC ChiralPak® AD-H column, 12% MeOH/CO2, 
4mL/min, 12 MPa, tmajor = 3.30 min, tminor = 6.02 min  
 
 




TBS acetylene nucleophile used. SFC ChiralPak® AD-H column, 12% MeOH/CO2, 
4mL/min, 12 MPa, tmajor = 3.30 min, tminor = 6.02 min  
 
 




SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 2.84 min, 
tminor = 4.49 min 
 
 




SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 2.09 min, 
tminor = 2.70 min. 
 
 






SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 5.48 min, 
tminor = 7.05 min.   
 
 












SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 4.31 min, 
tminor = 3.80 min. 
 
 




SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 7.49 min, 
tminor = 6.25 min. 
 
 




SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 8.75 min, 
tminor = 5.71 min. 
 
 





SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 2.96 min, 
tminor = 2.73 min. 
 
 





SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 6.01 min, 
tminor = 4.92 min. 
 
 




SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 6.60 min, 
tminor = 5.87 min (Linchpin 1.42a used). 
 
 




SFC ChiralPak® AD-H column, 12% MeOH/CO2, 4mL/min, 12 MPa, tmajor = 6.52 min, 
tminor = 5.80 min.  (Linchpin 1.42b used). 
 
 






X-ray Structure Determination of Compound 1.56a 
 
 Compound 1.56a, C15H27F2NO3Si, crystallizes in the monoclinic space group P21 
(systematic absences 0k0: k=odd) with a=8.0552(4)Å, c=10.8198(6) Å, β=110.377(6)°, 
V=891.54(8)Å3, Z=2, and dcalc=1.250 g/cm3. X-ray intensity data were collected on a 
Rigaku XtaLAB Synergy-S [1] HPC area detector (Dectris PILATUS3 R 200K), 
employing confocal multilayer optic-monochromated Mo-Kα radiation (λ=0.71073Å) at a 
temperature of 100K. Preliminary indexing was performed from a series of thirty 0.5° 
rotation frames with exposures of 0.25 seconds. A total of 1110 frames (8 runs) were 
collected employing ω scans with a crystal to detector distance of 34.000 mm, rotation 
widths of 0.5° and exposures of 2 seconds. 
 Rotation frames were integrated using CrysAlisPro [2], producing a listing of 
unaveraged F2 and σ(F2) values. A total of 16914 reflections were measured over the 
ranges 5.394 ≤ 2θ ≤ 55.048°, -10 ≤ h ≤ 10, -14 ≤ k ≤ 13, -14 ≤ l ≤14 yielding 4005 unique 
reflections (Rint = 0.0718). The intensity data were corrected for Lorentz and polarization 
effects and for absorption using SCALE3 ABSPACK [3] (minimum and maximum 
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transmission 0.5903, 1.0000). The structure was solved by direct methods – SHELXT 
[4]. Refinement was by full-matrix least squares based on F2 using SHELXL-2018 [5]. All 
reflections were used during refinement. The weighting scheme used was 
w=1/[α2(Fo2)+(0.0471P)2] where P = (Fo2 + 2Fc2)/3. Non-hydrogen atoms were refined 
anisotropically and hydrogen atoms were refined using a riding model. Refinement 
converged to R1=0.0372 and wR2=0.0883 for 3679 observed reflections for which F > 
4σ(F) and R1=0.0416 and wR2=0.0910 and GOF =1.048 for all 4005 unique, non-zero 
reflections and 207 variables. The maximum Δ/σ in the final cycle of least squares was 
0.000 and the two most prominent peaks in the final difference Fourier were +0.33 and 
=0.34 e/Å3. 
 
Figure 1. ORTEP Drawing of Compound 1.56a with 50% Thermal Ellipsoids 
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Table 1 lists cell information, data collection parameters, and refinement data. 
Final positional and equivalent isotropic thermal parametics are given in Tables 2. And 3. 
Anisotropic thermal parameters are in Table 4. Tables 5 And 6 list bond distances and 
bond angles. Figure 1 is an ORTEP representation of the molecule with 50% probability 
thermal ellipsoids displayed. 
 
Table 1. Summary of Structure Determination of Compound 1.56a 
Empirical formula C15H27F2NO3Si 
Formula weight 335.46 
Temperature/K 100 
Crystal system Monoclinic 







dcalc 1.250 g/cm3 
µ 0.161 mm-1 
F(000) 360.0 
Crystal size, mm 0.29 x 0.2 x 0.15 
2θ range for data collection 5.394 – 55.048° 
Index ranges -10 ≤ h ≤ 10, -14 ≤ k ≤ 13, -14 ≤ l ≤14 
Reflections collected 16914 
Independent reflections 4005[R(int) = 0.0718] 
Data/restraints/parameters 4005/1/207 
Goodness-of-fit on F2 1.048 
Final R indexes [I>=2σ (I)] R1 = 0.0372, wR2 = 0.0883 
Final R indexes [all data] R1 = 0.0416, wR2 = 0.0910 
Largest diff. peak/hole 0.33/-0.34 eÅ-3 








Table 2. Refined Positional Parameters for Compound 1.56a 
Atom x y z U(eq) 
Si1 0.56074(8) 0.65930(6) 0.46326(6) 0.01469(16) 
F1 0.6258(2) 0.41424(14) 0.44572(17) 0.0290(4) 
F2 0.5561(2) 0.51662(16) 0.26054(14) 0.0264(4) 
O1 0.8945(3) 0.54691(16) 0.01919(16) 0.0186(4) 
O2 0.8160(2) 0.65911(18) 0.16283(16) 0.0194(4) 
O3 0.9337(3) 0.32208(16) 0.36780(17) 0.0204(4) 
N1 0.8661(3) 0.44685(18) 0.19036(19) 0.0136(4) 
C1 0.8549(3) 0.5614(2) 0.1296(2) 0.0155(5) 
C2 0.9632(3) 0.4217(2) 0.0147(2) 0.0173(5) 
C3 0.8801(3) 0.3484(2) 0.1007(2) 0.0157(5) 
C4 1.1637(3) 0.4263(3) 0.0794(3) 0.0242(6) 
C5 0.9107(4) 0.3866(3) -0.1291(3) 0.0225(6) 
C6 0.6999(3) 0.2866(2) 0.0294(3) 0.0201(5) 
C7 0.6500(4) 0.1991(3) 0.1211(3) 0.0316(7) 
C8 0.5493(4) 0.3778(3) -0.0313(3) 0.0247(6) 
C9 0.8886(3) 0.4239(2) 0.3226(2) 0.0138(5) 
C10 0.8540(3) 0.5274(2) 0.4059(2) 0.0143(5) 
C11 0.6599(3) 0.5249(2) 0.3944(2) 0.0169(5) 
C12 0.5350(4) 0.7994(2) 0.4005(3) 0.0225(6) 
C13 0.6366(4) 0.6541(3) 0.6466(2) 0.0271(6) 
C14 0.3164(3) 0.6366(2) 0.3930(3) 0.0232(6) 














Table 3. Positional Parameters for Hydrogens in Compound 1.56a 
Atom x y z U(eq) 
H3 0.9648 0.286646 0.151401 0.019 
H4a 1.210679 0.486595 0.03594 0.036 
H4b 1.212587 0.347468 0.072529 0.036 
H4c 1.194306 0.447776 0.170727 0.036 
H5a 0.78416 0.390238 -0.169827 0.034 
H5b 0.950543 0.304808 -0.135963 0.034 
H5c 0.963988 0.44245 -0.172905 0.034 
H6 0.712215 0.237561 -0.042755 0.024 
H7a 0.744842 0.142024 0.15913 0.047 
H7b 0.544406 0.155185 0.071827 0.047 
H7c 0.629417 0.245063 0.190074 0.047 
H8a 0.531023 0.425559 0.037414 0.037 
H8b 0.442712 0333983 -0.078562 0.037 
H8c 0.579592 0.431105 -0.090753 0.037 
H10 0.878584 0.605847 0.371735 0.017 
H12a 0.760327 0.809431 0.443868 0.034 
H12b 0.574408 0.869424 0.417951 0.034 
H12c 0.608653 0.791904 0.307207 0.034 
H13a 0.760704 0.672777 0.682436 0.041 
H13b 0.616495 0.573604 0.67438 0.041 
H13c 0.57168 0.713125 0.677418 0.041 
H14a 0.259361 0.694017 0.432353 0.035 
H14b 0.288068 0.554633 0.410977 0.035 
H14c 0.276006 0.649525 0.299393 0.035 
H15a 0.951822 0.438454 0.584864 0.031 
H15b 0.955973 0.581365 0.600454 0.031 













Table 4. Refined Thermal Parameters (U’s) for Compound 1.56a 
Atom U11 U22 U33 U23 U13 U12 
Si1 0.0141(3) 0.0151(3) 0.0161(3) -0.0009(3) 0.0068(2) 0.0005(3) 
F1 0.0315(9) 0.0146(8) 0.0515(10) -0.0006(7) 0.0278(8) -0.0043(7) 
F2 0.0145(8) 0.0393(9) 0.0226(8) -0.0162(7) 0.0031(6) -0.0026(7) 
O1 0.0236(10) 0.0172(9) 0.0183(9) 0.0008(7) 0.0113(7) 0.0015(7) 
O2 0.0241(9) 0.0136(8) 0.0223(8) -0.0008(8) 0.0104(7) 0.0031(8) 
O3 0.0276(10) 0.0166(9) 0.0175(9) 0.0018(7) 0.0084(7) 0.0037(8) 
N1 0.0151(10) 0.0108(10) 0.0168(10) -0.0019(8) 0.0079(8) -0.0002(8) 
C1 0.0117(11) 0.0167(13) 0.0171(11) 0.0014(9) 0.0039(9) -0.0012(9) 
C2 0.0185(13) 0.0161(12) 0.0192(12) 0.0001(10) 0.0090(10) 0.0037(10) 
C3 0.0177(13) 0.0150(13) 0.0156(12) -0.0013(9) 0.0073(9) 0.0025(10) 
C4 0.0175(13) 0.0301(15) 0.0269(14) -0.0025(12) 0.0102(11) 0.0001(11) 
C5 0.0264(15) 0.0253(14) 0.0185(13) -0.0009(10) 0.0114(11) 0.0035(11) 
C6 0.0235(14) 0.0203(13) 0.0187(12) -0.0052(10) 0.0102(11) -0.0041(11) 
C7 0.0400(18) 0.0268(16) 0.0317(15) -0.0062(12) 0.0171(14) -0.0173(13) 
C8 0.0171(13) 0.0297(15) 0.0262(14) -0.0091(11) 0.0061(11) -0.0032(11) 
C9 0.0104(11) 0.0149(12) 0.0155(11) -0.0005(9) 0.0037(9) -0.0004(9) 
C10 0.0137(12) 0.0134(11) 0.0165(11) -0.0024(9) 0.0060(9) -0.0009(9) 
C11 0.0162(13) 0.0156(12) 0.0192(12) -0.0032(10) 0.0066(10) -0.0030(10) 
C12 0.0242(14) 0.0183(14) 0.0284(15) 0.0003(11) 0.0135(12) -0.0009(11) 
C13 0.0305(15) 0.0324(15) 0.0201(12) -0.0022(13) 0.0109(11) 0.0103(14) 
C14 0.0163(12) 0.0236(15) 0.0301(13) -0.0044(11) 0.0088(10) -0.0002(11) 
C15 0.0225(13) 0.0225(14) 0.0164(12) -0.0036(10) 0.0059(10) 0.0029(11) 
 
 
Table 5. Bond Distances in Compound 1.56a 
Si1-C11 1.939(3) Si1-C12 1.854(3) Si1-C13 1.862(2) 
Si1-C14 1.863(3) F1-C11 1.396(3) F2-C11 1.400(3) 
O1-C1 1.348(3) O1-C2 1.481(3) O2-C1 1.202(3) 
O3-C9 1.217(3) N1-C1 1.400(3) N1-C3 1.478(3) 
N1-C9 1.401(3) C2-C3 1.546(3) C2-C4 1.521(4) 
C2-C5 1.513(3) C3-C6 1.542(4) C6-C7 1.528(4) 
C6-C8 1.529(4) C9-C10 1.530(3) C10-C11 1.525(4) 









Table 6. Bond Angles in Compound 1.56a 
C12-Si1-C11 104.74(11) C12-Si1-C13 112.79(15) C12-Si1-C14 112.93(13) 
C13-Si1-C11 111.11(12) C13-Si1-C14 109.81(13) C14-Si1-C11 105.10(12) 
C1-O1-C2 110.09(17) C1-N1-C3 110.33(18) C1-N1-C9 127.1(2) 
C9-N1-C3 121.88(19) O1-C1-N1 108.38(19) O2-C1-O1 122.4(2) 
O2-C1-N1 129.2(2) O1-C2-C3 102.25(17) O1-C2-C4 107.7(2) 
O1-C2-C5 107.1(2) C4-C2-C3 110.7(2) C5-C2-C3 117.6(2) 
C5-C2-C4 110.7(2) N1-C3-C2 99.62(19) N1-C3-C6 111.88(19) 
C6-C3-C2 117.1(2) C7-C6-C3 111.3(2) C7-C6-C8 109.7(2) 
C8-C6-C3 113.5(2) O3-C9-N1 119.2(2) O3-C9-C10 121.8(2) 
N1-C9-C10 119.0(2) C9-C10-C15 110.3(2) C11-C10-C9 109.3(2) 
C11-C10-C15 111.0(2) F1-C11-Si1 109.69(16) F1-C11-F2 103.1(2) 
F1-C11-C10 108.7(2) F2-C11-Si1 105.60(17) F2-C11-C10 108.16(19) 
C10-C11-Si1 120.21(17)     
 
 
This report has been created with Olex2 [6], compiled on 2018.05.29 svn.r3508 for OlexSys. 
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